Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs

Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company. - 04/24/2025

Biotech Discovers Revolutionary Immunotherapy in Houston

Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note. - 04/24/2025

Analyst Reveals Undervalued Pharmaceutical Gem in Canada

In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential. - 04/14/2025

New Drug for Early AD Shown to be Efficacious, Safe

Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report. - 04/09/2025

Rest of 2025 Rich With Catalysts for Immunotherapy Co.

These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report. - 04/09/2025

Four-Year Data on New Drug for Early AD Positive

Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report. - 04/09/2025

Share Price Appreciation of Biotech Due Over Next Six Months

Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. - 04/08/2025

New Therapy for AATD Could be Best in Class

Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report. - 04/08/2025

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal

Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential. - 04/08/2025

Biotech Co. Has Promising AI-Accelerated Pipeline

Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy. - 04/07/2025

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.

OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest. - 04/07/2025

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe

Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said. - 04/07/2025

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results

Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential. - 04/04/2025

Regenerative Medicine Firm OK'd To Advance Trial in T1D

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication. - 04/03/2025

Cell Pouch Co. Peer Aborts Program Using Like Device

The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. - 04/03/2025

Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon

Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report. - 04/03/2025

New Jersey Pharma Co. Shares Positive Pediatric Study

Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note. - 04/02/2025

Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth

BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story. - 04/01/2025

GMP Production of Exosomes Slated for Later This Year

This is a next big step for the biotech in moving its investigational exosome therapy for chronic inflammation into the clinic, noted a D. Boral Capital report. - 03/31/2025

Biotech Co. Advances AI-Generated Cancer Treatments

Rakovina Therapeutics Inc. (RKV:TSX.V) receives the first synthesized batch of artificial intelligence-generated ATR inhibitor compounds developed in collaboration with Variational AI. Find out why the technology could revolutionize the way we treat cancer. - 03/28/2025

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases

Clinical-stage biotechnology company Coya Therapeutics Inc.'s (COYA:NASDAQ) regulatory T cell-derived exosome (Treg exosome) program is set to enter Good Manufacturing Production (GMP) late this year, paving the way for an initial clinical study. Find out why one analyst calls the company's work a "potential breakthrough." - 03/28/2025

Chen Highlights His Premium Silver, Gold Opportunities for Q2

Even with tariff chaos, asset manager Chen Lin of What is Chen Buying? What is Chen Selling? said he is still bullish in the near term for gold silver. Find out which stocks are his top picks for the coming quarter. - 03/25/2025

PDUFA Date Nearing for New PSVT Drug

If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report. - 03/19/2025

Two Use Cases for AI in Healthcare

In both, proprietary software platforms analyze heaps of data, but one focuses on genetics, the other neurology. Learn more about the companies behind the technology. - 03/14/2025

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons

MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next. - 03/14/2025

Biotech Stock Looks Like Is Has a Great Set Up

Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy. - 03/12/2025

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients

Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note. - 03/12/2025

AI Study Tracks Unexpected Cognitive Gains in Vascular Dementia Trial

Hemostemix Inc.'s (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) Phase 1 trial, in collaboration with Firefly Neuroscience Inc. (AIFF:NASDAQ), is evaluating ACP-01s impact on vascular dementia using AI-driven brain analysis. Early insights could reshape treatment approaches. - 03/11/2025

Biotech Advancing Pivotal Phase III Breast Cancer Trial

Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc. - 03/11/2025

FDA OKs Trial of Cell Reservoir in Thyroid Disease

In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report. - 03/10/2025

With Competitor Out, New Drug Gains Edge in Chronic Cough

Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report. - 03/10/2025

New Drug for Major Depressive Disorder Gets Good Surprise

When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report. - 03/10/2025

Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock. - 03/06/2025

Canadian Healthcare Co. Showcases Stable FQ424

Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy. - 03/06/2025

Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data

Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next. - 03/05/2025

Virtual Healthcare Breakthrough Expanding Access for 6.9M Medicaid Patients in New York

Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility. - 02/27/2025

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research. - 02/14/2025

Healthcare Tech Co. To Acquire Digital Health Platform

This will expand its ecosystem of AI-powered products. Read on to learn more about its offerings and rapidly growing sector. - 02/13/2025

New Strategic Moves Aim To Accelerate Growth in AI Healthcare

Light AI Inc. (ALGO:CBOE) announces major marketing campaigns, advisory board appointments, and a key regulatory partnership to drive growth. Discover how these strategic moves could shape the future of AI healthcare. - 02/12/2025

Kentucky Medical Co. Has Strong Operating Fundamentals

Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note. - 02/12/2025

AI Stock in an Uptrend That Is Likely To Continue

Technical Analyst Clive Maund explains why he thinks Light AI Inc. (ALGO:CBOE) is an Immediate Strong Buy. - 02/10/2025

Healthcare Pioneer Expands Revolutionary Treatment Platform

Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development." - 02/06/2025

Biotech Requests OK to Assess Device in Second Indication

The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report. - 02/06/2025

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company. - 02/04/2025

Washington D.C. Pharma Co. Receives FDA Acceptance

Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) recently received FDA acceptance of its request for a hearing regarding its tradipitant New Drug Application, reported an H.C. Wainwright & Co. analyst. - 01/28/2025

Biotech's Target Price 183.757% Higher Than Current

Read on to see why D. Boral Capital analyst Jason Kolbert gave IMUNON Inc. (IMNM:NASDAQ) a high target price. - 01/24/2025

AI Infrastructure Push: US$500 Billion Investment Accelerates Drug Discovery

Rakovina Therapeutics Inc. (RKV:TSX.V) highlights the transformative potential of the US$500 billion Stargate Initiative, set to revolutionize AI-driven drug discovery. Learn how this landmark investment could redefine oncology breakthroughs. - 01/23/2025

Biopharma Shares Multiple 2025 Catalysts

Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co. - 01/17/2025

Advanced AI Solutions Deliver Hope for CNS Cancer Treatment

Rakovina Therapeutics Inc. (RKV:TSX.V) has identified AI-designed drug candidates targeting advanced cancer treatments with CNS penetration. Read more about how this breakthrough could redefine oncology innovation. - 01/15/2025

Tech Innovator Achieves Breakthrough Multi-Market Success

Clean technology company BioLargo Inc. (BLGO:OTCQX) announces it had a "widely successful" and "transformative" 2024 and is looking forward to more revenue growth in 2025. Read why one expert thinks investors should be doubling down on the stock. - 01/15/2025

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections

Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research. - 01/10/2025

Biotech Advances Breakthrough Cancer Treatment Results

Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note. - 01/10/2025

Pharma Innovator Reveals Groundbreaking Diabetes Treatment

Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share. - 01/10/2025

Should You Double Down on This Story Stock?

Chris Temple of The National Investor explains why he believes you might want to double down on BioLargo Inc. (BLGO:OTCQX). - 01/07/2025

AI Company Unlocks Breakthrough Medical Diagnostics Platform

One company being listed on Cboe Canada starting January 8 is using AI and smartphones to help patients get quick and accurate diagnosis of their sore throats, helping to battle microbial resistance that threatens the effectiveness of antibiotics worldwide. - 01/06/2025

Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech

CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence. - 01/06/2025

Pharma Innovator Unlocks Multi-Disease Treatment Potential

Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating. - 01/03/2025

Drug Innovator Launches Pivotal Cancer Trial Breakthrough

Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note. - 01/03/2025

Miami Biopharma Sells Part of Business and Begins New Clinical Trial

Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating. - 01/02/2025

Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug

NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target. - 12/31/2024

Analyst Sees Major Growth for Biopharma With Weight-Loss Drug

Recent successes of weight-loss drugs like Ozempic and Wegovy have led H.C. Wainwright & Co. Analyst Ed Arce to be "intrigued" by MetaVia Inc.'s (MTVA:NASDAQ) new drug candidate. - 12/31/2024

Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy

Gain Therapeutics Inc. (GANX:NASDAQ) has announced the initiation of its Phase 1b clinical trial for GT-02287, a lead candidate targeting Parkinsons disease (PD), following regulatory approval in Australia. Read more about the trial aiming to redefine Parkinsons treatment and its potential global impact. - 12/30/2024

Maryland Biotech Gains Regulatory Approval

Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients. - 12/26/2024

Pharma Co. Signs License Agreement With Boston Medical Center

60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note. - 12/24/2024

FDA Expedites Review of Gene Therapy Co.'s Drug

Clinical stage genetic medicines company MeiraGTx Holdings Plc (MGTX:NASDAQ) says the FDA has granted regenerative medicine advance therapy (RMAT) designation to one of its treatments that could help thousands of patients. Read why one analyst thinks the stock is undersold. - 12/23/2024

Is This Centrally Positioned AI Healthcare Co. Set to Transform the Industry?

Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) offers potential upside to investors. - 12/20/2024

Medical Equipment Co. Shows Strong Profit Margin

Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report. - 12/20/2024

Biopharma Using AI to Find Promising Cancer Drug Candidates

Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development. - 12/19/2024

New Data Supports BLA Package

Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note. - 12/17/2024

New Quebec Law Affecting Healthcare Co.'s Bottom Line

Quebec-based staffing operator Premier Health of America Inc. (PHA:TSX.V) reported soft financial data for the fourth quarter of 2024 as the province's Bill 10 act limiting the use of per diem operations. Find out why this analyst thinks things will improve for the company. - 12/16/2024

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says

Clinical-stage biotechnology company Gain Therapeutics Inc.'s (GANX:NASDAQ) drug treating Parkinson's disease could be a "US$4 billion drug," according to one analyst who recently initiated coverage on the Maryland company. - 12/10/2024

California Biopharma Shows Promising Phase 1 Data

Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note. - 12/09/2024

FDA Decision on Drug for Bone Marrow Due Early 2025

The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report. - 12/06/2024

Drug Trial Shows Positive Interim Results for ALS Treatment

Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others. - 12/06/2024

AI Accelerates Breakthroughs in Cancer Drug Discovery

Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing cancer drug discovery with its Deep Docking AI platform. Read more about their recent developments and future plans. - 12/03/2024

Intratubal Insemination Device Shown Effective, Safe

Pregnancy rates with this "only new innovation for infertility in decades" were "impressive" in a pivotal study in women with male factor infertility, noted an H.C. Wainwright & Co. report. - 12/03/2024

Approval Sought in Japan for New Drug to Lower Cholesterol

The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report. - 12/03/2024

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative

Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced." - 12/03/2024

Is This California Biopharma Co. In the Right Place at the Right Time?

Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies. - 12/03/2024

Developer of Medical Instruments Attracts Research Coverage

Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report. - 12/02/2024

Two Firms Aim To Create Functional Cure for Type 1 Diabetes

Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs. - 11/22/2024

Biotech Initiates Phase III Trial for Heart Disease Drug

Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock. - 11/20/2024

Analyst Says Biotech's Data Supports Advancement Into Phase III

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note. - 11/19/2024

Breakthrough Therapy Shows Promising Long-Term Results for Depression

Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging." - 11/19/2024

Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions

Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach. - 11/15/2024

Prestigious Honors Show How This Defense Company Supports Veterans and Leads in Innovation

DroneShield Ltd. (DRO:ASX; DRSHF:OTC), headquartered in Warrenton, Virginia, has been honored with the prestigious 2024 HIRE Vets Medallion Award in recognition of its commitment to hiring and supporting U.S. military veterans. Read the CEO's response to the honor and the company's commitment to veterans. - 11/14/2024

Opportunity Arises for Co. With Cell Pouch

This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report. - 11/12/2024

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory

Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise. - 11/08/2024

New Blood Cancer Treatment Shows Continued Response

The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report. - 11/07/2024

Regenerative Med Co. Granted Second Tissue License

With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report. - 11/07/2024

Revolutionary AI Tools Take Center Stage in Medical Education Symposium

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). Read more to find out how this update is set to transform medical education and enhance training efficiency. - 11/05/2024

Medical Co. Ready for a Transformative F2025

The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates. - 11/05/2024

Pharma Stock Has Significant Upside Potential, Analyst Says

"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note. - 11/04/2024

AI Healthcare Co. With 'Bright' Outlook Closes Placement

Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on. - 10/31/2024

Biotech Shares Positive Phase I Data for Alzheimer's Treatment

Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%. - 10/31/2024

Mass. Biotech Shares Strong Q3 Results

Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note. - 10/29/2024

Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments

This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy. - 10/28/2024

Boston Biotech Announces Novartis Collaboration

Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note. - 10/28/2024

H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates

DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch. - 10/23/2024

Silver Break Out Confirmed

The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell. - 10/22/2024

NY Biopharma Shares Promising Clinical Data

Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note. - 10/18/2024

Is This AI Healthcare Stock Worth Being Overweight On?

Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on. - 10/09/2024

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.

H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers. - 10/09/2024

Mass. Biotech Receives FDA Approval

Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note. - 10/07/2024

AI Integration Enhances Capabilities of Defense Drones for Key Military Operations

Red Cat Holdings Inc. (RCAT:NASDAQ) and Palladyne AI Corp. have announced a new partnership to integrate Palladyne AIs artificial intelligence (AI) platform, Palladyne Pilot, into Red Cats Teal drones. Read how this changes the capabilities for smaller scale drone platforms. - 10/04/2024

CT Biotech Ready for Clinical Milestones

Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note. - 10/04/2024

Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial

Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton. - 10/03/2024

New Jersey Biotech Reports Positive Survival Data

H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price. - 10/02/2024

California Biotech's Target Price 200% Higher Than Current

F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients. - 09/30/2024

Target Price Raised on Biotech Co.

In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company. - 09/25/2024

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment

Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note. - 09/23/2024

AI Collaboration to Streamline Healthcare Administration and Improve Patient Outcomes

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers. - 09/19/2024

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine

A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential. - 09/17/2024

Co's. Cell Pouch Performs Well in Study

Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report. - 09/16/2024

Implanted Cell Device Reaches 5 Year Milestone

This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report. - 09/16/2024

Trial Data Help Position Cell Pouch for Commercial Success

The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report. - 09/16/2024

Is It Now Time To Buy This Biotech Stock?

Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows. - 09/16/2024

California Biotech Reports Positive QOL Improvements in Program

With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating. - 09/13/2024

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment

Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure. - 09/12/2024

Biotech Working on 'Functional Cure' for Type 1 Diabetes

Clinical-stage biotechnology company Sernova Corp.'s (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) Cell Pouch implantable technology can act as a "pseudo-organ," delivering therapeutic cells to the body. Find out why one newsletter author thinks the stock could deliver a big payoff for shareholders and for patients. - 09/10/2024

MA Biotech Reports Positive Meeting with FDA

Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note. - 09/09/2024

Healthcare Tech Firm and Leading University to Join Forces

The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform. - 09/07/2024

Mass. Biopharma Reports Positive Data and Announces New Program

Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts. - 09/06/2024

Pharma Co. Enrolls First Patient in Trial

Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy. - 09/05/2024

Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial

Florida-based Cyclo Therapeutics Inc. (CYTH:NASDAQ) says it has completed enrollment in its "pivotal" TransportNPC trial of Niiemann-Pick Type C1, a rare progressive genetic disorder. Find out why analysts are recommending the stock. - 08/16/2024

Long Term Care Co.'s Target Price Raised

Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results. - 08/14/2024

Promising Clinical Data and Strategic Partnerships Propel Oncology Co.

Elevation Oncology Inc.(ELEV:NASDAQ) reported its second-quarter 2024 financial results on August 6, highlighting significant progress in its clinical trials and ongoing business achievements. Read on to see why three experts believe this stock is a Buy. - 08/09/2024

AI Healthcare Co. Signs Partnership With Large Regional Health Plan

Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note. - 08/09/2024

Boston Biotech Reports Promising Interim Data

Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note. - 08/07/2024

New Firmware Update Enhances Counter-Drone Capabilities

DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has released its latest firmware update for its full range of Radio Frequency (RF) sensors. Read about what this advancement means for the technological power of the company's product line. - 08/06/2024

AI Healthcare Co. Creates AI Pharmacy Assistant

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource." - 08/02/2024

Exercised Warrants Show Confidence in AI-Driven Healthcare Innovations

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has successfully seen the exercise of nearly 800,000 warrants issued on conversion of special warrants in June for gross proceeds of about CA$500,000. See why one technical analyst rates this stock a Buy as the company solidifies its investor confidence. - 07/29/2024

Analyst Says CA Pharma Underappreciated by Investors

Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. - 07/23/2024

Analyst's Target Price for Biotech Massively Higher Than Current Price

Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price. - 07/22/2024

Study Shows 93% Cough Suppression With Co.'s Drug

Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market." - 07/18/2024

Could This Stock Be the Next Bellus Cough Treatment?

Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy. - 07/17/2024

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride

"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report. - 07/15/2024

Healthcare AI Company Achieves Key Milestones and Secures New Partnerships

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects. - 07/11/2024

Biopharma Co. Reports Strong FQ224 Results Driven

Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX). - 07/11/2024

Texas Biotech Announces Plans for Preclinical Obesity Studies

Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note. - 07/08/2024

AI Health Stock Heading Higher Expert Says

Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher. - 07/02/2024

New Patents and Strategic Partnerships Boost Smart Home Innovation

SKYX Platforms Corp. (SKYX:NASDAQ), a leader in smart platform technology, has announced the issuance of six additional patents in the U.S. and internationally, expanding its already robust patent portfolio to over 94 issued and pending patents globally. Find out how these partnerships affect upcoming projects and plans. - 07/01/2024

California Biotech Reports Positive Phase 3 Results

"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. - 06/25/2024

Major New Contract Marks Significant Milestone for Counter-Drone Tech Co.

DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has announced a significant new contract valued at AU$4.7 million from a non-government Swiss international customer. Find out why this is a major milestone for the company. - 06/24/2024

Chicago Alt. Medicine Co. Announces US$50M Share Repurchase Program

In a Roth MKM research note, analyst Nick Anderson noted that Verano Holdings Corp. (VRNO:CSE; VRNOF:OTCQX) was well-positioned to generate increasing cash flow. - 06/18/2024

Clean Tech Subsidiary Finds Manufacturer for Wound Solution

BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic. - 06/14/2024

Is This Pharma Co. the Next Eli Lilly?

Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly. - 06/11/2024

Positive Phase 2 Clinical Trial Results Announced for Drug Treating Idiopathic Hypersomnia

Zevra Therapeutics Inc. (ZVRA:NASDAQ), a company specializing in rare disease therapeutics, has announced positive final results from its Phase 2 clinical trial evaluating the safety and tolerability of KP1077 for treating idiopathic hypersomnia. - 06/10/2024

Rare Disease Co. Presents Positive Phase 2 KP1077 Data

Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note. - 06/06/2024

Co. Targets More Verticals in Safe Supply

This Canadian firm, with a streaming business model, intends to invest in two additional segments of the safe supply ecosystem. Here, learn more about this approach to reducing harms from illegal drugs. - 06/05/2024

Strong Q1 2024 Financial Results Reflect Positive Growth For AI Company

MultiSensor AI Holdings, Inc. (NASDAQ: MSAI) announced strong financial results for the first quarter of 2024. Read on for more about how this plays out in its role within the AI sector. - 05/24/2024

Co. Expands Telehealth Contract to New State

Reliq Health Technologies Inc. announced that a large U.S. health group has expanded its contract with the telehealth company to cover facilities in a new state. Read why one analyst thinks the stock is a Buy. - 05/22/2024

New Healthcare AI Partnership Aims to Transform Health Risk Assessments

Treatment.com AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector. - 05/21/2024

Pharma Co. Secures $650M Strategic Financing

According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine. - 05/16/2024

New COPD Drug Slated for Approval Decision This June

Ahead of the upcoming PDUFA date, several analysts recommend the biopharma behind this treatment as a Buy. Read on to learn why. - 05/15/2024

Pharma Stock Focuses on Successful Ensifentrine Launch

Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note. - 05/15/2024

Pharma Stock Nears FDA Approval

According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval. - 05/14/2024

Investor Conference Highlights New Strategic Directions for Addressing Opioid Crisis

Safe Supply Streaming has provided an update on Safety Strips, its recent acquisition. Read on for more about how this impacts the company's battle against the opioid crisis. - 05/13/2024

Tech Firm Eyes Market Expansion With Innovative Plug Tech

SKYX Platforms Corp. teams up with Ruee Appliances, blending innovative smart technology with robust manufacturing and financial support to tap into U.S., Chinese, and European markets. Read on to see why one technical analyst called the company's market "gigantic." - 05/09/2024

Breakthrough COPD Treatment Awaits FDA Approval, Promising Major Market Impact

Verona Pharma is poised for a pivotal breakthrough with its drug candidate, ensifentrine, potentially transforming COPD treatment pending an upcoming FDA decision. Read on for more. - 05/08/2024

Critical Reforms Stuck in Congressional Gridlock

McAlinden Research shares its thoughts on the current state of the cannabis market in light of recent legislative moves and two ETFs that may be impacted. - 05/07/2024

Medical School Renews Contract with Tech Co.

This move further validates the firm's Medical Education Suite. Discover why one analyst rates this healthcare-disrupting company as a Strong Buy. - 05/06/2024

Biotech Co. Positioned for Ensifentrine Approval, Analyst Says

According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval. - 05/06/2024

Pharma's Promising Path in COPD Treatment

As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock. - 04/26/2024

AI Healthcare Stock Has Bullish Setup, Expert Says

Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy. - 04/22/2024

PDUFA Date Coming Up for U.K. Biopharma

The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report. - 04/22/2024

Biopharma's New Drug for COPD Likely to be Approved

Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report. - 04/22/2024

New AI Solutions Set To Transform Medical Education and Clinical Practice

Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES). - 04/19/2024

Analyst Says Pharma Co. Has No True Competitor

Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note. - 04/19/2024

LA Biotech's Lower Revenue Will Be Short Lived

While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note. - 04/17/2024

Healthcare Co. Welcomes Possible AI Funding Effort in Canada

Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way. - 04/09/2024

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out

After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high. - 04/08/2024

Co. Adding 500 Patients to Its Mental Health Care Platform

This Canada-based health care technology firm is profitable and growing. Learn more about it here. - 04/03/2024

Analyst Encouraged by ON Gov's Decision To Sustain Fees

CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note. - 04/02/2024

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock

Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock. - 03/27/2024

AI Co. Funded To Develop AI Approach to Health Equity

Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock. - 03/27/2024

AI Medical App Passes Standard Student Test

This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector. - 03/26/2024

Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says

K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note. - 03/26/2024

Biotech Co.'s Target Price Significantly Higher Than Current

Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note. - 03/19/2024

Biotech Stocks Break Out

Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into. - 03/19/2024

Is This Pharma Set To Break Out After COPD Drug Approval?

Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024. - 03/15/2024

This Biotech Is a Potential Disruptor, Expert Says

Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy. - 03/12/2024

Wellness Co.'s New Initiatives Should 'Lower Barriers' Analysts Say

The Beachbody Company Inc.'s 4Q23 results have Roth MKM analysts maintaining their Buy rating. - 03/12/2024

Safe Supply Firm Announces Another Promising Acquisition

Safe Supply Streaming Co. adds another company to its portfolio, and continues advocating for harm reduction in the psychedelic sector. - 03/11/2024

Healthcare AI Firm Has 'Bright Future,' Analyst Predicts

Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade. - 03/08/2024

NY Biotech Has Potentially Game Changing Anxiety Therapy

Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note. - 03/07/2024

Bionic Medical Co. Has Sufficient Funds to Operate Through 2024

Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co. - 03/05/2024

'Safe Supply' Co. Secures Legal Flow of Coca Products

This is a milestone for the venture capital firm investing in efforts that address the toxic drug crisis in Canada and the U.S. Learn more about the company and the latest wave of drug reform. - 02/20/2024

Alt-Pharma VC adds 7% Stake in Testing Strip Firm

Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio. - 02/15/2024

Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says

Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly. - 02/12/2024

Wellness Co. Preparing for US Legislation

Wellness company Canopy Growth Corp. is taking steps forward while it waits for the U.S. to make legislative changes, according to a Roth MKM research note. - 02/12/2024

Drug Reformer Subsidiary Inspected for Dealer License

In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances. - 02/02/2024

Leadership Cuts Won't Slow This Biotech

While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report. - 01/26/2024

Pharma Co. Primed for Future Business

Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development. - 01/25/2024

Healthcare Co. Exceeds Expectations in Performance

Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note. - 01/24/2024

Innovator in Drug Policy Now Listed on the OTCQBA Venture Market

Safe Supply Streaming Co. Ltd. Announced that it is expanding availability for potential investors. Read on to see why this stock might represent an opportunity as drug policy changes. - 01/18/2024

Pharma Co. Invests in Clinical Psychedelics

ATAI Life Sciences N.V. has announced that it is investing in psychedelic treatments for Major Depressive Disorder and Alcohol Use Disorder. Read on to see why one analyst likes this company's stock. - 01/17/2024

Money Manager: The Year of Small Caps?

The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps. - 01/16/2024

Big Pharma's Looming Patents May Benefit One Biotech

Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024. - 01/10/2024

Biotech Co.'s Sales Could Grow To US$310 Million in 2028

Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report. - 01/10/2024

Telehealth Co. Adding Thousands to Large Contract

Reliq Health Technologies Inc. has signed a contract expansion with a large U.S. health plan, possibly adding as many as 50,000 new patients to its iUGO telehealth platform. - 01/10/2024

2024: Chen Leads With Biotech After Picking 2023's Top Stock

Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year. - 01/05/2024

Market Correction and One Cash Rich Biotech

In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value. - 01/03/2024

Boston Biotech Could Have Blockbuster Sales

Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report. - 01/03/2024

Pharma Co. Gets First US Patent for Repurposed Drug

Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast. - 01/02/2024

California-Based Pharma Co.'s Progress Offers Upside

While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company. - 01/02/2024

Contracts Add Thousands of Patients to Telehealth Platform

Reliq Health Technologies Inc. says it has signed new contracts with 10 physician practices in three states to add thousands more patients to its iUGO telehealth platform. - 12/28/2023

Co.'s Breast Cancer Therapy Shows Encouraging Activity

BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report. - 12/28/2023

Biotech Secures Additional Funding, Extending Cash Runway

Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co. - 12/27/2023

Biotech Bolsters ADC Pipeline Through Atreca Asset Buy

Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush. - 12/26/2023

US Biotech's Anti-Fungal Wins European Approvals

Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co. - 12/22/2023

Biotech Co. Reports Encouraging ALS Data but FDA Wants More

Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM. - 12/21/2023

Pharma Co. May Have Accelerated FDA Approval in 2024

TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co. - 12/20/2023

Lithium Co. Will Be a Substantial Outperformer

Michael Ballanger of GGM Advisory Inc. shares a quick note about why he has faith in Volt Lithium Corp. - 12/19/2023

Bioscience Co. Expands Collaboration

This bioscience company's price target implies 680% upside, according to a Roth MKM report. - 12/19/2023

Promising Biotech Selling Way Under Cash Value

Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater. - 12/18/2023

Texas Biotech Advances Lead Candidate in Resistant AML

Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock. - 12/14/2023

Biotech Seeks Approval of Synthetic Blood Vessel Graft

Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino. - 12/12/2023

Drugs Show Anti-Cancer Effects on Myeloma Cells

These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report. - 12/06/2023

Antibodies from Vaccine Remain Two Years Out

This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report. - 12/06/2023

Pharma Co. Reports Positive Data for Leukemia Combination Therapy

Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report. - 12/06/2023

Massachusetts Biotech Plummets as Skin Cancer Trial Fails

In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted. - 12/05/2023

Pharma Co.'s Partnership a Key Validation

Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report. - 12/04/2023

Biotech Announces New Responder in Breast Cancer Trail

Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar. - 11/30/2023

Biotech Receives First Approval; Drug Now Available

Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju. - 11/28/2023

Encouraging Early Data For Biotech's Cancer Therapies

In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar. - 11/21/2023

Strong Early Launch Metrics for Biotech's Skin Disease Drug

Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment. - 11/20/2023

Arizona Biotech Advances Multiple Cell Therapies

Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data. - 11/16/2023

Massachusetts Biotech Advances Novel Cytokine Therapies

Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note. - 11/15/2023

Massachusetts Biotech Presents Catalysts Into 2024

Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten. - 11/08/2023

Texas Biotech Exceeds Alzheimer's Trial Enrollment Target

This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino. - 11/08/2023

Expert Shares Thoughts on Six Stocks

Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell. - 11/07/2023

Biopharma Acquires Royalty on Approved Diabetes Drug

This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report. - 11/03/2023

Survey Results Positive for New HAE Drug

Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report. - 11/02/2023

Safety Profile of New IL-2 Molecule Better Than Like Drugs'

First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report. - 11/02/2023

Firm To Present Trial Results Update at SITC Meeting

Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report. - 11/02/2023

Add Back Positions in This Biotech

Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs. - 11/01/2023

Biotech to Advance New Type 1 Diabetes Drug Into Clinic

Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report. - 10/23/2023

Approval Likely in U.S., EU for New Drug for Prader-Willi

Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report. - 10/12/2023

Drug Reform Streaming Co. Starts Trading on CSE

This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement." - 10/12/2023

Diagnostics Biotech Beats Revenue Estimates in Q3/23

The Belgium-based company is well on its way to achieving, and possibly exceeding, full-year revenue guidance, noted an Oppenheimer report. - 10/11/2023

Chen Still Likes This Precious Metal in Q4

If you've been following asset manager Chen Lin's quarterly picks on Streetwise Reports, you know he is bullish on one particular precious metal, and the fourth quarter of 2023 is no exception. - 10/09/2023

Trial of New Drug for Acute Leukemia Meets Primary Endpoint

The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report. - 10/05/2023

New CAR-T Therapy Shows Potency in Certain Patients

Study results for patients with relapsed/refractory multiple myeloma continue to be "favorable," noted a ROTH Capital Partners report. - 10/04/2023

New Contract Adding Thousands of Patients to Telehealth Platform

This telehealth company has signed a contract with a physician network to add as many as 100,000 patients to its platform. Find out why the CEO says it is in a period of rapid growth. - 09/27/2023

Biopharma Co. Adds CTO to Team

This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report. - 09/21/2023

Trial Results Validate New Drug-Delivering Nasal Implant

This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report. - 09/20/2023

Biotech Co. Makes Strides on Three Fronts

This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report. - 09/19/2023

Telehealth Co. Signs Contract With Client in Eight States

This telehealth company has signed a new contract for its remote patient monitoring platform to be used by a leading healthcare company with dozens of locations in eight states. - 09/13/2023

Telehealth Co. Expands Platform To Cover Pediatric Patients

This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum. - 09/08/2023

Co. Reaches Major Milestone With Novel Drug

The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report. - 09/07/2023

Cryoablation System Gets Approved in Brazil

The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report. - 09/07/2023

After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment

Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug. - 09/06/2023

FTC Settles Suit, Potentially Averting Further Hurdles

McAlinden Research shares a deep dive into a market driver with alpha-generating potential. - 09/06/2023

Contract Adding Thousands of Patients to Co.'s Telehealth Platform

This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy. - 09/05/2023

New Vaccine for Chikungunya Shown To Be Safe in Youths

The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report. - 09/01/2023

Approved Drug for Skin Condition Shown Safe at Higher Dose

Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report. - 09/01/2023

Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023

Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into. - 08/31/2023

Catalyst Rich 12 Months Ahead for U.S. Biopharma Co.

Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report. - 08/29/2023

DNA Tech Co. Launches MRNA Platform and Files Two Patents

This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock. - 08/29/2023

FDA Approves New Oncology Drug for Clinical Trials

The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report. - 08/28/2023

Telehealth Co. Launches Monitoring Program for Acute Patients

Reliq Health Technologies Inc. has launched a new post-discharge program for acute care hospitals on its iUGO platform and signed contracts in California, Florida, and Puerto Rico. - 08/18/2023

Co. Still Undervalued Post Solid Q2/23

The multistate operator is on a growth trend and just raised its free cash flow guidance for the year, noted a ROTH Capital Partners report. - 08/16/2023

Med Tech Firm's Q2/23 Revenue Beats Target

The company is expected to gain greater market share in one segment of its business, warranting a price target increase, noted a ROTH Capital Partners report. - 08/10/2023

Telehealth Co. Inks Contracts With Rural Clinics in 5 States, Territories

Telehealth company Reliq Health Technologies signs contracts with 20 new rural health clinics (RHCs) in California, Nevada, Puerto Rico, Texas, and the U.S. Virgin Islands. - 08/09/2023

The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside

The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short. - 08/07/2023

Biotech Co. An Attractive Investment

Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment. - 08/04/2023

Telehealth Co. Continues To See Soaring Revenues

This telemedicine company just had its first profitable quarter, and now it could see revenues double twice over two fiscal years. - 08/02/2023

Co. Works to Strengthen Itself After Merger Ended

Its efforts include restructuring debt and divesting assets, noted a ROTH Capital Partners report. - 08/02/2023

Merger Between Two Firms Called Off

The deal broke down because the parties could not sell assets that had to be divested for it to go through, noted a ROTH Capital Partners report. - 08/02/2023

Co. Starts Using AI on Its Telehealth Platform

This telehealth company says it has started using artificial intelligence (AI) and machine learning (ML) with two of the clients on its platform. - 07/21/2023

Second Half of 2023 Is Catalyst Rich for This Biopharma Co.

The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report. - 07/19/2023

Top Pick Healthcare Technology Co. Trading at Deep Discount

The healthcare tech firm's shares are underperforming despite two consecutive record quarters and a "landmark" contract win, noted an Echelon Capital Markets report. - 07/19/2023

Healthcare Tech Firm Sells Noncore Assets for $6M

The resulting upfront valuation gain equates to an estimated $0.02 per share, noted an Echelon Capital Markets report. - 07/10/2023

Approval Sought in Japan for New SARS-CoV-2 Vaccine

The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report. - 07/07/2023

Co. Addresses Opioid Crisis Through Novel Platforms

This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted. - 07/07/2023

Up to 10,000 Patients To Join Telehealth Co.s Platform in Mexico

This company is expanding its telehealth platform into Mexico, where more than 10,000 new patients are expected to be on board by next June. - 07/06/2023

New Psoriasis Drug Shown More Effective Than On-Market One

Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report. - 07/06/2023

Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says

Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction. - 07/05/2023

Biotech Co. Remains Opportunity for Those With High Risk Tolerance

Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note. - 06/30/2023

Q3: Chen Is Still Bullish on This Precious Metal

Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023. - 06/29/2023

Telehealth Co. Expands to More Patients, Picks Up Coverage

Reliq Health Technologies Inc. continues to pick up more contracts with skilled nursing facilities (SNFs) and other health care groups. Now it also has gotten analyst attention. - 06/26/2023

New Drug for Bone Growth Disorder Improves Height Velocity

Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report. - 06/21/2023

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries

Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream. - 06/16/2023

777% Gain Implied in Analyst's Target Price on Biopharma Co.

Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report. - 06/14/2023

Telehealth Co. Expands With Six New Contracts in Three States

New contracts are expected to add more than 3,000 new patients to Reliq Health Technologies Inc.'s platform by the first quarter of next year, the company said. - 06/13/2023

Court Grants Firm Protection From Creditors

Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report. - 06/12/2023

Biotech Co. To Exit Health Care Services

Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future. - 06/12/2023

Key Catalyst for US Biopharma Stock on Track for Q4/23

Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report. - 06/09/2023

Medical Device Co. Completes Merger in Q1/23

Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report. - 06/08/2023

Healthcare Tech Firm Grows Revenue 10% YOY in Q1/23

This positive start to 2023 bodes well for the company turning EBITDA positive later this year, which is expected, noted an Echelon Capital Markets report. - 06/05/2023

FDA Approval, Private Placement Funding Buoy Biotech Firm

Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement. - 06/05/2023

Telehealth Co. Notches First Profitable Quarter

Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022. - 06/02/2023

Analyst Says Pharma Co. 'Meaningfully Undervalued'

"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note. - 06/01/2023

U.S. Firm's Earnings To Remain Robust Through 2023

Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report. - 05/25/2023

Animal Feed Company Evaluating Strategic Alternatives

Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit. - 05/23/2023

Wellness Co.'s Q1/23 Results Better Than Expected

Results for the first quarter of this year for Ayr Wellness Inc. were better than expected, reported an Echelon Capital Markets research note. - 05/19/2023

Telehealth Co. Signs Contract With US Health Plan Serving 1 Million Patients

Telehealth company Reliq Health Technologies signs a contract with a U.S. health plan that operates in five states with over 3,000 doctors and more than 1 million patients. - 05/18/2023

Biopharma Co. Ceases Program to Optimize Resources

This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report. - 05/16/2023

Digital Health Co. Grows Revenue and Reduces Expenses

This Canadian healthcare tech company is showing projected returns of over 241% for investors, noted an Echelon Capital Markets research note. - 05/10/2023

Telehealth Co. Expands into Arkansas

Telehealth company Reliq Health Technologies signs five new contracts in four states for its iUGO platform, including its first contract in the state of Arkansas, where chronic diseases cost billions annually. - 05/05/2023

Pharmaceutical Company Sets Gold Standard for New Drugs

Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history. - 04/26/2023

Adding Silver a Solid Move

Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market. - 04/24/2023

As Countries Bolster Defense, Opportunities Emerge

Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability. - 04/21/2023

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial

Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill. - 04/19/2023

Co.'s New Cell Therapy Shows Positive Effects

Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report. - 04/19/2023

Blockchain Co., Vets Group Team Up for App

A Vancouver blockchain company is partnering with a leading veterans advocacy group to launch a medical cannabis education and reward application for vets. - 04/19/2023

Oncology Co. Receives Buy Rating for New Drug Trials

A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report. - 04/18/2023

Biotech Rated Outperform Advances Top Drug Candidate

The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report. - 04/18/2023

Trial Results of New Pneumococcal Vaccine Compelling

Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report. - 04/18/2023

Follow-up Results From T2 Diabetes Trial Positive

One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report. - 04/14/2023

CEO: Telehealth Co. in 'More Comfortable Cash Position'

Telehealth company Reliq Health Technologies Inc. expects to be profitable for the quarter ending in June and initiate a share buyback program this year, its CEO told shareholders this week. - 04/14/2023

Biotech Co. Set To Reach New Highs

Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics. - 04/13/2023

Phase 3 Trial in Progress of New Ichthyosis Treatment

Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report. - 04/12/2023

Biopharma Co. Appoints Industry Experts in Key Positions

Recently, Appili Therapeutics Inc. (APLI.TSX) appointed a new director of non-clinical research and director of new product development. Read to see who these people are, what upcoming catalysts there are for the company, and what experts are saying. - 04/11/2023

Phase 2b Trial of New Drug for Ovarian Cancer Starts

The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report. - 04/11/2023

Safety Data From One Trial of New Drug Helpful to Another

The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report. - 04/05/2023

Biotech Co. Will 'Not Look Back' From Here

In light of its recent development of a product that purportedly has the ability to reset damaged DNA, technical analyst Clive Maund takes a look at Resverlogix Corp. - 04/05/2023

Firm Grows Revenue 38% in Q4/22

The company's material increase in profitability during the quarter is a healthy step toward reaching free cash flow break even status, noted an Echelon Capital Markets report. - 04/04/2023

Target Price on Texas-Based Drug Co. Implies 1,929% ROI

This biopharma expects two major catalysts, in the form of Phase 2 clinical trial data readouts, this year, noted a ROTH Capital Partners report. - 04/04/2023

Resverlogix Testing Cure for Covid, the Terrible Spike Protein and Heart Issues

In light of Resverlogix Corp.'s testing of a cure for long Covid, Bob Moriarty of 321gold.com reviews the company to tell you why he believes it may be a Buy. - 04/03/2023

New Treatment for Ovarian Cancer Shows Promise

Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report. - 03/30/2023

Telehealth Co. Signs Largest Client Yet

Onboarding will begin in April for the healthcare system that has more than 1,200 care centers in seven states. - 03/30/2023

Coverage Launched on Drug Co. With 140% Upside

The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report. - 03/29/2023

Trial of New Ophthalmic Drug Now Enrolled

More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report. - 03/29/2023

FDA Approval of New Gout Drug Likely, Analyst Says

Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report. - 03/27/2023

Biotech Improves Efficiency of Its New Immunotherapy

The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report. - 03/22/2023

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board

Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody. - 03/21/2023

Coverage Launched on Canadian Specialty Pharma Co.

This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report. - 03/15/2023

Telemedicine Co. Sees Record Revenues on Software, Services Sales

Reliq Health Technologies Inc. reports that software and services revenue continues to increase, leading to record cash intake for the quarter that ended Dec. 31, 2022. - 03/13/2023

Blockchain Co. Launches Digital Coupon Consumer App

Global Compliance Applications Corp. is launching a new app that will enable consumers to receive and share digital token coupons and store them in digital wallets. - 03/08/2023

New Skin Gene Therapy Gets PDUFA Date

The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report. - 03/01/2023

Novel Therapy Corp Captures More of US Licensing Market, First EU Segment

White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream. - 02/28/2023

AI-Infused Telehealth Platform Absorbs New Patients

Telemedicine company Reliq Health Technologies Inc., which uses artificial intelligence in its software's algorithms, has gained six new contracts and more than 3,000 new patients. - 02/22/2023

Biotech Co. Initiates Feasibility Study

This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn.  - 02/09/2023

Addiction Therapy Company Secures Major UK Endorsement

Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region. - 02/07/2023

New Drug for Hearing Loss Approved for Clinical Trials

Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report. - 01/30/2023

Biopharma Gains Another Shot on Goal With IND Approval

The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report. - 01/26/2023

Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus

Streetwise Reports sat down with Øyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus. - 01/25/2023

Med Tech Co. Well-Poised for Revenue Growth This Year

New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report. - 01/25/2023

Biopharma Creating COVID Drug Gets US$8.2M From the DOD

This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report. - 01/24/2023

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment

Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company. - 01/24/2023

Exploring Why The Economist Named this Biotech 'One To watch' in 2023

As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023. - 01/23/2023

Telehealth Co. Expects More Growth in 2023

Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program. - 01/20/2023

Biopharma Co.'s Burn Tissue Removal Product Approved

Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report. - 01/04/2023

Which Precious Metal Has Chen Excited for 2023?

It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year? - 12/28/2022

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio

Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company. - 12/28/2022

Target Price Boosted 400% on Biopharma Co.

The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report. - 12/27/2022

Biotech at Good Entry Point for Investors, Analyst Says

The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report. - 12/20/2022

Data on New Cell Therapy for LBCL Encouraging, Analyst Says

The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report. - 12/16/2022

Why One Fund Owns 13% of This Small-Cap Pharma

Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease. - 12/12/2022

Biotech Co. Signs US$735M Deal

Entrada Therapeutics Inc. shares traded 18.5% higher yesterday after the company reported it entered a global development collaboration with Vertex Pharmaceuticals Inc. to develop cutting-edge intracellular Endosomal Escape Vehicle (EEV™) therapeutics for use in treating myotonic dystrophy type 1. - 12/09/2022

Biopharma Co.'s Shares Triple in Value on US$5B License Deal

Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-license agreement with Akeso Inc. for its breakthrough bispecific antibody ivonescimab, which combines a blockade of PD-1 with an anti-VEGF into a single molecule designed to target cancer. Summit has agreed to pay Akeso an upfront payment of US$500 million, which it plans to finance via an equity rights issuance. - 12/07/2022

Biotech Co.'s Shares Soar to New 52-Week High

Prometheus Biosciences Inc. shares traded 170% higher to a new 52-week intraday high after the company reported positive results from two separate Phase 2 clinical studies for its PRA023, an anti-TL1A mAb used to treat inflammatory bowel disease. The company is actively planning to advance PRA023 into Phase 3 trials as a prospective treatment for ulcerative colitis and Crohn's disease in FY/23. - 12/07/2022

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial

Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline. - 12/05/2022

Target Price Boosted on Canadian Pharma Co.

This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report. - 11/30/2022

Biopharma Co. Now at a Bargain Price, Analyst Says

Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report. - 11/29/2022

Major Contract and Faster Commercialization for Chemicals Co.

Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile. - 11/29/2022

Expert Says Health Tech Co. Still in Good Spot To Buy

Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy. - 11/28/2022

Biopharma Co. Trades to New 52-Week High

Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial. - 11/28/2022

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection. - 11/23/2022

Life Sciences Co. Exceeds Expectations in Q3/22

During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report. - 11/22/2022

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report. - 11/22/2022

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share. - 11/22/2022

Blockchain Co. Signs Agreement With Insurance Co.

Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry. - 11/22/2022

FDA Awards Breakthrough Therapy Status for AMD Drug

Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration. - 11/21/2022

Pharma Co. Won't See Bump in Sales From New COVID Drug

The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report. - 11/18/2022

Biopharma Co. Hopes To Turn US$30M Into US$2B

CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types. - 11/17/2022

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration. - 11/16/2022

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon. - 11/14/2022

UK Co. Buys NARCAN® Nasal Spray Maker

Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met. - 11/14/2022

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts. - 11/11/2022

Biologics Co. Doubles Revenue in Q3/22

ADMA Biologics Inc. shares traded 27.5% higher yesterday after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million. - 11/11/2022

Pharma Co. Trades 200% Higher

Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma. - 11/10/2022

Medical Device Co.'s Q2/22 Results Better Than Expected

Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report. - 11/09/2022

Nine Stocks Expert Says Should Pique Your Interest

Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on. - 11/09/2022

Clean Nuclear Med Tech With Quantum Blue Sky

With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention. - 11/09/2022

Healthcare Firm Offers US$295M for Ophthalmology Co.

Shares of Oyster Point Pharma Inc. traded 38.5% higher yesterday after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share. - 11/08/2022

Pharma Co. Signs Global License Deal for Eye Drops

Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances. - 11/08/2022

Organ Transplant Co.'s Q3 Revenues Rise 378%

Shares of medical technology firm TransMedics Group Inc. traded 24% higher to a new 52-week high after the company reported Q3/22 financial results highlighting a 378% YoY increase in net revenue and raised its FY/22 revenue estimates to US$80-85 million. - 11/04/2022

Telemedicine Co. Surges on Revenue News

As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar. - 11/04/2022

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines

Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide. - 11/03/2022

Pharma Co. Earns Big Rewards from Global License Deal

Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue. - 11/02/2022

Biopharma Co. Trades 39% Higher

Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant. - 11/01/2022

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report. - 10/31/2022

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial

Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer. - 10/28/2022

Potential ROI With German Biopharma Co. Notable

This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report. - 10/27/2022

CRO Firm's Shares Rise on Q3 Earnings and Growth Prospects

Shares of full-service clinical contract research organization Medpace Holdings Inc. traded 37% higher yesterday after the company reported Q3/22 financial results that included a nearly 30% YoY increase in revenue. - 10/26/2022

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results

Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age. - 10/25/2022

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'

Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock. - 10/25/2022

Biopharma Co. Shows Large Potential Return

Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report. - 10/21/2022

Robotic Surgical Device Co.'s Shares Rise on Q3 Earnings

Shares of Intuitive Surgical Inc. traded 9% higher yesterday after the robotic surgical device maker reported Q3/22 earnings that included an 11% YoY increase in revenue and a 13% YoY increase in its installed da Vinci Surgical System base. - 10/20/2022

Companies Use Blockchain To Connect Hemp Growers, Consumers

Industrial hemp is legal in all 50 states, and companies are working to get CBD, insulation, textiles, and biofuel made from it to the masses. These three companies hope their partnership will help connect the growers and buyers. - 10/19/2022

Biotech Co.'s Target Price Over Three Times Current

Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current. - 10/13/2022

Biopharma Co. Partners With Merck for Combo Drug Trial

With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report. - 10/12/2022

Biopharma Co.'s Shares Roll to New 52-Week High Price

Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study. - 10/12/2022

Chen Reveals His Picks for Last Quarter

Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies. - 10/11/2022

US Firm Teams up With Leading Pharma Co. To Delay T1D Onset

Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022. - 10/07/2022

Biopharma Target Price 10 Times Current

Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current. - 10/06/2022

Biotech Co.'s Drug Showing 'Early Signs of Benefit'

With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report. - 10/06/2022

Trial Results of New Drug for An Eye Disease 'Encouraging'

The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report. - 10/06/2022

Co. Uses RNA Editing as Treatment for Rare Disease

The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report. - 10/03/2022

Interim Results From Phase 2b Trial Are 'Encouraging'

Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report. - 09/30/2022

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial

Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22. - 09/30/2022

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial

Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease. - 09/29/2022

Biopharma Asks for Emergent Use in US of New COVID Drug

The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report. - 09/29/2022

Oncology Co.'s Shares Erupt on Signing Global License Deal

Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors. - 09/27/2022

Opportunity for Investors Found in Psychedelics Space

Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report. - 09/27/2022

US Biotech Firm Keeps Growing Revenue

Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report. - 09/26/2022

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report. - 09/23/2022

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Argenx SE has "several upcoming catalysts," noted a Wedbush report. - 09/23/2022

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World

The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc. - 09/21/2022

FDA Approves Hearing Loss Drug for Child Chemo Patients

Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors. - 09/21/2022

Dermatology Co.'s Target Price Much Higher Than Current

The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report. - 09/20/2022

Important Catalyst Expected Soon for Cancer Drug Co.

The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report. - 09/20/2022

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data

Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23. - 09/20/2022

Second Trial of New Eczema Drug To Commence in Q4/22

The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report. - 09/17/2022

FDA Grants Approval for Drug Improving Kidney Function

Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function. - 09/16/2022

Price Target on US Biopharma Co. Boosted by $15

The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report. - 09/15/2022

New Drug Shown To Help Patients With Desmoid Tumors

This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report. - 09/15/2022

NDA for Dry Eye Disease Drug on Track for Q4/22 Submission

This and the biopharma's other treatment candidates for ocular diseases are underappreciated, which translates to an investment opportunity, noted an Oppenheimer report. - 09/15/2022

Several Trials of Co.'s Fluid Pump To Read Out This Year

Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report. - 09/14/2022

Co. Advancing Drug Class With Broad Potential

This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report. - 09/13/2022

Biotech Co.'s Target Six Times Current Price

One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price. - 09/13/2022

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive. - 09/13/2022

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run. - 09/12/2022

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report. - 09/12/2022

US Co. To Regain All Rights to Its AGHD Diagnostic Test

This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report. - 09/08/2022

Medtech Co. Meets Primary Endpoints in Ph. 3 Glaucoma Trials

Glaukos Corp.'s shares traded 18% higher yesterday after the company reported that in two separate Phase 3 trials, its iDose TR met its primary efficacy endpoints by lowering intraocular pressure in glaucoma patients. - 09/08/2022

Biopharma Co. Receives Approval From FDA Panel for ALS Drug

Amylyx Pharmaceuticals Inc.'s shares traded 51% higher after the company reported that a U.S. FDA advisory committee has voted to support approval of the firm's AMX0035 for use in treating amyotrophic lateral sclerosis. Although the committee's recommendation is not binding, it is expected that the decision will provide staunch support for approval of the firm's pending NDA for AMX0035, which has a target action date of September 29, 2022. - 09/08/2022

Biopharma Co. Transforming Injected Drugs Into Pills

This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it. - 09/07/2022

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling

Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen. - 09/07/2022

Two Talks On New Cancer Drug Slated for Meeting This Week

The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report. - 09/06/2022

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?

One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August. - 09/04/2022

Denmark Co. To Buy US Biopharma Co. for $1.1 Billion

Forma Therapeutics Holdings Inc. shares traded 51% higher yesterday after the company reported it agreed to be acquired by Denmark's Novo Nordisk A/S in an all-cash deal for $20.00 per share. With the acquisition, Novo Nordisk aims to expand its global presence in the treatment of rare blood disorders and sickle cell disease. - 09/02/2022

Expert Rates Pharma Co. An Immediate Buy

Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough. - 09/01/2022

FDA OKs Biopharma to Trial New Cell Therapy

Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report. - 08/30/2022

Pharma Co. Plans IND Filing for Dry Eye Disease Drug in Q4/22

Shares of OKYO Pharma Ltd. traded 23% higher after the company reported it intends to submit an IND to the U.S. FDA for its OK-101 for treating dry eye disease in Q4/22. Together with its manufacturing partner, AmbioPharm Inc., the firm is now preparing to initiate a phase 2 clinical study in Q1/23. - 08/30/2022

Delay in New Drug Filing Now Could Yield Benefits Later

The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report. - 08/29/2022

ACC Recommends Approved Drug for Lowering LDL

This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report. - 08/29/2022

Pharma Co. To Provide HHS With Smallpox Drug

Chimerix Inc. shares traded 8% higher after the company reported it has entered into a 10-year, $680 million contract with a U.S. Government health agency to deliver up to 1.7 million treatment courses of its TEMBEXA for use as a medical countermeasure for smallpox. - 08/29/2022

Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula

A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price. - 08/26/2022

First Data Due by Year End 2022 From Study of New HAE Drug

Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report. - 08/24/2022

New Schizophrenia Drug Has Chance of Getting FDA Approved

The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report. - 08/24/2022

Hedge Fund Doubles Position in Biotech Co.

A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement. - 08/23/2022

Expert Sees Even More 'Good News' From Pharma Co.

Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing. - 08/23/2022

Biotech Co. Has Multiple Shots on Goal

This developer of immunotherapies has a robust pipeline, several active clinical programs and, thus, numerous catalysts, noted an Oppenheimer report. - 08/22/2022

Price Target on Cancer Drug Co. Boosted

The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report. - 08/22/2022

Drug Developer Initiates Ph. 3 STGD1 Trial

Shares of Belite Bio Inc. traded 19% higher after the company reported it has initiated a pivotal Phase 3 clinical study in the U.S. for its LBS-008 for use in treating Stargardt disease. - 08/22/2022

Biopharma Co. Gains FDA Approval for Oral MDD Drug

Shares of Axsome Therapeutics Inc. traded 39% higher after the company reported that the U.S. FDA granted approval for its AUVELITY™ making it the first oral N-methyl D-aspartate (NMDA) receptor antagonist authorized for treating major depressive disorder in adults. - 08/19/2022

Healthcare Co. Brings Treatment to Canadian Alcohol Addiction Market

One healthcare company in the U.K. is bringing its proprietary Ketamine-assisted treatment for Alcohol Use Disorder to Canada. It's the second deal the company has made with a North American clinic operator this week. Find out why this won't be the last one. - 08/18/2022

Biotech Co. To Receive 66% Funding From UK Gov.

Expert Clive Maund reviews the latest update with Awakn Life Sciences Corp., including its recent rise in stock volume and the announcement that the company is to receive 66% funding support from the UK government for the development of its ketamine-assisted therapy treatment for alcohol use disorders. - 08/17/2022

Life Sciences Co. Gets Big Order for Livestock Feed Additive

This sale indicates the firm is continuing to forge a pathway into one of its large target markets, noted a Noble Capital Markets report. - 08/16/2022

Co. Pursuing Ketamine for Addiction Forms Partnership

In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report. - 08/16/2022

Co. Provides Ground-Floor Opportunity in Precision Oncology

Nuvectis Pharma Inc recently announced quarterly financial results and is continuing to advance its precision oncology programs. H.C. Wainwright & Co. LLC advised in an earnings update that the firm offers significant upside potential as it is rapidly advancing its drug candidates through clinical development and is looking for ways to expand to markets outside of the U.S. H.C. Wainwright stated that it is reiterating its Buy rating and $21 price target for Nuvectis Pharma. - 08/15/2022

HSCT/Gene Therapy Co. Sees Many Positive Catalysts in Q422

Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics. - 08/15/2022

Biotech Co. Nearing Milestones for HBV Drugs

Arbutus Biopharma Corp. presented clinical data to an international liver disease conference showing that its AB-729 continues to deliver strong reductions in HBsAg. The company is now conducting three separate combination therapy studies of its AB-729 and expects to achieve important milestones when the initial data readouts are released in H2/22. H.C. Wainwright & Co. affirmed its Buy rating for Arbutus Biopharma and adjusted its price target to $7.50. - 08/15/2022

Healthcare Co. Enters US Alcohol Addiction Treatment Market

One analyst says this healthcare co. has the opportunity to generate attractive CAPEX-light, high margin SaaS-like recurring revenues, which investors are currently getting for free, after the biotech firm entered the US market for alcohol addiction treatment through off-label licensing deals with a network of treatment clinics. - 08/15/2022

Expert Expects Life Science Co. To Do Exceptionally Well

Avivagen is an early-stage life sciences company with a patented product for immune support that causes dramatic and profitable improvements in livestock. They have been increasing their sales and market penetration at a dramatic rate, and I believe them to be at an inflection point. Research coverage is expecting a 7x return. - 08/15/2022

Firm Sees Boost in Sales of Health Chewable for Dogs

Recent orders from Avivagen Inc. are helping the developer of this product build a recurring revenue stream, noted a Noble Capital Markets report. - 08/15/2022

Diagnostics Co. Secures Global Deal for Resistant Bacteria ID Kit

Accelerate Diagnostics Inc. shares traded 25% higher after the company reported Q2/22 earnings and announced it entered into a commercial agreement with Becton, Dickinson and Co. that will allow it to deliver rapid antimicrobial identification and susceptibility diagnostics to clinicians and patients worldwide. - 08/15/2022

Feedstock Additive Co. Gets Massive Order for Brazil Market

The widespread use of antibiotics in animal feeds, as well as over-prescription by physicians for therapeutic treatment of human infections, is leading to a growing resistance to antibiotics that is killing close to 1 million people each year. One company believes it has developed at least part of the solution through a beta carotene food additive that boosts immunity and contributes to better overall health. - 08/11/2022

Testing Confirms Drug Candidate Differs From Peers

Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report. - 08/10/2022

Demand for Co.’s Antibiotic Free Animal Feed Is Raising

With consumers moving away from artificial meat products and other preservatives, Avivagen Inc.'s antibiotic free animal feed seems to be just what they're looking for. With orders coming in and demand raising, expert Clive Maund shares his view on the potential of this life science company. - 08/10/2022

Pharma Co. Achieves Record Sales of LEMS Drug in Q2

Shares of Catalyst Pharmaceuticals Inc. traded 24% higher to a new 52-week high after the company reported that in Q2/22 net product revenues from sales of its FIRDAPSE® increased 57.7% YoY to $53.0 million. FIRDAPSE® has been approved by both the U.S. FDA and Health Canada as a treatment for adult patients with Lambert-Eaton myasthenic syndrome, a rare autoimmune disease in which a person's immune system attacks its body's own tissues at the neuromuscular junction. - 08/10/2022

Cardiovascular Device Co. On Pace to Double Revenue in FY22

Shares of Shockwave Medical Inc. traded 17% higher to a new 52-week high after the company advised that it posted a 116% YoY increase in revenue during Q2/22 and raised the midpoint for its FY/22 revenue guidance by $25 million to $465-475 million. - 08/09/2022

Biotech Co. Awakes To Good News

Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development. - 08/06/2022

Biopharma Co. Planning BLA for DMD Drug

Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares. - 08/05/2022

SRT Device Maker's Revenues Rise 124% in Q2

Sensus Healthcare Inc.'s shares traded 30% higher after the company reported it achieved a 124% YoY increase in revenue in Q2/22. The company advised that demand continues to remain strong for its superficial radiation therapy (SRT) devices which provide minimally invasive and non-surgical alternatives for non-melanoma skin cancer & keloid removal. - 08/05/2022

Environmental Tech Co. Builds up to a Major Bull Market

After a few weeks of observation, expert Clive Maund believes Bion Environmental Technologies Inc. may be due for a major uptrend and is building up to a major bull market. - 08/04/2022

Ins. Provider to Offer Med Tech Co.'s CGM to its 45M Members

Shares of Senseonics Holdings Inc. traded 31.5% higher yesterday after the company reported that Elevance Health (formerly Anthem) has approved coverage of its Eversense® E3 implantable continuous glucose monitor to its forty-five million covered members. - 08/04/2022

ChemoCentryx Shares Double on $4B Cash Bid from Amgen

Shares of ChemoCentryx Inc. traded 110% higher after the company reported it agreed to be acquired by Amgen Inc. for $52.00 per share in an all-cash deal valued at $4 billion. With the purchase, Amgen aims to cement its leadership position in inflammation and nephrology with the addition of ChemoCentryx's TAVNEOS® (avacopan) which the U.S. FDA approved late last year to treat ANCA-associated vasculitis, a serious autoimmune disease. - 08/04/2022

MRI Device Maker's Earnings Come In at High End of Forecasts

IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40). - 08/03/2022

Expert Says Biotech Co. Is a ‘Strong Buy’ After Phase 2 Study

Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil. - 08/02/2022

Expert Believes Health Co. Blooms With Opportunity

Expert Clive Maund touches on the latest news with Bloom Health Partners Inc. from the enthusiastic buying toward the end of June to whether he believes the health company is still bullish. - 08/02/2022

Tech Co. ‘Right at the Point of Breakout'

BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news. - 08/02/2022

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment

After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company. - 08/01/2022

Drug Candidate Repairs Motor/Sensory Function in Stroke

Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair to damage from ischemic stroke seven days following the event. - 07/29/2022

Additional Study Review Reveals Patients Coughed Much Less

A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought. - 07/28/2022

Biotech Co. Granted New Patent for Breast Cancer Vaccine

Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa. - 07/27/2022

Biopharma Co. Signs Exclusive License Deal for Ricin Antigen

Shares of Soligenix Inc. traded 8% higher after the company reported it formed a strategic global partnership to supply SERB Pharmaceuticals with its novel ricin antigen for use in developing a therapeutic treatment against ricin poisoning. - 07/27/2022

Biomedical Firms Merger Makes Programming Cells Easier

Shares of Zymergen Inc. traded 16% higher after the company reported it agreed to be acquired by Ginkgo Bioworks Inc. in an all-stock transaction valued at $300 million. - 07/26/2022

Cancer Co.'s Price Target Adjusted After Reverse Stock Split

Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share. - 07/25/2022

Radiotherapy Co. On-Track With Two Clinical Trials

Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22. - 07/24/2022

Pro Athlete Benefits From Co.'s Wound Treatment Device

Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system. - 07/22/2022

Medical Device Firm Maintains Growth Momentum in Q2/22

electroCore Inc.'s Q2/22 and H1/22 revenues are up quarter over quarter and year over year, respectively, and the upward trend is expected to continue through year-end 2022, noted an H.C. Wainwright & Co. report. - 07/21/2022

Amazon Makes $3.9B Bid for Virtual Primary Care Co.

Shares of One Medical traded nearly 70% higher after the company reported it agreed to be acquired by Amazon Inc. for $18.00 per share in an all-cash deal valued at $3.9 billion. - 07/21/2022

Biotech Co.'s Phase 3 Trial First to Get Grant

A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat alcohol use disorder. It could be a catalyst for the share price. - 07/20/2022

Drug Repurposing Co. Provides Opportunity for High Rewards

Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company. - 07/20/2022

Trial Results Show New Drug Improves Dry Eye Symptoms

These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an H.C. Wainwright & Co. report. - 07/19/2022

Biopharma Co. Looks to Expand New Drug Label Down the Road

ScPharmaceuticals Inc. just released topline results from a Phase 2 pilot study supporting the drug developer that is pursuing the expansion of its new drug label, noted an H.C. Wainwright & Co. report. - 07/18/2022

Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’

Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with alcohol use disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD. - 07/15/2022

Pharma Co. Reduces Mortality Rates by 70% in ALS Trial

Shares of Clene Inc. traded 38% higher yesterday after the company reported that its CNM-Au8 was shown to significantly decrease mortality in its RESCUE-ALS long-term extension trial. - 07/15/2022

Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry

One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report. - 07/14/2022

Biopharma Co. Posts 17% BMI Reduction in Ph. 2 Trial

Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its Phase 2 clinical study of setmelanotide in hypothalamic obesity. The data shows that after 16 weeks of treatment with setmelanotide, patients experienced a 17.2% mean reduction in BMI and a mean weight loss of 15.8%. - 07/14/2022

Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.

One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments. - 07/13/2022

Three Analysts Like Healthcare Co.'s Upside

It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care. - 07/11/2022

Pharma Looks To Improve Potential Psychedelic Stroke Drug

Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September. - 07/11/2022

New Drug Is Shown to Help Stopped or Reduced Bile Flow

Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report. - 07/10/2022

New DMD Drug Yields 'Compelling' Data

A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report. - 07/09/2022

Amended Agreement to Benefit Two Biotech Firms

In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report. - 07/08/2022

Co. Makes Financing Deals Around Two of Its Approved Drugs

The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report. - 07/07/2022

Strong Data Suggest FDA Will Approve New Lymphoma Drug

A green light is expected for the treatment after its developers submit a biologics license application for it, planned for H2/22, noted an H.C. Wainwright & Co. report. - 07/06/2022

The FDA Is Expected to Approve New Narcolepsy Drug

Avadel Pharmaceuticals Plc., the biopharma company behind this treatment, is currently undervalued and rated Outperform, noted an Oppenheimer report. - 07/05/2022

Laser Device Co. Gains FDA Approval for Next-Gen Catheter

Ra Medical Systems Inc. shares traded 36% higher after the firm reported it received U.S. FDA 510(k) clearance for its DABRA 2.0 Catheter. The DABRA 2.0 is incorporated into the company's DABRA Excimer Laser System which is used by vascular surgeons in procedures to treat lower extremity and peripheral vascular disease. - 07/05/2022

Trial of New Alzheimer's Drug Slated for Early 2023

The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report. - 07/01/2022

MedTech Co.'s Shares Maneuver Higher on Q1 Revenue Growth

Shares of personalized, member-focused healthcare solutions company Accolade Inc. traded 29% higher after the company reported financial results for Q1/23 highlighting a 44% YoY increase in revenue and significant improvements in adjusted gross margin. - 07/01/2022

Chen's Top Picks for Q3

Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter. - 06/30/2022

BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt.

Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses. - 06/30/2022

New Alzheimer's Drug Shows Promise as Monotherapy

Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report. - 06/29/2022

Dental & Animal Health Supplier Posts 10% Yearly Sales Gains

Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins. - 06/29/2022

Small Cap Joins With Japan Pharma to Advance Next Generation Cancer Treatment

Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates. - 06/28/2022

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report. - 06/27/2022

Approval Likely of New Gel for Skin Condition, Analyst Says

The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report. - 06/27/2022

EU Biopharma Co. Makes $247M Bid for US Oncology Co.

Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share. - 06/27/2022

Gene Therapy Co. Releases Data From Huntington's Study

Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial. - 06/23/2022

PE Firm to Take Health Tech Co. Private in $1.1B Deal

Shares of healthcare technology and services firm Convey Health Solutions Holdings Inc. traded 138% higher after the company reported it received a proposal from majority shareholder TPG Inc. to take the company private. TPG has offered to buy all outstanding shares in Convey that it does not already own for $10.50 per share in cash. - 06/22/2022

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial

Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial. - 06/22/2022

Results of Dermatitis Clinical Trial Due This Summer

Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report. - 06/21/2022

New Positive Data Seem to Support Drug Label Expansion

Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report. - 06/21/2022

New Drug for Heart Failure on Path to Approval, Analyst Says

The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report. - 06/20/2022

NFL Player Teams With Biopharma Co. to Help SCD Patients

Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease. - 06/17/2022

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report. - 06/16/2022

Biotech Co. Advances 3 New Clinical Stage Assets

Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report. - 06/16/2022

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22

These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research. - 06/14/2022

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results

Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps. - 06/13/2022

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models. - 06/10/2022

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition. - 06/10/2022

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results

Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder. - 06/10/2022

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report. - 06/09/2022

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success

After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough. - 06/08/2022

Biopharma Co. Meets Primary Endpoints in ARDS Trial

MediciNova Inc. shares traded 9% higher after the company released top-line data from its Phase 2 study of MN-166 (ibudilast) in hospitalized COVID-19 patients deemed to be at elevated risk for acute respiratory distress syndrome. In the study, MN-166 demonstrated significant decreases in respiratory failure. - 06/08/2022

FDA Approves Co.'s New Medical Grade Air Hygiene Device

Shares of AeroClean Technologies Inc. traded 150% higher after the company reported it received 510k clearance from the U.S. FDA for its Pūrgo™ medical-grade indoor air purification technology that uses UV-C LEDs to eradicate airborne bacteria, fungi, and viruses, including COVID-19. - 06/07/2022

Approved Drug Shows Promise in Follicular Lymphoma

Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report. - 06/06/2022

FDA Approval of Drug Could Be on the Way

"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection. - 06/03/2022

Bristol Myers to Buy Precision Oncology Co.

Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share. - 06/03/2022

Precision Oncology Co. Signs $1.325B Licensing Deal

Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved. - 06/02/2022

Important Data for COVID Drug Candidate Due This Month

The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report. - 06/02/2022

Monkeypox Virus Test Could Yield Revenue for Its Creator

The Utah-based diagnostics firm has multiple shots on goal with this specific molecular test and with its convenient, fast testing platform, both in development, noted an H.C. Wainwright & Co. report. - 05/31/2022

Cancer Patients Have Partial Response With Drug

The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report. - 05/28/2022

Cancer Targeting Drug Better Tolerated Than Others

A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report. - 05/27/2022

50% Revenue Growth Expected This Year for Biopharma Co.

The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report. - 05/26/2022

Trial Shows Colon Cleansing Device to Be Effective

"The positive results could drive physician adoption when scheduling colonoscopies for hard-to-prepare patients going forward," noted an H.C. Wainwright & Co. report. - 05/26/2022

FDA Approves New Skin Resurfacing Device

Apyx Medical Corp. shares traded 50% higher after the company reported it received U.S. FDA 510(k) clearance for its Renuvion Dermal Handpiece for use in specific cosmetic dermal resurfacing procedures. - 05/26/2022

Target Price on Drug Co. Suggests Possible Huge Returns

Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report. - 05/25/2022

US Biopharma Co. Chooses One Endpoint for Phase 3 Trial

With this strategic decision, the company hopes to increase the chances its dry eye disease drug gets greenlighted, noted a BTIG report. - 05/24/2022

Cannabis Firm Posts Improved Q2 FY22 YOY

Compared to the previous year, the company's overall operating results for the quarter are better, noted a Noble Capital Markets report. - 05/23/2022

Innoviva Buys Remaining Shares in Advanced Antibiotic Co.

Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share. - 05/23/2022

H2/22 Slated to Be Catalyst Rich for Pharma Co.

Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs. - 05/21/2022

US Pharma Co. Granted FDA Approval for IV Smallpox Drug

SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox. - 05/20/2022

New Improved Drug Expected to Get FDA Approval Next Month

Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock. - 05/20/2022

Firm Reports Encouraging Trial Results in Cystinosis

New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc. - 05/19/2022

EU Co. Secures Smallpox Vaccine Order to Target Monkeypox

Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox. - 05/19/2022

Coverage Launched on Co. in Alzheimer's Drug Space

This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report. - 05/17/2022

Clinical Catalysts for Biotech's Stock On Track for Mid 2022

Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report. - 05/15/2022

Biopharma Co. to Launch Two Clinical Trials This Year

Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report. - 05/14/2022

Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm

Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development, and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer. - 05/13/2022

First Results From Biotech Co.'s Lymphoma Program Are Impressive

This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report. - 05/13/2022

Pfizer Offers $11.6B to Buy Biopharma Co.

Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities. - 05/10/2022

Ophthalmic Med Tech. Firm Sees 166% Gain in LAL Implants

Shares of RxSight Inc. traded 7% higher after the company reported Q1/22 financial results which highlighted a 157% YoY increase in revenue and a 208% increase in unit sales of its Light Delivery Devices (LDD™s) utilized in cataract surgery procedures to implant its RxSight Light Adjustable Lens® (LAL), which it says is "the world's first and only adjustable intraocular lens (IOL) that is customized after cataract surgery." - 05/06/2022

Analyst Says Avivagen Is a Strong Buy

With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy. - 05/05/2022

Biopharma Co. Licenses Orphan Drug to UK Firm for $450M

Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver. - 05/05/2022

Pilot Launch of VLN Cigarettes in Progress

These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report. - 05/03/2022

FDA Expands Use for Transcarotid Stent

Silk Road Medical Inc. shares traded 12% higher after the company reported that the U.S. FDA granted expanded authorization for its ENROUTE® transcarotid stent system for use in preventing stroke in patients deemed to be at standard risk for adverse events from carotid endarterectomy. - 05/02/2022

Biotech Co. Advances COVID-19 Vaccines Toward Approval

They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report. - 05/01/2022

Is Reliq Health Technologies a Nutrimental 'Buy'?

After recovering from a short "character assassination," Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good 'buy'. - 04/29/2022

Could a New Prescription Drug Treat This Common Ailment?

The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report. - 04/27/2022

Biopharma Co. Posts 32% YoY Gain in Proprietary Sales

Alkermes Plc. shares traded 12% higher after the Ireland-based company reported Q1/22 financial results and reiterated its FY/22 business outlook. - 04/27/2022

Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials

Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies. - 04/25/2022

FDA Grants RMAT Status for T-Cell Therapy for Six Viruses

Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients. - 04/20/2022

Senior Biotech Analyst's Top 3 Stocks

Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies that are addressing as-of-yet unmet market needs. - 04/19/2022

Biotech Co.'s Shares Quadruple on $250M Buyout Bid

Shares of Checkmate Pharmaceuticals Inc. traded 330% higher to a new 52-week high after the company reported it agreed to be acquired by Regeneron Pharmaceuticals Inc. for $10.50 per share in cash. - 04/19/2022

Life Sciences Co. Expected to Attract Partners, Big Pharma

"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company tackling neurodegenerative diseases. - 04/19/2022

EU PE Firm Makes $1.2B Bid for US Medical Device Co.

Shares of Natus Medical Inc. traded 29% higher after the company reported it agreed to be acquired by ArchiMed Group, a France-based private equity firm, for $33.50 per share in cash. - 04/18/2022

Vaccine Maker Awarded Approval for COVID-19 Vaccine

Shares of Valneva SE traded 8.5% higher after the company reported that the U.K.'s MHRA has granted Conditional Marketing Authorization for its inactivated whole-virus COVID-19 vaccine candidate called VLA2001 for primary immunization in adults between 18 and 50 years old. - 04/14/2022

GSK Offers $1.9B for Cancer-Focused Pharma Co.

Shares of Sierra Oncology Inc. traded 38% higher after the company reported it agreed to be acquired by GlaxoSmithKline Plc. for $55 per share in cash. - 04/13/2022

Cannabis Firm Increases YOY Revenue By 352% in 2021

The company is expected to outperform again in 2022 given its focus on strategic growth and acquisitions, noted a Noble Capital Markets report. - 04/12/2022

Biopharma Firm Signs $452M License Deal for BMT Drug

Shares of Actinium Pharmaceuticals Inc. traded 24% higher after the company reported it entered into a licensing and supply agreement for its antibody radiation conjugate, Iomab-B, with Sweden's Immedica Pharma AB for sales in Europe, the Middle East and North Africa. - 04/12/2022

Novel Drug Reduces COVID-19 Deaths by 55% in Ph. 3 Trial

Shares of Veru Inc. traded 180% higher after company reported interim data from a Phase 3 clinical study of its COVID-19 drug candidate sabizabulin which was shown to reduce deaths in hospitalized patients by 55%. - 04/11/2022

Co. Uses Protein Modulation to Treat Cancer

Nurix Therapeutics Inc. shares traded 13% higher after the company reported Q1/22 financial results and released an outline for two poster presentations that will be submitted at the American Association for Cancer Research Annual Meeting this weekend. - 04/09/2022

Surgical Device Maker's Shares Rise 7% on Q3 Earnings

Shares of AngioDynamics Inc. traded higher after the company reported Q3/22 financial results highlighting a 28.6% YoY increase in net Med Tech sales. - 04/07/2022

FDA Approves Bipolar and Schizophrenia Drug

BioXcel Therapeutics Inc. reported that the U.S. FDA has approved its IGALMI™ (dexmedetomidine) Sublingual Film for use in acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. - 04/06/2022

Imaging Co. Launches S. Korea Chip Production

Shares of Nano-X Imaging Ltd. traded 9% higher after the company reported it opened a new semiconductor chip fabrication plant in South Korea. The 12,000 sq. meter facility was commissioned to produce the firm's Nanox.SOURCE semiconductor chips for its novel digital Nanox.ARC 3D x-ray system. - 04/05/2022

Telemed Tech Co. Expands Markets and Revenue in 2022

A quarter of the way into the year, this global healthcare technology company is experiencing “phenomenal growth,” with “a lot of growth ahead of us” for the rest of this year. - 04/04/2022

Can We Make a Pill to End the Pandemic?

Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors. - 04/04/2022

Cannabis Infused Beverage Company Stock in 'Very Good Spot' to Purchase

Technical analyst Clive Maund explains why he rates this company a strong speculative buy. - 04/04/2022

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial

NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors. - 04/02/2022

Chen's Top Picks for Q2 2022

Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks. - 04/01/2022

Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial

Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer. - 03/31/2022

Biotech Firm's Shares Double on $6B Deal

Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets. - 03/29/2022

Shares Rise 10% After FDA Approval of Implantable Lens

STAAR Surgical Co. shares traded higher after the company reported that the U.S. FDA approved its EVO Visian® Implantable Collamer® Lenses to correct myopia (nearsightedness) and myopia with astigmatism. - 03/28/2022

Biotech Co. Posts Positive Data in Ph. 1/2 Kidney Cancer Trial

Shares of 4D Pharma Plc. traded 28% higher after the company reported positive interim results from its Phase 1/2 study of its MRx0518 in combination with Merck & Co.'s KEYTRUDA® (pembrolizumab) for use in treating renal cell carcinoma. - 03/23/2022

Biotech Co. Gets $2M Grant for Parkinson's Treatment

Shares of SQZ Biotechnologies Co. traded 17% higher after the company reported that it has been awarded a $2 million grant from the NIH to develop a new cell replacement therapy for use in treating Parkinson's disease. - 03/22/2022

Co. Awaits FDA Approval of Drug, Prepares for Launch

The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report. - 03/21/2022

Drug Co. Gets PDUFA Date for TKI

"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report. - 03/20/2022

Produce Co. to Acquire Grower of Greens

The transaction will increase the acquirer's returns and lower its operating risk, noted a ROTH Capital Partners report. - 03/19/2022

Pharma Co. Gains FDA Approval for Epilepsy Seizure Drug

Shares of Marinus Pharmaceuticals Inc. jumped 16.4% higher near the end of trading today after the company reported that the U.S. FDA granted approval for its ZTALMY® (ganaxolone) in treating a rare type of genetic epilepsy called CDKL5 deficiency disorder. - 03/19/2022

Catalyst Could Push Pharma to Break Out

This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says. - 03/18/2022

Mental Health Co. Hosts Phase II Trials for LSD, Psilocybin

This mental health company is pioneering a unique, new treatment for mental health issues such as depression and PTSD in which psychedelics are administered by medical professionals in specialized clinics. - 03/16/2022

Biopharma Co. Enjoys Gains From Kidney Cancer Drug

Shares of this pharmaceuticals co. traded 22% higher after the company reported Q4/21 and FY/21 financial results that included a 17% sequential gain in net revenue from sales of its FOTIVDA® (tivozanib), which has been approved by the U.S. FDA for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC). - 03/14/2022

License Revenues Kick in for Biopharma Co.

Shares of Clearside Biomedical Inc. traded 42% higher after the company reported Q4/21 and FY/21 financial results and provided an update regarding positive developments at the company including the receipt of over $20 million in milestone payments from its commercial development partner. - 03/12/2022

Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings

An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year. - 03/10/2022

Biotech Firm Should Increase Sales by 20% This Year

This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report. - 03/10/2022

Medical Device Co. Changes Tack to Drive Topline Growth

This medical device company is improving its laser ablation system and working toward U.S. approval for its use in a second application, noted a Ladenburg Thalmann report. - 03/09/2022

Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval

Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma. - 03/09/2022

Regenerative Medicine Co. Posts 38% Sales Gain in 2021

Organogenesis Holdings Inc. shares traded 23% higher after the company reported FY/21 financial results that included a 46% YoY increase in revenue from its Advanced Wound Care products sales. - 03/02/2022

This Year Should Be Catalyst Rich for Oncology Pharma Co.

An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report. - 03/01/2022

Co. to Rebound After Q4/21 Sales Down Due to Virus Surge

The 2022 outlook for a cancer detection and therapy solutions company is positive given its focus on dermatology and implementing new commercial strategies, noted an Oppenheimer report. - 03/01/2022

Primary Care Operator to Open 40 New Centers in 2022

Shares of a Medicare-focused and AARP endorsed primary care facility operator traded 27% higher after the company reported FY/21 financial results that included a 64% YoY increase in capitated revenue. - 03/01/2022

Biotech to Take Novel Cancer Drug to Market in H1/22

This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases. - 02/28/2022

Super Computers Create Powerful Drugs for Alzheimer's

A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins. - 02/25/2022

Pharma Co. Posts 364% YOY Revenue Increase in Q421

Aerie Pharmaceuticals Inc. shares traded 30% higher after the ophthalmology-focused pharmaceutical company reported Q4/21 and FY/21 financial results and announced the appointment of a new Chief Medical Officer. - 02/25/2022

Imaging Diagnostics Co.'s Shares Rise 35% on FY21 Earnings

Lantheus Holdings Inc. shares traded to a new 52-week high after the firm reported Q4/21 and FY/21 financial results that included a 25.3% increase in annual revenue. The firm also advised that the FDA approved the sNDA for its isolator-based drug manufacturing facility for diagnostic ultrasound enhancing agent DEFINITY® for patients in the U.S. with suboptimal echocardiograms. - 02/24/2022

Q1 Results of Cannabis Firm Down YoY

Despite a dampened Q1 FY22 performance and an uncertain future, parts of a cannabis firm's story remain attractive, warranting a Market Perform rating, noted a Noble Capital Markets report. - 02/24/2022

Beauty Health Provider Posts 118% Increase in FY22 Sales

Shares of Beauty Health Co. traded 32% higher after the company that is credited with creating the category of hydradermabrasion reported Q4/21 and FY/21 financial results outlining significant improvements in sales, margins and adjusted earnings. - 02/23/2022

HC Staffing Firm Posts Triple-Digit Revenue Gains in Q421

Shares of a health care professional staffing and services company traded 12% higher after the company reported Q4/21 financial results that included a 116% YoY increase in revenue and a 1,149% YoY increase in net income. - 02/19/2022

Cannabis Cos. Expected to Post Better Revenues As of Q2/22

Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report. - 02/18/2022

Pharma Co. Decreases BMI by 14.3% in Obesity Trial

Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS). - 02/18/2022

Dialysis Equip. Co. Posts Record FY21 Sales

Shares of a wireless mobile dialysis equipment maker traded 15% higher after the company reported FY/21 financial results highlighting a 105% YoY increase in revenue to $102.6 million. - 02/17/2022

Small-Cap Drug Co. Fights Clinicians' COVID Stress

In a recent interview with Streetwise Reports, Cybin Inc.'s General and IP Counsel Robert Mino explained the company's position at the forefront of mental health treatment via psychedelics. "This sector has the potential to improve the human condition on a massive scale." - 02/15/2022

Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences

Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share. - 02/14/2022

Canadian Hedge Fund CIO Talks Top 2022 Prospects

AlphaNorth Asset Management was recently recognized with multiple performance awards at the 2021 Alternative IQ Canadian Hedge Fund Awards. The AlphaNorth Partners Fund won first place for its five-year annualized return gaining 40.35% for the period. The fund also placed second for its three-year return and third for its one-year return. Streetwise Reports sat down with CIO Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022. - 02/09/2022

Mental Health Co. Brings Psychedelics to the World

In Citi's Jan. 25, 2022 Psychedelic Call Series broadcast, Novamind CEO Yaron Conforti and Chief Medical Officer Dr. Reid Robison discussed how the company is increasing people's access to psychedelic therapies for mental health disorders. - 02/09/2022

Digital Medical Co.'s Earnings Are Just What the Doctor Ordered

Doximity Inc. shares traded 25% higher after the digital medical platform provider used by 80% of all physicians in the U.S. reported Q3/22 financial results that included a 67% YoY increase in revenue. - 02/09/2022

Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table

In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19. - 02/08/2022

Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?

Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal. - 02/07/2022

Drug Re-Purposing Co. Pursues Novel Stroke Therapies

Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke. - 02/03/2022

Co. Focused on Pipeline of Drug Candidates

In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report. - 01/31/2022

Biopharma Co. to Resubmit BLA to FDA for Type 1 Diabetes

Shares of Provention Bio Inc. traded 29% higher after the company reported that following its Type B meeting and conversations with the U.S. FDA, it is now planning to resubmit a Biologics License Application for delay of clinical type 1 diabetes in at-risk individuals. - 01/31/2022

Neuroscientist With Research Program Joins Biotech's SAB

ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program. - 01/29/2022

Pharma to Test if DMT Helps Brain Regain Function Post Stroke

During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman. - 01/28/2022

Co. Meets Goals in COVID Drug Trial

Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data. - 01/28/2022

FDA Approves First Tubeless Insulin Delivery Device

Shares of Insulet Corp. traded 15% higher after the company reported its Omnipod® 5 automated insulin delivery system has received clearance from the U.S. FDA. The Omnipod® 5 is the first tubeless system to be monitored and controlled remotely using a smartphone. - 01/28/2022

Read Why These 3 Institutions Like This Water Tech Co.

Forward Water Technologies Corp. is exploring applications for its forward osmosis water technology in the lithium extraction industry. - 01/26/2022

Possible Treatment for CRC Shows Promise

New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report. - 01/25/2022

Co. Looks to New Structures of Psychedelic Drug for Strokes

Algernon Pharmaceuticals Inc. has included novel salt forms of a psychedelic drug being investigated to combat strokes in its intellectual property applications. - 01/25/2022

Bone Cancer Drug Meets Goals, Stocks Rise

Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size. - 01/25/2022

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen

Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report. - 01/24/2022

Fourth COVID-19 Vaccine Shot Shown Less Effective

BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report. - 01/24/2022

‘Strong Data’ Expected From Todos Medical Data Lock

Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir. - 01/24/2022

GNC to Distribute Products for CBD Co.

The agreement with GNC is a step toward Charlotte's Web Holdings' goals of expanding consumer access to its products and becoming cash flow positive this year, noted a ROTH Capital Partners report. - 01/22/2022

First NSCLC Patient Dosed With Trial Therapeutic

Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report. - 01/22/2022

Fund Triples Holding of Drug Repurposing Firm

Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report. - 01/20/2022

US Cannabis Firm in 'State of Flux'

With several market factors working against Stem Holdings, its future is uncertain, noted a Noble Capital Markets report. - 01/19/2022

Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B

Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met. - 01/19/2022

Biotech Could Launch Trial of Polyp Screening Test in March

The start of the C-Scan study would be a major milestone for Check-Cap, noted an H.C. Wainwright & Co. report. - 01/18/2022

Derm Biopharma Named Top Growth Pick For 2022

Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report. - 01/18/2022

This Pharmaceutical Company Has a Brilliant Concept

Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company. - 01/17/2022

Ph1 Trial Results of Dementia Drug Positive

Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report. - 01/12/2022

Cell Firm Joins With Food Co. to Create Meat Substitute

Pluristem Therapeutics and Tnuva will incorporate a new company that will use its own funding and resources to develop cell-based synthetic meat products, noted a Dawson James Securities report. - 01/12/2022

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial

Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study. - 01/12/2022

Biotech Co. Partners With Life Sciences Firms

2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report. - 01/11/2022

HealthCare Solutions Co. Gains 8 Million New Members in 2021

Accolade Inc. shares rose 27% after the company reported Q3/22 financial results that included a 117% increase in YoY revenue. The firm highlighted that in calendar year 2021, its membership increased four-fold from 2 million to 10 million. - 01/11/2022

2022 to Be Catalyst Rich for Biopharma

The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report. - 01/10/2022

Enrollment Done for COVID-19 Drug Trial

Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report. - 01/10/2022

Co.'s samRNA Vaccines Protect Better Against COVID Variants

Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio. - 01/07/2022

AI Driven Drug Firm Partners With Merck

Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies. - 01/07/2022

Co. Partners to Test New Cancer Vaccines

Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea. - 01/06/2022

Medical Co. Strikes $3B Deal to Buy Digital Care Firm

Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash. - 01/06/2022

Chen Lin's Top 6 Investment Ideas

In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022. - 01/05/2022

New Muscular Dystrophy Drug Shows Promise

Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial. - 01/05/2022

Co. Plans to Make 100M Rapid COVID Tests Monthly

Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22. - 01/05/2022

Lead Cancer Drug Gets Fast Tracked

Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment. - 01/03/2022

Analyst: Drug a 'Hidden Gem for 2022'

Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish." - 12/31/2021

Co.'s COVID-19 Test Detects Omicron Variant

H.C. Wainwright & Co. gives Sorrento Therapeutics a Buy rating after initial testing shows its COVISTIX detects COVID-19's Omicron variant. - 12/30/2021

Co. Looks To US For Help Fighting Strokes

Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs. - 12/29/2021

Co. Still Compelling After Drug Trial Failure

"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report. - 12/29/2021

Co. Rated Outperform As Heart Failure Drug Nears Potential Approval

"Cytokinetics' pipeline of muscle-directed therapies has potential to address several diseases with high unmet medical need and may generate significant revenue across pipeline programs," noted an Oppenheimer report. - 12/25/2021

Analyst: Question Lingers Over Biotech’s Cell Therapy

A DawsonJames report notes that Brainstorm Cell Therapeutics’ autologous stem cells in amyotrophic lateral sclerosis will need further study to prove their effectiveness. - 12/23/2021

Coverage Initiated on Biopharma Co. After Turnaround Story

"With Acasti Pharma shares trading near cash levels yet current resources sufficient to achieve key development milestones across the pipeline over 2022-2023, we recommend investors build a position," noted an Oppenheimer report. - 12/23/2021

Analyst Highlights Top Picks in Biotech for 2022

Aldeyra Therapeutics, in the ophthalmology space, and SQZ Biotechnologies, in the cell therapy sector, have "advantages that their specific approaches allow," noted a BTIG report. - 12/20/2021

FDA Grants Approval for CNS-Focused Biopharma Firm's Bipolar Disorder Drug

Intra-Cellular Therapies Inc. shares traded 19% higher to a new 52-week high after the company reported the U.S. FDA has approved the use of its CAPLYTA® (lumateperone) for treatment of adults with bipolar depression. - 12/20/2021

Co. Launches Pivotal Phase in Alzheimer's Agitation Drug's Trial

BioXcel Therapeutics' lead drug candidate for agitation in Alzheimer's disease patients could serve a substantial market, noted an H.C. Wainwright & Co. report. - 12/17/2021

Analyst Says Regeneron Could Be 'Biotech Champion'

Regeneron Pharmaceuticals Inc.'s stock was up 36% in 2021 while the NASDAQ Biotechnology Index remained flat, Oppenheimer analyst Hartaj Singh reported in a Dec. 16 research note. - 12/17/2021

Co.'s Shares Gain 27% After FDA Nears Drug Approval

Shares of Calliditas Therapeutics AB traded higher after the company reported the U.S. FDA granted accelerated approval for its TARPEYO™ (budesonide) to reduce proteinuria in IgA nephropathy. - 12/16/2021

Target Price Raised on Biotech Based on Management Update

During its recent R&D Day, Prometheus Biosciences announced new strong trial data, another new indication for its lead therapeutic candidate and progress in developing a subcutaneous formulation of it, according to an Oppenheimer report. - 12/13/2021

Arena Pharma Takes Center Stage With Pfizer's $6.7B Cash Buyout

Arena Pharmaceuticals shares traded 80% higher after the company reported it agreed to be acquired by Pfizer Inc. for $100.00 per share in cash in a deal valued at $6.7 billion. - 12/13/2021

Biopharma Explains How Its Technology Evolved, Describes Current Programs

F-star Therapeutics "has methodically delivered scientific/preclinical/early clinical data validating its platform bispecific technology," noted an Oppenheimer report. - 12/11/2021

Biopharma's Anti-PD-L1 Antibody Advances in Two Oncologic Indications

Checkpoint Therapeutics' "cosibelimab represents a competitive asset on both efficacy and safety with an expected added advantage of lower net price," an H.C. Wainwright & Co. report noted. - 12/10/2021

Biopharma Partners to Commercialize Enzyme Used for Kidney Transplant Patients

The partnership allows Hansa Biopharma to "enter new markets without the cost and risk of building out country-specific commercial organizations for a single product," an H.C. Wainwright & Co. report indicated. - 12/10/2021

California-Based Biopharma Advances Lead Asset in COVID-19, Other Indications

Humanigen has applications for lenzilumab in the works with U.S., United Kingdom and European drug regulatory agencies, noted a ROTH Capital Partners report. - 12/08/2021

CRO's Shares Rise 18% on Preliminary Q4/FY Financial Results

Shares of contract research organization Inotiv Inc. traded higher after the company reported select preliminary unaudited financial results for Q4/21 and FY/21 which included a 90.7% YoY increase in revenue and a 123.0% increase in gross profit. - 12/08/2021

Biopharma Seeks to Add Idiopathic Hypersomnia to Narcolepsy Drug's Label

Harmony Biosciences Holdings intends to conduct a Phase Three trial next year to evaluate Wakix as a treatment for idiopathic hypersomnia, according to an Oppenheimer report. - 12/07/2021

Partnership With Chewy.com Sends Pet Health Insurer's Shares to the Top of the Pack

Shares of pet healthcare insurer Trupanion Inc. reached a new 52-week high after the company reported it is teaming up with Chewy Inc. to offer an exclusive line of pet wellness and health insurance products to Chewy's 20,000,000 customers. - 12/07/2021

Medical Device Firm Engages Distributor for Its TransDermal Infusion System

Sensus Healthcare's "needle-free treatment presents a clear competitive advantage in the aesthetic dermatology space," an H.C. Wainwright & Co. report noted. - 12/06/2021

Phase Two Studies Start for Therapy for Chemo-Treated Breast Cancer Patients

New clinical trials for G1 Therapeutics’ Cosela are “central to our investment thesis,” H.C. Wainright & Co. noted in a new research report. - 12/06/2021

Biopharma Launches Clinical Trial of Primary Asset in Endometrial Cancer

"Solid tumors offers a substantial opportunity for Karyopharm Therapeutics' Xpovio (selinexor) that perhaps investors have not yet realized," noted an H.C. Wainwright & Co. report. - 12/06/2021

Biotech Firm’s T-Cell Therapy Gets Positive Results in B-Cell Non-Hodgkin’s Lymphoma Study

Adicet Bio Inc. shares traded 37% higher after the company reported positive interim data from its Phase 1 GLEAN Study of ADI-001, which the firm noted is the first-ever allogeneic, off-the-shelf, gamma delta CAR T investigational cell therapy. - 12/06/2021

Antibody-Drug Conjugate Developer Achieves High Objective Response Rates in Ovarian Cancer Study

ImmunoGen Inc. shares traded 30% higher after the company announced positive topline data from its pivotal Phase 3 SORAYA Trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer. - 11/30/2021

Biopharma Launches COVID Vaccine Program in South Africa & Mexico

Oramed Pharmaceuticals' oral vaccine offers "convenience and safety advantages as well as coverage of emergent variant strains," noted a Nov. 29, 2021 H.C. Wainwright & Co. report. - 11/30/2021

Emerging SARS-COv-2 Variant Is Revenue Growth Opportunity for Vaccine Developer

Just a few days after the WHO deemed the COVID-19 Omicron variant a serious global health concern, leading mRNA-based vaccine developers BioNTech and Pfizer, along with rival Moderna, advised that if needed, the companies would be capable of developing a vaccine for the new mutating strains within roughly 100 days. H.C. Wainwright & Co. commented in a research note that it reiterates its "Buy" rating for BioNTech SE. - 11/30/2021

NRx Pharma's COVID-19 Vaccine Displays Effectiveness Against Delta Variant in Phase 2 Clinical Trial

Shares of NRx Pharmaceuticals Inc. traded 50% higher after the company commented on new data released by the Israel Institute for Biological Research regarding the effectiveness of its BriLife® COVID-19 Vaccine against the SARS-CoV-2 "Delta" variant. - 11/29/2021

Gene Therapy Firm's Shares Rise 120% on Topline Data From Pivotal Dystrophic EB Study

Shares of Krystal Biotech Inc. reached a new 52-week high after the company reported it met both primary and secondary endpoints in its pivotal GEM-3 trial of VYJUVEK™ in patients diagnosed with Dystrophic Epidermolysis Bullosa, a rare and severe skin disease. - 11/29/2021

Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment

Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome. - 11/20/2021

RNA Silencing Platform Firm Receives US$3.3 Billion Buyout Offer From Novo Nordisk

Shares of Dicerna Pharmaceuticals Inc. traded 78% higher after the company reported it entered into a definitive agreement to be acquired by Novo Nordisk A/S of Denmark for $38.25 per share in cash. - 11/18/2021

Novavax Submits Request to EMA for Conditional Marketing Authorization for COVID-19 Vaccine

Shares of Novavax Inc. traded 10% higher after the firm confirmed that the European Medicines Agency is now reviewing its COVID-19 vaccine filing for conditional marketing authorization. The firm advised that an opinion from the agency is expected within a few weeks. - 11/17/2021

Biotech Co.'s Shares Gain 32% After Posting Meaningful Renal Response Rates in Ph. 2 Lupus Study

Shares of Kezar Life Sciences Inc. rose to a new 52-week high after the company reported promising interim results from its Phase 2 trial of KZR-616 in patients with lupus nephritis. - 11/16/2021

EyePoint Pharma Reduces Wet AMD Treatment Burden by 79% after 6 Mo.'s in Phase 1 Trial

Shares of EyePoint Pharmaceuticals Inc. reached a new 52-week intraday high after the company reported positive data from its Phase 1 DAVIO study of EYP-1901 in Wet AMD and announced plans to move forward to additional Phase 2 clinical trials in 2022. - 11/15/2021

Trial of Psilocybin Therapeutic in Treatment Resistant Depression Yields Positive Topline Results

"We believe this data begins to form the basis of an approvable program for Compass Pathways' COMP360" in this indication, noted a BTIG report. - 11/14/2021

Contakt World Technologies Partnership Will Help Satisfy Demand for Vaccine Passport Technology

Contakt World plans to build a diversified health technology SaaS platform and address inequity of health access through technology. - 11/12/2021

Advanced Medical Genetics Co. Notches 66% YoY Increase in Q3 Revenue

Invitae Corp. reported Q3/21 financial results that highlighted an 89% YoY increase in billable volume to 296,000 tests. Ladenburg Thalmann & Co. Inc. stated in a research note that it has a "Buy" rating for the company with a $55.00/share price target. - 11/12/2021

Robotic Surgical Systems Co.'s Shares Gain 21% on Q3 Earnings and Forward Revenue Outlook

Stereotaxis Inc. shares traded higher after the company reported Q3/21 financial results and confirmed its FY/21 revenue guidance. The company added that it is sufficiently funded and is on pace towards doubling its system revenue in FY/22. - 11/11/2021

Microbiome Therapeutics Co.'s Shares Rise on Q3 Earnings & Partnership With Swiss Manufacturing Firm

Shares of Seres Therapeutics Inc. traded 20% higher after the company reported Q3/21 financial results and announced it is partnering with Bacthera in Switzerland to manufacture medicine for use in c.Diff treatment. - 11/10/2021

US DEA OKs Use of Psychedelics by This Mental Health Network

Clinics that deliver novel psychiatric treatment and host clinical trials of psychedelic medicine have positioned Novamind for breakthroughs in mental health treatment. - 11/09/2021

Key Data Readouts Expected in 2022 for Developer of Cancer Immunotherapies

Results expected are for trials of Jounce Therapeutics' two lead product candidates, vopratelimab and pimivalimab, both monoclonal antibodies, noted a ROTH Capital Partners report. - 11/08/2021

Programmed T Cell Therapies Co. Receives $250M Investment From Blackstone to Advance Adult Leukemia Treatment

Autolus Therapeutics Plc. shares traded 28% higher after the company reported that Blackstone Life Sciences is investing up to $250 million in the firm to develop obe-cel in treatment of adult Acute Lymphoblastic Leukemia and advance its broader targeted T- Cell technology platform. - 11/08/2021

Specialty Pharma Co. Increases Revenues by 22% in Q3; Raises FY Sales and Earnings Forecast

Shares of brand, generic and injectable drug maker Endo International traded 25% higher after the company reported Q3/21 financial results and raised its FY/21 revenue and EPS guidance. - 11/05/2021

Robotic Surgical Device Maker's Shares Maneuver Higher on Q3 Earnings

Shares of robotic performance-guided surgery device maker Asensus Surgical Inc. traded 21% higher after the company reported Q3/21 financial results that included a 215% increase in YoY revenue. - 11/04/2021

Surgery Center Operator Posts 23% Increase YTD Revenue and Raises FY21 Adjusted EBITDA Estimates

Surgery Partners shares traded 18% higher after the company reported Q3/21 financial results that included a 12.7% increase in YoY revenue and a 6.2% increase in the number of same-facility procedures performed. - 11/03/2021

Precision Medicine Co.'s ASM Treatment Drug Gaining Rapid Market Adoption

Wedbush Securities Inc. advised that global precision therapy company Blueprint Medicines Corp.'s therapeutic AYVAKIT is gaining traction in patients diagnosed with advanced systemic mastocytosis and gastrointestinal stromal tumors. Wedbush reiterated its Outperform rating for the company and raised its 12-month price target by $4.00 to $136.00 per share. - 11/03/2021

Psychedelic Drug Trials Accelerate as Decriminalization Spreads, Investment Expands

McAlinden Research Partners estimates it may be only a matter of time before psychedelics become part of a biotech boom. - 11/03/2021

SLT Company's 'Cell Replacement in a Bottle' a Powerful Option in Treating Genetic Diseases

BTIG commented in a research report that Sigilon Therapeutics is developing a powerful and widely applicable "cell replacement in a bottle" as a potential functional cure for genetic diseases. BTIG advised it is initiating coverage on the company with a "Buy" rating and $14/share price target. - 11/02/2021

Diversified Bio-Pharma Firm Gains FDA Approval for Adrenocorticotropic Hormone Gel for Multiple Indications

Shares of ANI Pharmaceuticals Inc. traded 50% higher after the company reported the U.S. FDA approved its Purified Cortrophin Gel for use in treating multiple sclerosis, rheumatoid arthritis and nephrotic syndrome. - 11/01/2021

Cannabis Firm to Enter Colorado Market Via Acquisition

The target company "brings numerous positives to Stem Holdings dba Driven By Stem," noted a Noble Capital markets report. - 10/27/2021

Medpace Shares Rise 13% on Higher Q3 Earnings & Forward Outlook

Shares of Medpace Holdings Inc. climbed to a new 52-week high after the CRO, a provider of full-service clinical trial development services, reported financial results for Q3/21 that included a 28.3% increase in YoY revenue. - 10/26/2021

Global Distribution Deal for Antibiotic Alternative for Livestock ‘Could Be a Game Changer’

Analyst David Bautz at Zacks Small-Cap Research wrote bullishly on Avivagen's eight-year distribution deal targeting the U.S., Brazil, and Thailand in an Oct. 11 report: The AB Vista deal “could be a game changer for the company as Avivagen now has a global partner that gives immediate credibility to the OxC-beta technology." - 10/25/2021

Radius Health Reports Positive Topline Data from Ph. 3 Metastatic Breast Cancer Trial

Shares of Radius Health Inc. traded 17% higher after the firm reported positive topline results from the Phase 3 EMERALD study of elacestrant in ER+/HER2- advanced or metastatic breast cancer (mBC). - 10/20/2021

Aquaculture Firm to Provide US Gulf Coast Distributor with 25,000 Pounds of Live Gourmet-Quality Shrimp

NaturalShrimp Inc.'s shares traded 12% higher after the company reported it entered into an agreement with Gulf Seafood Inc. for delivery of 25,000 lbs. of naturally grown, chemical and antibiotic-free, live shrimp. - 10/19/2021

New French Vaccine May 'Play an Important Role in Overcoming' COVID-19

Valneva SE shares traded 40% higher after the company reported positive results from its Phase 3 clinical trial of its COVID-19 vaccine candidate, VLA2001. The firm claimed that VLA2001 produced superior neutralizing antibody titer levels compared to AstraZeneca's AZD1222 (ChAdOx1-S) vaccine in the study. - 10/18/2021

DarioHealth Contracts With National Health Plan to Offer Behavioral Health Services to Millions of Members

DarioHealth Corp. shares traded 17% higher after the company reported it entered into an agreement with an unnamed national healthcare provider to make its behavioral health products available to millions of the plan's members. - 10/14/2021

Company Releases iOS-Based App for Cannabis Purchase and Delivery

The potential is "enormous" for Stem Holdings Inc. dba Driven By Stem's new app, Budee Cannabis Delivery, given it is available in the Apple App Store, a Noble Capital Markets report noted. - 10/14/2021

Pacira Bids to Acquire Flexion to Expand Leadership Position in Non-Opioid Pain Management

Flexion Therapeutics Inc. shares traded 60% higher after the company reported it entered into a definitive agreement to be acquired by Pacira BioSciences Inc. for $8.00 per share in cash plus an additional non-tradeable contingent value right worth up to $8.00 per share in cash if five specific milestones are met. - 10/11/2021

ChemoCentryx Shares Double After FDA Approves TAVNEOS™ for Treatment of ANCA-Associated Vasculitis

Shares of ChemoCentryx Inc. traded 96% higher after the company reported the U.S. FDA approved its orally administered TAVNEOS™ (avacopan) for use in treatment of ANCA-associated vasculitis, a systemic autoimmune disease that often results in kidney or other major organ damage and failure that can be fatal if left untreated. - 10/10/2021

Merus Shares Rise 37% After Firm Presents Multiclonic Antibodies Clinical Data to Molecular Targets & Cancer Therapeutics Summit

Shares of Dutch oncology company Merus NV traded higher after the firm presented early and preclinical data for two full-length, multispecific antibodies, MCLA-158 and zenocutuzumab, to the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. - 10/07/2021

Reliq's Telemedicine Platform Helps Free Up Hospital Space for COVID-19 Delta Patients

Simultaneously, demand is growing for Reliq Health's iUGO Care software as virtual healthcare delivery increases during the COVID-19 pandemic. - 10/06/2021

Voyager Shares Lift Off After Firm Signs License Deal With Pfizer for Next-Gen AAV Capsids for Gene Therapy Programs

Shares of Voyager Therapeutics Inc. traded 51% higher after the company reported it entered into a license and option agreement with Pfizer Inc. for two of its TRACERᵀᴹ AAV capsids that will be utilized to enhance Pfizer's neurologic and cardiovascular gene therapy programs. Voyager will receive an upfront payment of $30 million and is eligible to receive up to $600 million more plus product sales-based royalties, if all options are exercised and certain milestones are achieved. - 10/06/2021

SmileDirectClub Granted Patent for Mobile Oral Care Bus to Serve Remote Regions in the US & UK

SmileDirectClub Inc. shares traded 15% higher after the company reported that the U.S. Patent & Trademark Office has allowed its new patent for the firm's mobile SmileBus concept whereby its SmileShop on wheels is mobilized to expand access to convenient, affordable oral care in remote areas across the U.S. and the U.K. - 10/05/2021

Xenon Pharma Shares Gain 80% on Positive Data in Phase 2b Focal Epilepsy Trial

Shares of Xenon Pharmaceuticals Inc. soared to a new 52-week high after the company reported topline data from its Phase 2b X-TOLE clinical study demonstrating that its epilepsy drug candidate XEN1101 successfully met several primary and secondary efficacy endpoints and decreased monthly focal seizure frequency by 50% or greater from baseline. - 10/04/2021

Merck and Ridgeback Post Interim Data From Phase 3 Antiviral Drug Trial Showing 50% Reductions in Hospitalizations and Deaths in Mild and Moderate COV

Shares of Merck & Co. Inc. traded 9% higher after the company reported that in a global Phase 3 clinical trial conducted together with its partner Ridgeback Biotherapeutics, oral antiviral molnupiravir reduced risk of hospitalization or death by 50% versus placebo in patients with mild or moderate COVID-19. Merck plans to submit an Emergency Use Authorization application to the U.S. FDA and if authorized it would make molnupiravir the first approved oral antiviral medicine for COVID-19. - 10/03/2021

Coverage Initiated on Nanomedicine Firm, Upside 'Potentially Significant' With Upcoming Trial Results

"With Clene's potential to realize several multibillion-dollar revenue opportunities, we see its roughly $480 million enterprise value as offering attractive risk-reward," an Oppenheimer report noted. - 10/01/2021

Alzamend Shares Rise After FDA Gives Positive Response to Pre-IND Filing for Immune-Boosting Alzheimer's Vaccine

Shares of Alzamend Neuro Inc. traded 36% higher after the company reported that the U.S. FDA responded favorably to its Pre-IND application for AL002, a cell-based therapeutic vaccine designed to restore patients' immunological systems, providing them with the ability to combat Alzheimer's Disease. The FDA has granted the firm approval to initiate a combined Phase 1/2 clinical trial in Q1/22. - 09/30/2021

COVID-19 Vaccine Could Be Approved in Q4/21 for 5 to 11 Year Olds

"Label extension for BioNTech and Pfizer's Comirnaty [vaccine] to include use in these younger individuals ought to buoy revenue growth near term," noted an H.C. Wainwright & Co. report. - 09/30/2021

Biopharma Expands Clinical Program of Lead Drug Candidate to Treat Chronic Cough

Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial. - 09/29/2021

Cannabis Firm Expands Footprint in Central California With New Distribution Center

"The expansion is expected to drive topline sales with greater efficiency," noted a Noble Capital Markets report. - 09/28/2021

Telemedicine Tech Firm Poised to Generate $11 Million of Revenue

Reliq Health Technologies signs contracts with three new clients for its proprietary remote healthcare delivery and care tracking platform, which has particularly significant implications during the era of the COVID-19 pandemic. - 09/24/2021

Nanotech Co.'s Shares Trade Higher After Developing Antimicrobial Coating for PPE

ZEN Graphene Solutions Ltd. shares traded 13.5% higher after the company reported it delivered its first revenue-generating shipment of ZENGuard, a patent-pending coating with 99% antimicrobial activity. The first commercial shipment follows the firm's announcement yesterday that Health Canada determined ZENGuard enhanced surgical masks are safe for use by Canadians. - 09/23/2021

Dynavax Shares Shoot Up 30% After Its Partner Clover Biopharma Met All Key Efficacy Endpoints in Ph. 2/3 COVID-19 Vaccine Trial

Shares of Dynavax Technologies Corp. established a new 52-week high after the company reported that in the global Phase 2/3 SPECTRA COVID-19 vaccine study its collaborative partner Clover Biopharmaceuticals met all primary and secondary efficacy endpoints. Clover's vaccine, which was developed using Dynavax's CpG 1018 adjuvant, demonstrated 100% efficacy against severe COVID-19 and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2, including the Delta, Gamma, and Mu variants. - 09/22/2021

'Poised for Two Key Readouts in Q1/22' as Biopharma Advances Pipeline

Rezolute's two drug candidates, one for congenital hyperinsulinism and the other for diabetic macular edema, are discussed in an H.C. Wainwright & Co. report. - 09/21/2021

Inotiv Makes $545 Million Bid for Envigo RMS Holdings to Fortify Research and Drug Discovery Platforms

Shares of Inotiv Inc. traded 27% higher to a new 52-week high after the company reported it entered into agreement to acquire Envigo RMS Holding Corp. in a cash and stock deal valued at $545 million which will serve to create a one-stop-shop, discovery-to-approval solution for drug developers. - 09/21/2021

Target Price Raised on Biopharma After It Acquires Company, Splits Stock

AzurRx BioPharma now has five additional shots on goal "with the imminent full acquisition of just one compound," a ROTH Capital Partners report noted. - 09/20/2021

Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study

Edesa Biotech Inc. shares reached a new 52-week high after the company reported positive results from its Phase 2/3 monoclonal antibody study in hospitalized COVID-19 patients. - 09/20/2021

Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference

Innate Pharma S.A. shares traded 38% higher after the company reported its development partner AstraZeneca Plc. reported positive interim results from its Phase 2 COAST Study to the European Society for Medical Oncology Congress. When taken together with durvalumab, monalizumab was shown to improve progression-free survival and objective response rates in patients with unresectable, Stage III non-small cell lung cancer. - 09/18/2021

Leap Therapeutics Shares Skip Higher on Positive Preliminary Data From Gastric Cancer Study

Shares of Leap Therapeutics Inc. traded 38% higher after the company reported positive preliminary data from the Phase 2a DisTinGuish Study of DKN-01 plus tislelizumab at the European Society for Medical Oncology Congress. - 09/16/2021

French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients

ROTH Capital Partners LLC advised in a research report that Inventiva S.A. has initiated enrollment in its highly anticipated pivotal Phase 3 Study of Lanifibranor in individuals diagnosed with nonalcoholic steatohepatitis. ROTH rates Inventiva a "Buy" with a 12-month price target of €55/share which represents a nearly four-fold increase over the current share price. - 09/15/2021

Instil Bio Receives FDA Approval to Initiate Expanded Phase 2 Advanced Melanoma Study

Shares of Instil Bio Inc. traded 16% higher after the company reported it received IND clearance from the U.S. FDA to initiate a Phase 2 clinical trial in advanced melanoma patients. - 09/15/2021

Biopharma Co. Posts Positive Objective Response & Disease Control Rates in Ovarian Cancer Studies

H.C. Wainwright & Co. advised in a research report that updated data from Mersana Therapeutics Inc.'s expansion study supports its UPLIFT Study and will provide the basis for a new Phase 3 study in 2022. H.C. Wainwright rates Mersana a "Buy" with a target price of $28.00/share. - 09/14/2021

aTyr Pharma's Fusion Protein Achieves Consistent Dose Response in Pulmonary Sarcoidosis Trial

Shares of aTyr Pharma Inc. traded 48% higher after the firm reported its ATYR1923 produced positive results in a Phase 1b/2a clinical study by demonstrating consistent favorable dose responses in pulmonary sarcoidosis patients. - 09/13/2021

Sanofi Makes US$1.9 Billion Offer to Buy Kadmon Holdings to Solidify Its Transplant Business

Shares of Kadmon Holdings Inc. traded 70% higher after the firm reported it agreed to be acquired by Sanofi SA for $9.50 per share in cash. Sanofi aims to strengthen its transplant business with the addition of Kadmon's Rezurock™ (belumosudil), an FDA-approved, first-in-class treatment for patients 12 years and older with chronic graft-versus-host disease. - 09/08/2021

Medical Device Company's Improved Fundamentals Offer Multiple Expansion Potential

ROTH Capital Partners LLC commented in a research report that it is maintaining its "Buy" rating and raising its FY/22 revenue estimates for Dynatronics Corp. to $41 million after the firm pre-announced Q4/21 revenue figures that exceeded prior estimates. - 09/07/2021

Adaptimmune Partners With Genentech to Develop & Market Cancer-Targeted Allogeneic T-Cell Therapies

Adaptimmune Therapeutics Plc. shares traded 33% higher after the firm reported it formed a strategic partnership with Genentech to develop several "off-the-shelf" and advanced personalized cancer-targeting allogeneic T-cell therapies. - 09/07/2021

Impel NeuroPharma Gains FDA Approval for First Therapeutic to Deliver DHE to Vascular-Rich Upper Nasal Space for Migraine Treatment Using POD Tech

Shares of Impel NeuroPharma Inc. traded to a new 52-week high after the company reported that the U.S. Food and Drug Administration has approved TRUDHESA™ (dihydroergotamine mesylate), a patient friendly nasal spray that delivers rapid relief and treatment for acute migraine. - 09/04/2021

Reliq Health Technologies Rides Telehealth Reimbursement Wave

Global telemedicine company will turn a profit in the current quarter and experience rapid growth after new contracts to provide chronic care management and medicare and medicaid reimbursements expand. - 09/02/2021

Biopharma's Antibody Approved as Hodgkin's Lymphoma Treatment in China

"This marks the first regulatory approval of an OmniAb antibody discovery engine-derived antibody since Ligand Pharmaceuticals first acquired the technology in 2016," noted an H.C. Wainwright & Co. report. - 08/31/2021

AC Immune Shares Rise 16% After Phase 2 Alzheimer's Trial Data Shows Significant Reductions in Cognitive Decline

AC Immune SA shares set a new 52-week intraday high after the company reported positive cognitive results for tau-targeting monoclonal antibody semorinemab in a clinical study of patients with mild-to-moderate Alzheimer's disease. - 08/31/2021

Israeli Biopharma Advances Five Drug Candidate Trials in Q2/21

The progress Can-Fite BioPharma made with these studies is briefly summarized in a Dawson James Securities report. - 08/30/2021

Third Implantation of Device Firm's Total Artificial Heart That 'Could Save Many Patients Who May Die'

An H.C. Wainwright & Co. report noted that Carmat's Aeson implant "could save many patients who may die, due to [a] shortage of donor hearts, while waiting for a heart transplant." - 08/30/2021

Poseida Shares Point Higher After FDA Clears NDA for Relapsed/Refractory Multiple Myeloma Treatment Candidate

Shares of Poseida Therapeutics traded 10% higher after the company reported that the U.S. Food and Drug Administration granted clearance for its Investigational New Drug Application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for use in treating relapsed/refractory multiple myeloma. - 08/30/2021

Bolt Bio Partners With Innovent Biologics to Create Three New Cancer Treatments

Shares of Bolt Biotherapeutics Inc. traded nearly 10% higher after the company reported it is collaborating with Innovent Biologics to develop three new oncology Boltbody™ ISAC programs. - 08/28/2021

Dermatological Device Company to Acquire Laser System Firm

An H.C. Wainwright report noted that "this deal is an opportunity for STRATA Skin Sciences to substantially increase its long-term, recurring revenue base." - 08/24/2021

With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon

A BTIG report noted that Legend Biotech's cilta-cel has the potential "to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class profile." - 08/24/2021

Biopharma's Amino Acid Compound Shows Anti-Inflammatory Effect

Studies suggest that Galmed Pharmaceuticals' Amilo-5MER has "therapeutic potential in a number of inflammatory diseases," according to an H.C. Wainwright & Co. report. - 08/23/2021

Trillium Receives US$2.26B Buyout Bid, Shares Trade 190% Higher

Trillium Therapeutics shares traded 190% higher after the company reported it agreed to be acquired by pharmaceutical giant Pfizer Inc. for $18.50 per share in cash. - 08/23/2021

Specialty Pharma's Q2/21 Results 'Fundamentally Ahead of Expectations'

A ROTH Capital Partners report noted that Assertio Therapeutics' business model is starting to gain traction. - 08/23/2021

Flora Shares Sprout Higher on H1 Financial Results and Positive FY Sales Outlook

Shares of natural cannabis firm Flora Growth Corp. rose 43% after the company reported H1/21 financial results and indicated it expects H2/21 revenues will be in the range of US$9-11 million. - 08/20/2021

Inovalon Receives $7.3 Billion Buyout Offer From Nordic Capital Led Equity Consortium

Inovalon Holdings Inc. shares traded 8% higher after the cloud healthcare technology platform firm reported it entered into an agreement to be acquired by an equity consortium led by Nordic Capital and Insight Partners for $41.00 per share in cash. - 08/19/2021

Biotech Offering Significant Return Potential Advances Lead Breast Cancer Trials

An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected. - 08/18/2021

Global Specialty Pharma Co. Strongly Beats on Consensus Q2 Revenue and Earnings Estimates

Paradigm Capital Inc. stated in a research report that Knight Therapeutics Inc. posted significantly better than expected operating and financial results in Q2/21 that greatly exceeded analysts' estimates. Meanwhile, insiders continue to add to their positions, and the company has filed a new NCIB allowing it to purchase up to 10% of the float during the next 12 months. - 08/18/2021

Platform Therapeutics Co. Posts Positive Revenue Surprise in Q2 on Higher Dermatology Product Sales

Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.'s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a "Buy" rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential. - 08/18/2021

Diagnostics Firm Readies for Pivotal FDA Study of Device That Detects Bacterial Lung Infections

Promising early results and a new line of equity support Avisa Diagnostic’s drive for IDE approval of its rapid-response breath test for pneumonia, TB, CF, and other lung ailments. - 08/18/2021

Cannabis Products Retailer Achieves Record Sales in Q3 FY21

Gross sales of Stem Holdings dba Driven by Stem during the quarter were 104% higher than they were a year ago. - 08/17/2021

Travere Posts Positive Topline Data in Phase 3 IgA Nephropathy Study, Shares Trade Higher

Travere Therapeutics shares traded 14% higher after the company reported positive interim results from its ongoing Phase 3 PROTECT study of sparsentan in treating IgA nephropathy, a chronic kidney disease that can lead to end-stage renal disease. - 08/16/2021

Clover Health Shares Grow 12% after Posting Q2 Earnings and 229% Platform User Growth

Shares of Clover Health Investments Corp. traded higher after the company reported Q2/21 financial results that included a 140% increase in YoY revenue. - 08/12/2021

Coverage Initiated on Developer of Treatment for Myelofibrosis, GvHD, COVID-19

A BTIG report noted that CTI Biopharma's Pacritinib "has the potential to be a lead therapeutic in the myelofibrosis space and in additional indications that could provide material value to CTI and CTI's shares over time." - 08/11/2021

U.S. Cannabis Sector to Show 'Secular Growth With Margin Improvements,' Analyst Says

Behind that forecast, in part, are positive cannabis legislative developments and increasing consumer cannabis use, which are covered in a ROTH Capital Partners report. - 08/11/2021

Liquid Avatar Unveils New App to Confirm COVID-19 Testing Status, Reduce New Outbreaks of the Pandemic

The Liquid Avatar Credential Ecosystem, or LAVCE, is designed to carry a secure, digital record of a person’s verifiable COVID-19 testing credentials, and future healthcare applications of the technology are expected. - 08/11/2021

Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College

Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors. - 08/10/2021

Fulcrum Shares Soar on Positive Interim Data in Phase 1 Sickle Cell Disease Study

Fulcrum Therapeutics shares rose 125% and set a new 52-week high after the company reported Q2/21 financial results and released positive interim results from its Phase 1 sickle cell disease trial. - 08/10/2021

Cortexyme Expects to Release Positive Topline Data from Ph. 2/3 Alzheimer's Trial by Late Autumn

Shares of Cortexyme Inc. traded 47% higher to a new 52-week high after the company reported Q2/21 financial results and provided an update regarding its ongoing Alzheimer's and periodontal disease clinical trials. - 08/09/2021

STAAR Shares Burst Higher after Firm Posts 77% Increase in Q2 Net Sales and Raises FY Outlook

Shares of STAAR Surgical Co. traded 20% higher after the company reported Q2/21 financial results highlighting a 93% YoY increase in net sales of its Implantable Collamer® Lenses. - 08/06/2021

US-Based Biopharma 'In Full Reset Mode,' Analyst Says

An H.C. Wainwright & Co. report notes that Agios Pharmaceuticals "is rapidly rebooting and has made critical progress on various fronts." - 08/04/2021

Biopharma Makes 'Solid Clinical Progress' in Q2/21

The highlights of Oryzon Genomics' Q2/21 clinical advancements were recapped in a Roth Capital Partners report. - 08/04/2021

Novavax Shares Get a Boost as EC Orders up to 200 Million Doses of Its COVID-19 Vaccine

Novavax Inc. shares traded nearly 19% higher after the company reported the finalization of an advance purchase agreement with the European Commission to provide up to 200 million doses of its COVID-19 Vaccine. - 08/04/2021

Translate Bio Shares Rise 29% on Sanofi's $3.2 Billion Buyout Bid

Shares of Translate Bio Inc. soared to a new 52-week high after the company reported it agreed to be acquired by its collaborative partner Sanofi SA for $38 per share in cash in a deal valued at $3.2 billion. - 08/03/2021

Gene Editing May Terminate Virus Transmission, Combat Heart and Brain Disease With a Single Shot

McAlinden Research Partners explores the acceleration of gene-editing technology and notes the market is poised to expand as the World Health Organization (WHO) creates new standards for companies to follow. - 08/02/2021

Annovis Shares Rise on Positive Phase 2 Alzheimer's and Parkinson's Disease Trial Results

Shares of Annovis Bio Inc. traded 20% higher after the company reported positive interim data from its Phase 2 clinical studies of ANVS401 (Posiphen) for treatment of Alzheimer's and Parkinson's diseases. - 08/02/2021

Sorrento Therapeutics Proceeds with COVID-19 Drug Treatment Trial

The latest developments concerning Sorrento Therapeutics, its product portfolio and partners are summarized in a Dawson James Securities report. - 07/28/2021

Biopharma Creates New Business Unit Ahead of Commercial Product Launch

The purpose of HTG Molecular Diagnostics' new therapeutics division and early interest in the biopharma's commercial-ready Transcriptome Panel are covered in an H.C. Wainwright & Co. report. - 07/28/2021

Rritual Superfoods at Full-Throttle, Adding CVS, Amazon Along the US Distribution Superhighway

Knox Henderson takes a close look at Rritual Superfoods and its plans to ramp up mass distribution. - 07/28/2021

Tilray Shares Fly High on Strong Q4 and FY Revenue Growth

Shares of Tilray Inc. traded 25% higher after the company reported FY/21 financial results that included a 27% YoY increase in net revenues to $513.1 million driven by a 55% growth in cannabis revenue following its Aphria acquisition. - 07/28/2021

Cannabis Market Delivering for Consumers and Investors

As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value. - 07/21/2021

Coverage Initiated on Company with a 'Genuine Physiological Heart Replacement Therapy'

The investment thesis for the device company Carmat, whose therapy "allows patients to live with almost normal quality of life," is presented in an H.C. Wainwright & Co. report. - 07/21/2021

Biopharma Partners with NIH to Advance Women's Hormone-Free Contraceptive

A Roth Capital Partners report calls this a "very cost-effective and strategic move" for Daré Bioscience. - 07/21/2021

Rapidly Growing Virtual Healthcare Firm Adds Three New US Group Medical Practice Clients

Reliq Health Technologies advised it entered into agreements with three physician practices in Texas for its iUGO Care platform. - 07/21/2021

HCA Healthcare Shares Gain 15% on Strong Q2 Performance and Raised FY Outlook

HCA Healthcare shares established a new 52-week high after the company reported a greater than 30% increase in YoY revenue in Q2/21. - 07/20/2021

Small Bio-tech Gets $17.7 Million Backing from U.S. Department of Defense to Treat SARS-CoV-2 Delta Variant

Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets. - 07/20/2021

Cytokinetics Shares Rise 41% on Positive Phase 2 Redwood-HCM Trial Data

Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial. - 07/19/2021

Zynex Shares Rise as Firm Notches Significant Q2 Order Growth and Raises EBITDA Outlook

Zynex Inc. shares traded 10% higher after the electrotherapy medical device maker reported a 247% YoY growth in orders during Q2/21 and raised the range for its EBITDA estimates in the quarter by $1.2 million. - 07/16/2021

Merger of Two Biopharmas 'Brings a New Dawn'

The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report. - 07/14/2021

FDA, EMA Approve Drug Firm's Phase 3 Liver Cancer Trial Design

The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report. - 07/14/2021

US Cannabis Sales Hold Strong as Industry Lays Out New Lobbying Efforts to Expedite Federal Reform

McAlinden Research Partners expects activity and revenues in the cannabis space to continue ramping up as the US crosses the point at which legalization is not a question of "if" but "when." - 07/14/2021

Alphatec Shares Rise After Firm Announces Strong Organic Revenue Growth in Q2

Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue. - 07/12/2021

Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery

Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke. - 07/09/2021

Biopharma Files New Drug Application for Lead Clinical Product

A review of Daré Bioscience's lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a Roth Capital Partners report. - 07/07/2021

Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity

The encouraging work Regeneron Pharmaceuticals completed thus far, and the next challenge in this program, are laid out in an H.C. Wainwright & Co. report. - 07/07/2021

Biohaven Posts Revenue of $93 Million in Q2 for Its Migraine Medicine

Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded 12% higher to a new 52-week high after the company reported preliminary Q2/21 net product revenue of $93 million for NURTEC ODT, which it claims is the first and only FDA approved medicine for both acute and preventive migraine treatment. - 07/07/2021

ALX Oncology Shares Rise on Positive Response and Survival Data in Phase 1b Gastric Cancer Trial

Shares of ALX Oncology Holdings Inc. traded 10% higher after the company reported new data from its Phase 1b ASPEN-01 study of ALX148 demonstrated a robust objective response in patients with gastric or gastroesophageal junction cancer. - 07/06/2021

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases

Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. - 07/02/2021

Pulse Bio Shares Beat Higher on Launch of CellFX NPS System in Canada

Pulse Biosciences shares traded 27% higher after the company announced it secured a $50 million private placement one day after it reported the first CellFX® procedure using its proprietary Nano-Pulse Stimulation technology had been performed in Canada. - 07/01/2021

Coverage Initiated on Developer of Psychedelic Drugs for PTSD, Smoking Cessation

The investment thesis for Mydecine Innovations Group is presented in a ROTH Capital Partners report. - 06/30/2021

Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Stroke

Repurposing extends a drug's reach and value, and Algernon Pharmaceuticals' strategy of finding and demonstrating new uses for existing drugs reduces risk, accelerates time to market and increases capital efficiency. - 06/30/2021

Biotech Takes a 'Disruptive Drug Development Approach' to Destroy Dysregulated Transcription in Cancer

Kronos Bio's key assets are reviewed in an H.C. Wainwright & Co. report. - 06/30/2021

Cerevel Shares More Than Double on Positive Topline Results in Phase 1b Schizophrenia Trial

Shares of Cerevel Therapeutics hit a new 52-week high after the company released positive topline results for its CVL-231 in a Phase 1b clinical trial in schizophrenia patients. - 06/29/2021

Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial

Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis. - 06/28/2021

Eli Lilly Receives FDA Breakthrough Therapy Designation for Alzheimer's Treatment

Eli Lilly and Co's shares traded 8% higher and reached a new 52-week high after the company reported the FDA granted its investigational antibody therapy donanemab Breakthrough Therapy designation for use in treating Alzheimer's disease. - 06/24/2021

Price Target Raised on Biopharma Achieving Positive Atopic Dermatitis Study Results

Aclaris Therapeutics' new clinical trial data and a recent financing are discussed in an H.C. Wainwright & Co. report. - 06/23/2021

Biotech Reports Encouraging Efficacy Data in Wet AMD, Target Price Raised 66%

These new results, from a Clearside Biomedical trial, are presented and interpreted in a ROTH Capital Partners report. - 06/23/2021

Analyst: Health Care Services/Tech Firm's 'Biggest Transaction Gets Even Bigger'

How the acquisition has grown and its effects on CloudMD Software & Services are addressed in a Research Capital Corp. report. - 06/23/2021

3D Systems and CollPlant Biotech to Create Bioprinted Breast Reconstruction Treatment Solutions

3D Systems Corp. shares rose 27% after the company reported it is partnering with CollPlant Biotechnologies to develop bioprinted solutions use to improve breast reconstruction treatments. - 06/22/2021

Anavex Posts Strong Correlated Biomarker Data in Phase 2 Adult Rett Syndrome Trial

Anavex Life Sciences shares traded 13% higher after the company reported that ANAVEX®2-73 (blarcamesine) biomarker correlated highly with the predetermined efficacy endpoints in its Phase 2 clinical trial of adult patients with Rett syndrome. - 06/21/2021

Entera Bio Granted Patent for Oral Parathyroid Hormone by EU Patent Authority

Entera Bio shares traded 25% higher after the firm received a foundational patent from the EU patent office for its oral parathyroid hormone using its platform oral protein delivery technology to treat osteoporosis and hypoparathyroidism. - 06/17/2021

Biotech Reports Positive Preclinical COVID-19 Study Results

These data and next steps for Novan's antiviral SB019 are provided in a ROTH Capital Partners report. - 06/16/2021

Immuno-oncology Firm Advances Lead Asset in Mesothelioma

The status of ONCOS-102 in several of Targovax's development programs is discussed in an H.C. Wainwright & Co. report. - 06/16/2021

Altimmune Posts Positive Interim Weight Loss Results in Phase 1 ALT-801 Trial

Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants. - 06/16/2021

Clearside Biomed Shares Rise 37% on Positive Data in Phase 1/2a Wet AMD Trial

Clearside Biomedical shares reached a new 52-week high after the company reported that the first cohort in its dose-escalating Oasis Trial of CLS-AX for treatment of neovascular age-related macular degeneration met all primary endpoints. - 06/15/2021

Enochian Bio's Shares Rise 54% After FDA Accepts Pre-IND Request for Potential HIV Cure

Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus. - 06/14/2021

Sorrento's COVID Test Approved in Mexico

This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report. - 06/09/2021

Tilray Shares Climb Higher on Roll Out of New Medical Cannabis Brand Symbios

Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points. - 06/09/2021

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom

McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies. - 06/04/2021

Kindred Bio Shares Rise 29% after Achieving 100% Survival Rate in Canine Parvovirus Study

Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus. - 06/03/2021

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer

Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors. - 06/03/2021

Innovative Life Sciences Company Boosts Immune Function in Livestock Without the Use of Antibiotics

Avivagen's OxC-beta™ Livestock products could play a pivotal role in the global mandate to remove all in-feed antibiotics as growth promoters. - 06/02/2021

Biotech Receives National Cancer Institute Resources Award for Ovarian Cancer Vaccine Program

The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report. - 06/02/2021

Biotech Firm Confirms 100% Accuracy of COVID-19 Mutation Assays

Applied DNA Sciences' SARS-CoV-2 mutation panel and its validation are discussed in a ROTH Capital Partners report. - 06/02/2021

Constellation Pharma Shares Sparkle on $1.7 Billion Buyout Offer

Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share. - 06/02/2021

Analyst: Clinical News, Catalysts Portend 'Rich' Q2/21 for Biopharma

Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report. - 05/26/2021

Analyst: New Data Show Cancer Therapeutic 'Continues to Deliver Benefit'

Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report. - 05/26/2021

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug

Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer. - 05/24/2021

Biopharma Has 'Trials Progressing; Multiple 2022 Data Readouts' Including for PTSD

Updates on Aptinyx's three central nervous system drug candidates and the company's Q1/21 earnings are delivered in an H.C. Wainwright & Co. report. - 05/19/2021

Analyst Highlights Two Key Catalysts for Biotech

The biopharma aTyr's upcoming drug application and clinical-trial results are discussed in a ROTH Capital Partners report. - 05/19/2021

Sarepta Therapeutics Posts Positive Results in Duchenne Muscular Dystrophy Study

Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne's Muscular Dystrophy, had "positive 12-week expression and safety results." - 05/18/2021

Apellis Gains FDA Approval for Empaveli to Treat Chronic Blood Disorder

Shares of Apellis Pharmaceuticals Inc. traded 20% higher after the company reported it received U.S. FDA approval for EMPAVELI (pegcetacoplan) for use in treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic life-threatening blood disorder. - 05/17/2021

Analyst: Biotech Expecting a 'Catalyst-Rich' Second Half of the Year

An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year. - 05/13/2021

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial

Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. - 05/13/2021

Multiplan Shares Rise on Strong YoY Gain in Q1 Net Income and Forward Outlook

Multiplan Corp. shares traded 17% higher after the company reported Q1/21 net income of $45.9 million, compared to a net loss of $2.6 million in the corresponding quarter last year. - 05/13/2021

Life Sciences Firm Is at 'an Inflection Point with Significant Sales Increases Just around the Corner'

Noble Capital Markets noted in a research report that shortly after receiving its largest single order to date, a 4.4-ton order for OxC-beta Livestock, Avivagen Inc. has received a new order for 4 tons per month from its representative in Mexico. - 05/12/2021

Second Sight Shares Shine Brightly After Firm Posts Orion Study Results

Second Sight Medical Products Inc. shares traded 25% higher after the company reported the results from a two-year study of its Orion Visual Cortical Prosthesis System. - 05/12/2021

AbbVie's Allergan Aesthetics to Acquire Soliton for $550 Million

Soliton Inc. shares traded 25% higher after the company reported it had agreed to be acquired by AbbVie Inc.'s Allergan Aesthetics for $22.60 per share in an all cash transaction. - 05/10/2021

Telehealth's Transformation of Healthcare Will Outlive the Pandemic, Boost AI Applications

COVID-19 brought record-setting investment to the healthcare industry in 2020, but this year is shaping up to be even better, reports McAlinden Research Partners. Demand for telehealth services skyrocketed during the pandemic, and funding is starting to follow suit. - 05/07/2021

Virtual Care Solutions Company Adds New Clients, Expands Care Management Team

Reliq Health Technologies reported the addition of four new skilled nursing facility customers in the southern U.S. and announced plans to expand its Care Management Team to meet the growing demand for Care Management Services. - 05/07/2021

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue

Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. - 05/07/2021

Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'

Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report. - 05/05/2021

Firm Doubles in Size by Adding Four New Psychedelic Mental Health Clinics

Novamind Inc. is opening four new psychedelic mental health clinics as part of the company's national expansion strategy, giving it the capability to conduct 65,000 client visits in 2021. - 05/05/2021

BioNTech Shares Gain 11% on Filing COVID-19 Vaccine Expanded Use Request to EMA in Children Ages 12 to 15

BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine. - 05/03/2021

CryoLife Shares Trade 18% Higher on Q1 Financial Results

Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million. - 04/30/2021

Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial

Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer. - 04/29/2021

Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients

The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report. - 04/28/2021

Company Receives Its Largest Order for Antibiotic-Free Animal Feed Product

Avivagen Inc. reported it received a 4.4 metric tonne purchase order for OxC-beta Livestock from UNAHCO representing its largest single order to date. - 04/28/2021

ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50%

ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. - 04/28/2021

Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial

Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study. - 04/27/2021

Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors

Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price. - 04/23/2021

Healthcare Services Group Shares Rise 13% on Q1 Earnings and Quarterly Dividend Increase

Healthcare Services Group Inc.'s shares traded 13% higher after the company reported Q1/21 financial results that included a 22% YoY increase in net income. - 04/21/2021

Is the Trend Turning for This Psychedelic Stock?

Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. - 04/19/2021

Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site

Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion. - 04/16/2021

Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever

A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health management companies." - 04/16/2021

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3

Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. - 04/15/2021

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio

Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. - 04/14/2021

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial

Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. - 04/13/2021

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial

Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. - 04/09/2021

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'

Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." - 04/07/2021

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue

Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. - 04/07/2021

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine

Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. - 04/07/2021

Nano-X Imaging Receives Go Ahead from FDA for Single Source Digital X-Ray

Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray. - 04/05/2021

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD

United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. - 04/01/2021

Coverage Initiated on Health & Wellness Firm About to Launch Retail Sales, Sees 'Substantial Upside Potential'

Clarus Securities' initiation report on Rritual Superfoods views the company "as an attractive growth story for investors looking to gain exposure to a large and rapidly growing functional food and beverages market." - 03/30/2021

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF

Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. - 03/30/2021

Shockwave Medical Reports 100% Increase in Preliminary Q1 Revenue

Shockwave Medical Inc. shares gained 19% after the company announced that sales of its recently launched C2 Coronary IVL System are growing steadily and are driving revenue growth. - 03/30/2021

Data from Humanigen's Phase 3 COVID-19 Trial Show 54% Increase in Survival Rates

Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumab™ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation. - 03/29/2021

ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial

ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. - 03/25/2021

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April

Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report. - 03/24/2021

Rritual Superfoods Hits the Superhighway to Nationwide Distribution and Impressive Share Gains

Knox Henderson delves into the value proposition behind Rritual Superfoods, which has just started trading this month. - 03/24/2021

Aptose Biosciences Shares Rise 55% on Q4 Financial Results and Promising Clinical Trials

Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers. - 03/24/2021

Investor Campbell Becher's Three Core Assets

The former Bay Street investment banker is finding himself going narrower and deeper. - 03/22/2021

Mental Health Firm Partners with Merck on Treatment-Resistant Depression Trial

Novamind Inc. reported it is teaming up with Merck to conduct a new Phase 2a study addressing treatment-resistant depression at a key clinical research site owned by its subsidiary company Cedar Clinical Research. - 03/22/2021

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates

Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about. - 03/22/2021

Clovis Oncology Shares Rise on Positive Data from Phase 3 Ovarian Cancer Trial

Shares of Clovis Oncology Inc. traded 55% higher after it reported that in the Phase 3 ARIEL4 study Rubraca (rucaparib) significantly improved progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA Mutation. - 03/19/2021

Biopharma Advances Alcohol-Associated Hepatitis Trial, Receives Analgesia Drug Approval

These corporate events and the Q4/20 financials of DURECT are summarized in an H.C. Wainwright & Co. report. - 03/17/2021

Health Tech Company to Provide Patient Care Platform for 25+ Florida Nursing Facilities

Reliq Health Technologies reported it entered into a new contract with a physician practice in Florida to provide its iUGO Care platform to over 25 skilled nursing facilities statewide. - 03/17/2021

Pharma Developer to Release Topline Data from Phase 2b COVID-19 Trial by Month-End

Algernon Pharmaceuticals reported that it expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021. - 03/16/2021

Oncternal Therapeutics Shares Trade Higher After Firm Reports 39% Growth in FY20 Grant Revenue

Oncternal Therapeutics shares traded 18% higher after the company reported Q4/20 and FY/20 financial results showing higher revenues from grants and improved operating expense without incurring any reductions in Research and Development activities. - 03/12/2021

Vir Shares Head Higher as Phase 3 COVID-19 Trial with GSK Achieves 85% Reduction in Hospitalization and Death

Vir Biotechnology shares traded 30% higher after the company together with its development partner GlaxoSmithKline reported that in the Phase 3 COMET-ICE trial VIR-7831 was shown to reduce hospitalization and risk of death in early treatment of adults with SARS-CoV-2. - 03/11/2021

Biopharma Begins Phase 2 COVID Clinical Trial

An update on two of Can-Fite BioPharma's studies involving its lead drug candidate Piclidenoson is provided in a Dawson James report. - 03/10/2021

Materialise Shares Print 27% Higher on Upward Trend in Q4 Revenue

Shares of 3D printing firm Materialise NV traded higher after the company reported FY/20 financial results and indicated that sequential quarterly revenue rebounded, increasing by 11.1% in Q4/20. - 03/09/2021

RadNet Shares Rise 17% on Record Q4 Revenue and Bright Outlook for 2021

Shares of RadNet Inc. reached a new 52-week high after the diagnostic imaging company reported record revenue and adjusted EBITDA for Q4/21 and offered positive financial guidance for FY/21. - 03/08/2021

Two Studies of Life Sciences Firm's Feed Supplement to Be Featured in Journal

The positive results of two studies of Avivagen's OxC-beta in broiler poultry are slated for publication in Poultry Science. - 03/08/2021

Investors Seeing Green as FDA Approves Second Sight Medical's Argus 2s Retinal Prosthesis System

Second Sight Medical Products shares trade more than 400% higher after the company reported that the FDA granted approval for its Argus 2s Retinal Prosthesis System designed to deliver useful artificial vision to blind individuals diagnosed with retinitis pigmentosa. - 03/05/2021

Amgen Offers $1.9 Billion to Acquire Five Prime Therapeutics

Five Prime Therapeutics shares traded 78% higher after the company reported it entered into a definitive agreement to be acquired by biotech giant Amgen for $38 per share in cash. - 03/04/2021

U.S. Biopharma Making a 'Bold Move into a Large Market Opportunity'

This latest undertaking of Dicerna Pharmaceuticals and the near-term catalysts of some of its other programs are described in an H.C. Wainwright & Co. report. - 03/03/2021

Virtual HealthCare Tech Firm Reports Q2 Sequential Revenue Growth of 108%

Reliq Health Technologies reported financial results for Q2/21 that demonstrated significant increases in quarterly revenues and gross margins; management expects to achieve profitability in the quarter ending June 30, 2021. - 03/03/2021

FDA Grants Expanded Use in General Surgery for Asensus Surgical's Robotic Laparoscopic Platform

Asensus Surgical shares traded 16.5% higher after the company reported it received clearance from the U.S. Food & Drug Administration for its Senhance© Surgical System for use in general surgical procedures. - 03/03/2021

Biopharma Chooses Firm to Co-Conduct Psychedelic Dose Trial

Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer. - 03/02/2021

Virtual HealthCare Tech Firm Contracts to Provide Patient Care Platform to US Nephrology Clinic

Reliq Health Technologies reported it signed a new agreement with a Texas-based nephrology clinic to provide its iUGO Care platform to patients with chronic kidney disease. - 02/26/2021

Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck

Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share. - 02/25/2021

Telehealth Tech Company Continues Rapid Growth in COVID-Changed Landscape

Reliq Health introduces iUGO Home services and just added a care management network in California with 50 clinics and over 500 physicians. - 02/24/2021

Analyst: All Systems Are Go for Testing, Testing and More Testing

This Dawson James report explains why ProPhase Labs is perfectly positioned to benefit from expanded COVID testing. - 02/24/2021

U.S. Cannabis Company 'Cashed Up with Catalysts Materializing'

The many reasons why Columbia Care is 'due for a catch-up trade' are discussed in an Echelon Capital Markets report. - 02/24/2021

Owens & Minor Shares Soar 36% After Firm Reports Record Q4 Earnings and Positive 2021 Outlook

Shares of Owens & Minor Inc. soared to a new 52-week high after the company reported Q4/20 and FY/20 financial results that were boosted by a 58% gain in global products revenue and increases in elective medical procedures. - 02/24/2021

Company's Antibiotic-Free Livestock Feed Product Shows Positive Results in Subclinical Mastitis Dairy Trial

Avivagen Inc. reported that data from a New Zealand OxC-betaT™ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal. - 02/22/2021

Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results

New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report. - 02/17/2021

Virtual HealthCare Tech Firm Contracts with California Network of 500+ Doctors and 50 Clinics

Reliq Health Technologies reported it signed a new contract with a care management network for its iUGO Care platform to deliver customized healthcare to senior citizens in the Asian-American community throughout California. - 02/17/2021

Digital Therapeutics Leader DarioHealth Makes a Critical Acquisition

Independent financial analyst Matt Badiali discusses DarioHealth's latest acquisition and what it means for the company's growth. - 02/17/2021

Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer

Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development. - 02/17/2021

PAVmed Shares Increase 28% after First US Patient Treated with CarpX Device for Carpal Tunnel Syndrome

PAVmed Inc. shares reached a new 52-week high after the company reported that the first patient in the U.S. was successfully treated with its CarpX^® Device, a minimally invasive carpal tunnel release surgical instrument. - 02/16/2021

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial

Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol. - 02/12/2021

ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook

Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results. - 02/12/2021

AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial

Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease. - 02/11/2021

Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT

Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients. - 02/10/2021

Pacific Biosciences Shares Rise 22% on $900 Million Investment from Japan's SoftBank

Shares of Pacific Biosciences of California traded to a new 52-week high after the firm reported that a Softbank Group subsidiary will invest $900 million to support its growth initiatives. - 02/10/2021

Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke

This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report. - 02/05/2021

Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases

The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report. - 02/05/2021

Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers

DELIC aims to become a leader in psychedelic health and wellness clinics. - 02/04/2021

Align Technology Shares Grind 12.5% Higher after Firm Posts Record Q4 Revenue of $834.5 Million

Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion. - 02/04/2021

Neurosciences Firm Provides Insight on Recent Alzheimer's/Amyloid Field Developments

ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class." - 02/03/2021

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals

Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share. - 02/03/2021

Cassava Shares Triple After Interim Trial Data Shows Simufilam Improves Cognition and Behavior in Alzheimer's Disease

Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients. - 02/02/2021

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT, the 'Spirit Molecule'

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021. - 02/01/2021

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics

Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. - 02/01/2021

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial. - 01/29/2021

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19. - 01/28/2021

Coverage Initiated on Biotech 'Improving Drugs Via Prodrug'

KemPharm's key near-term catalyst, lead value driver and other pipeline drug candidates are discussed in a ROTH Capital Partners report. - 01/27/2021

Life Sciences Co. Receives Large Livestock Feed Order from New Client in Mexico

Avivagen Inc. reported it has secured a six tonne order for OxC-beta™ Livestock from a new customer in Queretaro City, Mexico. - 01/27/2021

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients. - 01/27/2021

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen. - 01/26/2021

Telemedicine Firm Partners to Offer Reliq Health's iUGO Care RPM and CCM Platforms

iDocsWeb reported it formed a strategic partnership with Reliq Health Technologies to offer that firm's iUGO Remote Patient Monitoring, Chronic Care Management and Behavioral Health solutions platforms to its U.S. customers. - 01/25/2021

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis. - 01/25/2021

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. - 01/22/2021

Healthcare Tech Firm Announces New Multilingual IVR Product

Reliq Health Technologies launched a multilingual interactive voice recognition product called iUGO Care IVR and has contracted with a Maryland physician practice to offer the service to patients speaking Russian and English. - 01/21/2021

Imagin Medical Is Bringing Cystoscopy into the 21st Century

Dr. KSS, MD, PhD, editor-in-chief of PubBio.co, profiles a small cap that "is poised to bring to clinic a next-generation of must-have cystoscopy equipment." - 01/21/2021

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study

Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2. - 01/20/2021

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2. - 01/20/2021

Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin

Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform. - 01/19/2021

Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial

Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis. - 01/19/2021

Neurosciences Firm Outlines Strategic Priorities for 2021

ProMIS Neurosciences discusses its four priority areas in 2021. - 01/15/2021

Avinger Shares Rise 40% on Launch of Image-Guided Device to Diagnose and Treat PAD

Shares of Avinger Inc. reached a new 52-week high after the company reported it initiated a full commercial launch of its Tigereye™ Image-Guided CTO Crossing Catheter system for diagnosing and treating peripheral artery disease. - 01/15/2021

As Psychedelics Move Mainstream, Small Cap Positions Itself at the Center of the Industry

Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector. - 01/13/2021

Inari Shares Flow 14% Higher on Triple Digit YoY Growth in Procedures and Revenues

Shares of Inari Medical Inc. established a new 52-week high after the company reported that preliminary revenue in Q4/20 increased year-over-year by greater than 140%. - 01/13/2021

Mesoblast Reports Phase 3 Trial Data Showing Substantial Reductions in Cardiac and Stroke Events in CHF Patients

Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure. - 01/11/2021

A Novel, First-in-Class Blood Clotting Agent Takes Shape as a Bloody Compelling Investment

Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of PubBio.co. Can it go the distance through proof of concept? - 01/11/2021

Pharma Developer Outlines 2021 Clinical Program Initiatives

Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials. - 01/08/2021

Chimerix Expands Late-Stage Oncology Pipeline Through $78M Oncoceutics Acquisition

Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million. - 01/08/2021

Small-Cap Tech Stock Sees Huge Rise; What's Next?

Technical analyst Clive Maund charts Leonovus and discusses what could lie ahead for the stock after it gained 150%. - 01/07/2021

Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results

The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report. - 01/06/2021

This Tiny Digital Healthcare Company's Sales Should Rocket Higher

Independent financial analyst Matt Badiali profiles a small cap whose blood glucose monitoring system works with any smartphone. - 01/06/2021

Change Healthcare Shares Surge 30% on $7.8B Merger with UNH's OptumInsight

Change Healthcare shares rose to a new 52-week high after the company reported it will be combining its operations with UnitedHealth's OptumInsight in an all cash purchase transaction for $25.75 per share. - 01/06/2021

This Tiny Tech Stock Is Quietly Building a Huge Business in Air Quality

Independent financial analyst Matt Badiali discusses how mCloud's technology is making it possible for office buildings to reopen during the pandemic. - 01/05/2021

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease

Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil. - 01/04/2021

Biopharma Appoints Adviser for Phase 3 COVID-19 Trial

Revive Therapeutics selects Dr. John Fahy, California-based pulmonary medicine expert and researcher, to join its team. - 01/04/2021

Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease Trial

Pandion Therapeutics shares traded 35% higher after the company reported positive top-line data from its Phase 1a clinical study of PT101 for treating autoimmune diseases including ulcerative colitis and systemic lupus erythematosus. - 01/04/2021

California Biotech Advances Two COVID-19 Products

Recent news concerning Sorrento Therapeutics' SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report. - 12/30/2020

Biotech On Track for Trio of Drugs in Clinical Trials in 2021

The next steps for advancing Oramed Pharmaceuticals' oral therapy candidates are provided in an H.C. Wainwright & Co. report. - 12/30/2020

DermTech Shares Rise 32% on Geisinger Health Support for Skin Cancer Test

Shares of DermTech Inc. climbed to a new 52-week high after the company reported it has received positive medical coverage by Geisinger Health System for its pigmented lesion assay, a non-invasive test for detecting melanoma. - 12/30/2020

Phase 3 COVID-19 Trial on Track for Independent Safety, Efficacy Review

Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication. - 12/29/2020

Myovant Shares Rise 25% on $4.2 Billion Development Partnership with Pfizer

Shares of Myovant Sciences established a new 52-week high after the company entered into an agreement with Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) for advanced prostate cancer and relugolix combination tablet for women's health in the U.S. and Canada. - 12/28/2020

Analyst: Differences Between Two Possible COVID-19 Therapies Noteworthy

The factors that set Athersys' stem cell product MultiStem apart from a competitor's therapeutic are provided in a Dawson James Securities report. - 12/23/2020

Positive Data from Phase 3 Adult ADHD Trial Lifts Supernus Pharma Shares 17% Higher

Supernus Pharmaceuticals shares reached a new 52-week high price after the company reported positive results from its Phase 3 Study of SPN-812 for treating adults with attention deficit hyperactivity disorder. - 12/23/2020

Life Sciences Company to Acquire Psychedelic Pharmaceutical Firm's Psilocybin Program

Revive Therapeutics reported it has submitted a non-binding letter of intent to acquire 100% of PharmaTher Inc.'s psilocybin program. - 12/22/2020

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study

Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial. - 12/21/2020

Agios Pharma Agrees to Sell Oncology Business to Servier for US$2 Billion Plus Royalties

Shares of Agios Pharmaceuticals traded 30% higher after the company reported that it has agreed to sell its oncology research business to France's Servier Group in a transaction valued up to US$2 billion in cash plus future royalties. - 12/21/2020

Life Sciences Firm Reports Year of Record Breaking Orders

Avivagen Inc. reported FY/20 audited financial results that included a 20.5% increase in YoY revenue. - 12/18/2020

BioTelemetry Shares Beat Higher on Royal Philips $2.8 Billion Buyout Offer

Shares of BioTelemetry Inc. rise 16.5% to a new 52-week high after Royal Philips agreed to acquire the company for US$2.8 billion, or US$72.00 per share in an all cash transaction. - 12/18/2020

Humanigen Shares Rise on Completing Phase 1 Brain Cancer Trial Enrollment

Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme. - 12/17/2020

Why XPhyto's PCR Test Kit Is a Game Changer for COVID-19 Testing

Extraordinary achievement promises to help turn the tide against the COVID 19 pandemic, Knox Henderson writes. - 12/17/2020

US Specialty Pharma Makes 'Another Acquisition to Bolster Topline'

The transaction details and expected impact on Aytu BioScience's balance sheet are provided in a Ladenburg Thalmann report. - 12/16/2020

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends'

Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report. - 12/16/2020

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial

Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators. - 12/16/2020

Eli Lilly's $1.04 Billion Buyout Offer Sends Prevail Therapeutics' Shares 82% Higher

Shares of Prevail Therapeutics reached a new 52-week high after the company reported it has signed a definitive agreement to be acquired by Ely Lilly in a deal valued up to $1.04 billion. - 12/15/2020

Alexion Pharma Shares Jump 30% on AstraZeneca's $39 Billion Buyout Offer

Shares of Alexion Pharmaceuticals reached a new 52-week high after the company reported it entered into a definitive agreement to be acquired by AstraZeneca in a combination cash and stock deal valued at US$39 billion. - 12/14/2020

NantHealth's Shares Gain 35% after Presenting Breast Cancer Treatment Insights to Texas Conference

Shares of NantHealth Inc. climbed to a new 52-week high after the healthcare IT company presented what it called significant treatment insights at the 2020 San Antonio Breast Cancer Symposium. - 12/11/2020

TG Therapeutics Shares Rise 40% on Positive Topline Data from Two Phase 3 RMS Trials

Shares of TG Therapeutics reached a new 52-week high after the company released positive topline results from the Phase 3 ULTIMATE I & II Studies of ublituximab as a monotherapy for treating relapsing multiple sclerosis. - 12/10/2020

Grenwich Shares Skyrocket 2,300% After Firm Presents 5-Year Clinical Breast Cancer Trial Data Showing 0% Recurrence

Shares of Grenwich Lifesciences soared more than 2,300% to a new 52-week high after the company gave a poster presentation of 5-year data for the Phase 2b GP2 clinical trial that showed 0% recurrence of breast cancer. - 12/09/2020

Curis Shares Soar 300% on Positive Data from Two Ongoing Phase 1 Cancer Studies

Curis Inc. shares reached a new 52-week high after the cancer therapeutics developer reported positive preliminary data from two Phase 1 studies, one treating relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes and another treating relapsed or refractory non-Hodgkin's lymphoma. - 12/08/2020

Fate Therapeutics Shares Twist 37% Upward on Data from Two Phase 1 B-cell Lymphoma Trials

Fate Therapeutics shares set a new 52-week high after the firm reported positive interim data from its Phase 1 Study of FT516 in combination with rituximab for B-cell lymphoma. In a separate Phase 1 study, the company presented the results of a patient treated with natural killer cell cancer immunotherapy FT596 in refractory diffuse large B-cell lymphoma. - 12/07/2020

Biotech's Potentially Disruptive Diagnostics Platform on 'Cusp of Commercialization'

Recent trial results, a timeline to the launch of Quotient's system and the reasons the debut should be successful are discussed in a Cowen report. - 12/06/2020

BioCryst Awarded FDA Approval for Medicine Preventing Attacks in HAE Patients

BioCryst Pharmaceuticals shares traded 17% higher after the company reported that the FDA approved its once-daily oral therapy ORLADEYO™ (berotralstat) for prevention of attacks in hereditary angioedema patients. - 12/04/2020

Oramed Pharma Shares Gain 11% as Firm Initiates Phase 2 NASH Trial of Oral Insulin

Shares of Oramed Pharmaceuticals traded higher after the company announced that it has initiated a Phase 2 NASH trial of oral insulin as a complementary agent or alternative to insulin injections. - 12/03/2020

Biotech Licenses Platform for Faster Pathway for Cancer and COVID-19 Vaccine Trials

The rationale behind OncoSec Medical using this system is discussed in a Dawson James report. - 12/02/2020

Patterson Company's Shares Gain 13% on Q2 Earnings and 9.5% YoY Sales Growth

Patterson Companies shares traded higher and set a new 52-week high after the firm reported Q2/21 financial results which included a 12.1% YoY increase in dental equipment and consumable supply sales. - 12/02/2020

Novavax Shares Get a Boost from Developments at Three Separate COVID-19 Vaccine Trials

Novavax shares traded 11% higher after the company finalized enrollment in two advanced COVID-19 vaccine clinical trials with a third one slated to commence in the coming weeks. - 11/30/2020

Rhythm Pharma Earns FDA Approval for Chronic Weight Management Drug for Rare Genetic Obesity Diseases

Shares of Rhythm Pharmaceuticals traded 25% higher after the FDA granted approval of IMCIVREE™ (setmelanotide) as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency. - 11/27/2020

Pharma Developer Raises Enrollment Goal for Multinational Phase 2b/3 COVID-19 Trial

Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition. - 11/25/2020

Biopharma Targeting Glioblastoma Multiforme Commences Clinical Program

Preclinical results for Black Diamond Therapeutics' kinase inhibitor, BDTX-1535, are reviewed in an H.C. Wainwright & Co. report. - 11/25/2020

U.S. Biopharma Expands Into ALS, Doses First Patient in 'Potentially Pivotal' Trial

The design of Apellis Pharmaceuticals and its partner's clinical study is presented in a ROTH Capital Partners report. - 11/25/2020

Renalytix AI Shares Climb 30% on Q1 Earnings and EUA for JV's SARS-CoV-2 IgG Antibody Test Kit

Shares of Renalytix AI Plc. traded 30% higher after the company reported Q1/21 financial results and that its joint venture with Mt. Sinai Health System was granted Emergency Use Authorization by the FDA for its SARS-CoV-2 IgG antibody test kit. - 11/25/2020

Biotech Collaborates to Advance Psychedelics Use in Cancer, Other Applications

Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm. - 11/23/2020

Precision BioSciences & Eli Lilly Partner to Develop In Vivo Therapies for Genetic Disorders

Precision BioSciences shares traded 13% higher after the company reported it is partnering with Eli Lilly & Co. to develop in vivo therapies for genetic disorders with an initial focus on Duchenne's muscular dystrophy and two other undisclosed gene targets. - 11/20/2020

Corcept Therapeutics Shares Rise 25% on Favorable U.S. Patent Office Ruling

Shares of Corcept Therapeutics reached a new 52-week high after the firm reported that the U.S. Patent Trial and Appeals Board affirmed that all claims pertaining to its U.S. Patent No.10,195,214 are valid. - 11/19/2020

Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering

Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock. The report came one day after the firm advised it had completed enrollment of its Phase 2b/3 Pivotal DAZZLE Study of KSI-301 in patients with wet age-related macular degeneration. - 11/18/2020

Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies

Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits. - 11/17/2020

Psychedelic Company Expected to Begin Trading Nov. 18

Delic Corp., a thought leader in psychedelics, will trade on the Canadian Securities Exchange. - 11/17/2020

Moderna Shares Get a Boost from Phase 3 COVID-19 Vaccine Trial Data Demonstrating 94.5% Efficacy

Moderna shares traded 10% higher to a new 52-week high after the company reported its COVID-19 vaccine candidate, mRNA-1273, met its primary endpoint in the first interim analysis of the Phase 3 COVE Study by achieving an efficacy rate of 94.5%. - 11/16/2020

Life Sciences Firm Completes Development of Dissolvable Oral Psilocybin

Revive Therapeutics reported that it has developed an oral thin-film strip psilocybin product with doses ranging from 1 to 20 milligrams. - 11/14/2020

Urovant Sciences Shares Double on Sumitovant Biopharma Buyout Offer

Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash. - 11/13/2020

Biotech Involved in COVID-19, Neurodegenerative Diseases Reports Q3/20 Results

ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus. - 11/12/2020

Biotech Comments on FDA Advisory Committee Recommendation of Not Licensing Alzheimer's Drug

ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab. - 11/11/2020

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December

Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020. - 11/11/2020

Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic

Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report. - 11/11/2020

Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial

Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer. - 11/11/2020

Individuals Succeed Using This Digital Therapy—Now It's Moving to Insurers

Independent financial analyst Matt Badiali profiles a digital therapeutics company that is changing diabetes treatment. - 11/10/2020

Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned

Pfizer shares traded 9% higher to a new 52-week high after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021. - 11/09/2020

Draganfly Screening Technology Battles Campus, Public Facilities Health Challenges

Knox Henderson delves into how Draganfly's cutting-edge technology is making it possible for universities and other organizations to operate safely during the pandemic. - 11/09/2020

Glaukos Shares Pressured Higher After Firm Reports 11% Rise in Q3 Revenue

Shares of Glaukos Corp. traded 9% higher after the company reported Q3/20 financial results that included an 11% YoY increase in glaucoma and corneal health net sales. - 11/06/2020

U.S. Biotech Developing Cancer Therapeutics Has 'Deep Pipeline'

ImmunoGen's broad pipeline that "could support long-term growth" is discussed in an H.C. Wainwright & Co. report. - 11/04/2020

Supernus Pharma Shares Trade Up 21% on 52% Increase in Q3 YoY Revenue

Shares of Supernus Pharmaceuticals traded higher after the company reported financial results for Q3/20 that included a 52% increase in total revenues versus the same period in 2019. - 11/04/2020

Inspire Medical's Shareholders Rest Comfortably on Q3 Earnings and Raised FY Outlook

Shares of Inspire Medical Systems traded 30% higher and set a new 52-week high after the company reported Q3/20 financial results that included a 72% rise in YoY revenue. - 11/03/2020

Multinational Phase 2b/3 COVID-19 Study Approved to Continue

Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy. - 11/02/2020

Acadia Healthcare Shares Rise 20% on Q3 Earnings and Positive Forward Guidance

Shares of Acadia Healthcare reached a new 52-week high after the company reported Q3/20 financial results that included a 7.5% YoY increase in revenue at its U.S. health facilities. - 10/30/2020

Biotech Expects Interim Analysis Data from Phase 3 COVID-19 Study by Year-End

Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial. - 10/28/2020

Exact Sciences Shares Rise 29% as Firm Announces Q3 Earnings, a Capital Raise and Two Acquisitions

Exact Sciences Corp. shares reached a new 52-week high after the maker of cancer screening test Cologuard reported Q3/20 financial results that included a greater than 86% increase in year-over-year revenue. - 10/27/2020

Mirati Therapeutics' Shares Rise 12.5% on Positive Data from Cancer Studies

Mirati Therapeutics' shares reached a new 52-week high after the company reported preliminary data for Adagrasib (MRTX849) demonstrated durable anti-tumor activity in its non-small cell lung cancer and colorectal cancer studies. - 10/26/2020

Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month

ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic. - 10/23/2020

Align Technology Shares Head Straight Up on 20.9% Q3 Revenue Growth as Firm Celebrates its 9 Millionth Invisalign Patient

Shares of Align Technology traded 35% higher and climbed to a new 52-week high after the company reported Q3/20 financial results that included a 20.9% YoY increase in net revenues. - 10/22/2020

Biotech Secures Supplier of Psilocybin, Other Psychedelics

Revive Therapeutics will use these products in future studies and clinical trials. - 10/21/2020

Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial

Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder. - 10/20/2020

BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals

Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction. - 10/19/2020

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury

Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co. - 10/19/2020

Organogenesis Shares Rise 20% on Q3 Net Revenue Growth and FY Guidance

Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue. - 10/15/2020

Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled

Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug. - 10/14/2020

Life Sciences Firm Lands Record 4 Metric Tons Order for Antibiotic-Free Feedstock

Avivagen Inc. reported that it has received a record purchase order for its OxC-beta™ product from UNAHCO. - 10/14/2020

Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment

The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report. - 10/14/2020

Allscripts Agrees to Sell Its CarePort Health Business for $1.35 Billion

Shares of Allscripts Healthcare Solutions traded 30% higher after the company reported it has agreed to sell its CarePort Health business to WellSky Corp. for $1.35 billion. - 10/14/2020

Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate

Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate. - 10/13/2020

CareDx Shares Trade Up 15% After Announcing 57% YoY Increase in Q3 Revenue

CareDx shares established a new 52-week high after the company reported that preliminary revenue in Q3/20 increased 57% year-over-year to $53.0 million. - 10/08/2020

StreetSmart Live! Presents Algernon Pharmaceuticals

Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events. - 10/08/2020

Immunotherapy Firm Announces Positive Top-Line Trial Results for Severe and Critical COVID-19 Patients

The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report. - 10/07/2020

Creator of Antibiotic-Free Livestock Supplement Extends Reach in Mexico

Avivagen reports that it has gained both new customers and increased access to prospective ones. - 10/07/2020

Ocular Therapeutix Shares Rise 25% After Firm Reports 250% Sequential Increase in Q3 Revenue

Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter. - 10/07/2020

Biopharma's Multinational COVID-19 Study Hits 75% Enrollment Mark

Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end. - 10/05/2020

MyoKardia Shares Don't Skip a Beat on $13.1 Billion Acquisition by Bristol Myers Squibb

Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash. - 10/05/2020

American Renal Associates Agrees to Private Equity Firm's $853 Million Buyout Offer

Shares of American Renal Associates traded 67% higher and set a new 52-week high after the company reported that it has entered into a definitive agreement to be acquired by a Nautic Partners LLC affiliate for $11.50 per share in cash. - 10/02/2020

CloudMD: The Best Bet in Telehealth?

Peter Epstein of Epstein Research reviews the reasons he believes CloudMD is poised for substantial growth compared to peers. - 10/01/2020

AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm

Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis. - 10/01/2020

Coverage Initiated on Telemedicine Firm in 'Strong Position for Long-Term Growth'

The investment thesis for CloudMD Software & Services is presented in a Mackie Research Capital Corp. report. - 09/30/2020

Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial

Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19. - 09/30/2020

Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial

Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin. - 09/30/2020

Genetron Receives FDA Breakthrough Approval for Hepatocellular Carcinoma Detection Device

Genetron Holdings Ltd. shares traded 25% higher after the company reported it has received Breakthrough Device Designation from the FDA for its blood-based next-generation sequencing test for early hepatocellular carcinoma detection. - 09/30/2020

Aptorum Shares Skyrocket Upon Launching Infectious Disease Liquid Biopsy Unit

Shares of Aptorum Group Ltd. traded nearly 300% higher after the company reported it launched an infectious disease liquid biopsy start-up subsidiary. - 09/29/2020

GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test

GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test. - 09/28/2020

Owens & Minor Shares Climb 50% after Raising FY/20 Earnings Guidance by 66%

Shares of Owens & Minor Inc. reached a new 52-week high after the company raised FY/20 earnings guidance by 66% and advised it expects the positive earnings trend to continue in 2021. - 09/24/2020

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study

Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. - 09/23/2020

California-Based Biotech Receives COVID-19 Trial Clearance

The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report. - 09/23/2020

Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens

ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies. - 09/23/2020

AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study

AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands. - 09/22/2020

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients

Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. - 09/21/2020

Biopharma Advances Development of Psilocybin-Based Therapeutics

Revive Therapeutics provides an update on its psychedelics therapeutics programs. - 09/21/2020

Pharma Greenlighted to Continue Multinational COVID-19 Study

This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial. - 09/18/2020

Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19

Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data. - 09/17/2020

Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial

Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients. - 09/17/2020

Further Trial Data Analyses 'Reinforce' Profile of Biopharma's Multiple Sclerosis Drug

The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report. - 09/16/2020

Arrowhead Shares Point Higher on Positive Interim Data in Phase 2 Liver Disease Trial

Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease. - 09/16/2020

Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results

Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy. - 09/15/2020

Amwell, with $100 Million Google Investment and Access to 80 Million Patients, Expected to Begin Trading on NYSE Sept. 17

Virtual care company American Well Corp., which operates under the name Amwell®, is expected to begin trading on the New York Stock Exchange on Thursday, September 17, under the symbol AMWL. - 09/15/2020

Immunomedics' Shares Double on Gilead's $21 Billion Buyout Offer

Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash. - 09/14/2020

As COVID Is Turbocharging the Adoption of TeleHealth, Small Cap Is Growing Exponentially

All three brokerage firms that cover the rapidly expanding CloudMD Software & Services rate the company a Speculative Buy, and now the company has gained a toehold in the U.S. - 09/09/2020

Life Sciences Company Posts Record Q3 Revenue Due to Successful Recurring Purchase Model

Avivagen Inc. reported unaudited financial results for Q3/20 that included record revenue and product sales volumes that nearly eclipsed FY/19 levels. - 09/09/2020

Intra-Cellular Shares Soar on Positive Bipolar Depression Study Findings

Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy. - 09/09/2020

U.S. Medical Device Firm to Acquire Developer of Dissection Stent

The specifics of the deal and the next steps for CryoLife are presented in a Ladenburg Thalmann report. - 09/09/2020

Trillium Shares Get Boost from Dose Escalation Trial Data and Pfizer's $25 Million Equity Investment

Trillium Therapeutics shares traded 37% higher after the company reported updated results from its ongoing TTI-622 and TTI-621 Dose Escalation Studies along with a $25 million equity investment from Pfizer Inc. - 09/09/2020

Biopharma Achieves 'Big Phase 3 Win' for its Pediatric Intrahepatic Cholestasis Drug

The recent study results of Albireo Pharma's lead therapeutic candidate are discussed in an H.C. Wainwright & Co. report. - 09/09/2020

Biotech Partners with University to Evaluate Psilocybin for Treating Methamphetamine Use Disorder

Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder. - 09/04/2020

Life Sciences Firm Gains Protocol Approval for Phase 3 COVID-19 Study

Revive Therapeutics reported that a renowned independent institutional review board has approved its proposed Phase 3 clinical trial protocol for Bucillamine in COVID-19. - 09/02/2020

Aimmune Therapeutics Shares Soar on Nestlé Health Science's $2.6 Billion Buyout

Aimmune Therapeutics shares traded 170% higher after the company reported it entered into a definitive agreement to be acquired by Nestlé for $34.50 per share in cash. - 08/31/2020

Firm Submits Clinical Protocol for IRB Approval for Phase 3 COVID-19 Trial

Revive Therapeutics reported it submitted the clinical protocol for independent Institutional Review Board approval for its Phase 3 study of Bucillamine in COVID-19. - 08/28/2020

VBI Shares Climb 34% After Identifying Two One-Dose COVID-19 Vaccine Candidates

VBI Vaccines shares traded higher after the company reported preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines. - 08/27/2020

Firm's Home Health Monitoring System Provides the 'Most Comprehensive Offering in the Telehealth Space'

As the Covid pandemic accelerates the adoption of telemedicine technology, Reliq Health Technologies' recent contracts represent exponential growth. - 08/26/2020

Fluidigm Shares Climb 34% After FDA Authorizes Saliva-Based COVID-19 Test

Fluidigm Corp. shares reached a new 52-week high after the firm reported the FDA granted Emergency Use Authorization for saliva-based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19. - 08/26/2020

CytoDyn Receives the UK's MHRA Approval for Phase 3 COVID-19 Study

CytoDyn Inc. shares traded higher after the company reported it received authorization from the U.K.'s MHRA to proceed with its Phase 3 study of leronlimab in patients with severe-to-critical COVID-19. - 08/24/2020

Cryoport to Acquire CRYOPDP for €49 Million to Expand Global Supply Chain

Shares of Cryoport Inc. reached a new 52-week high after the company reported it signed an agreement to acquire French firm CRYOPDP in an all cash transaction valued at €49 million. - 08/21/2020

CureVac Shares Rise on Talks with EC to Supply 405 Million mRNA-Based COVID-19 Vaccine Doses

CureVac NV shares traded 13% higher after the company reported it is in advanced discussions with the European Commission to supply up to 405 million doses of a potential mRNA-based COVID-19 vaccine. - 08/20/2020

Biotech Releases Positive Interim Results from Cystic Fibrosis Study

This and other recent key events of AzurRx BioPharma are recapped in a ROTH Capital Partners report. - 08/19/2020

California Biopharma to be Acquired by Sanofi for $3.6 Billion

The deal is summarized and Principia Biopharma's Q2/20 clinical achievements are recapped in an H.C. Wainwright & Co. report. - 08/19/2020

Momenta Pharmaceuticals Shares Rise 69% on $6.5 Billion Johnson & Johnson Takeover Bid

Shares of Momenta Pharmaceuticals set a new 52-week high after the company reported it entered into a definitive agreement with Johnson & Johnson to be acquired for $52.50 per share in cash. - 08/19/2020

Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial

Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2. - 08/17/2020

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20

One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test. - 08/14/2020

Telemedicine Firm Continues Expansion by Acquiring Majority Interest in Ontario Medical Clinic

The clinic will be integrated into the CloudMD EMR platform. - 08/14/2020

Mesoblast Shares Rocket Higher as FDA Committee Votes in Favor of Remestemcel-L for Pediatric SR-aGVHD Patients

Shares of Mesoblast Ltd. traded 50% higher after the company reported that the U.S. FDA's Oncologic Drugs Advisory Committee voted nine to one in favor of remestemcel-L (RYONCIL™) for efficacy in children with steroid-refractory acute graft versus host disease. - 08/14/2020

Life Sciences Firm Signs MOU for Phase 3 COVID-19 Study

Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19. - 08/14/2020

Biotech Develops Oral Film Strips for Psychedelic Medicine Delivery

This development is a technical milestone for Revive Therapeutics and its drug delivery technology. - 08/12/2020

Pennant Group Shares Fly 40% Higher on Q2 Earnings and Raised FY Adjusted EPS Guidance

Shares of The Pennant Group reached a new 52-week high after the company reported a 12.1% increase in Q2/20 revenue and raised FY/20 adjusted EPS guidance by 34.2%. - 08/12/2020

Life Sciences Company Registers First Non-Antibiotic Livestock Feed Additive Sale in Brazil

Avivagen Inc. reported it achieved its first sale of OxC-beta™ Livestock in Brazil, the world's third largest livestock feed market. - 08/12/2020

Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia

Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea. - 08/11/2020

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial

Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection. - 08/10/2020

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space?

Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile. - 08/10/2020

$18.5 Billion Merger Could Mean Big Gains for These Five Tiny Telemedicine Stocks

Independent financial analyst Matt Badiali examines five small companies poised to profit as digital health becomes mainstream during the coronavirus pandemic. - 08/10/2020

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial

Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. - 08/08/2020

Biopharma Preparing to Initiate Phase 3 COVID-19 Trial

Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September." - 08/07/2020

Denali Shares Rise 37% on Advancement of DNL151 into Late Stage Parkinson's Trials

Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen. - 08/06/2020

US Immunology Firm Lands Government Contract, Raises Cash

These two CytoSorbents events are discussed in a Dawson James report. - 08/05/2020

Tech Firm Explains Key Feature of its Contact Tracing Solution

Loop Insights' technology lacks the adoption challenges that app-based solutions face. - 08/05/2020

Fulgent Genetics' Shares Reach New 52-Week High After Posting 105% Increase in Q2 Revenue

Shares of Fulgent Genetics traded 22% higher after the company reported it posted a record $17.1 million in Q2/20 revenue and completed a record 180,513 billable tests in the quarter. - 08/05/2020

Mobile Health Tech Firm Joins with US Healthcare Group to Bring Care Platform to 50,000 Patients

Reliq Health Technologies reported it has entered into a new contract with Diversified Healthcare Partners to provide its iUGO Care platform to more than 50,000 patients in three U.S. states. - 08/04/2020

Biopharma Gets FDA Approval for Phase 3 COVID-19 Trial

Revive Therapeutics' trial will test Bucillamine in patients with mild to moderate COVID-19. - 08/04/2020

Ten Good Reasons to Invest Now Pre-Market in Acurx Pharmaceuticals

Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years. - 08/03/2020

Coverage Initiated on 'Emerging Colossus in Diagnostics and Life Science'

Meridian Bioscience's business segments, revenue and growth as well as COVID-19's positive impact on them are reviewed in an H.C. Wainwright & Co. report. - 07/29/2020

Digital Health Firm Signs Deal to Acquire Vancouver Medical Clinic Serving 60,000 Patients

CloudMD reported it entered into a definitive agreement to acquire South Surrey Medical Clinic in Metro Vancouver in a combination stock and cash deal valued at CA$700,000. - 07/29/2020

Kodak Shares Triple in a Flash on $765 Million Loan from DFC for New Pharmaceutical Unit

Eastman Kodak shares traded more than 200% higher after the company reported it is forming a new business unit to produce essential pharmaceutical components funded by the U.S. International Development Finance Corporation. - 07/28/2020

TCR2 Therapeutics Reports Positive Results in Mesothelin-Expressing Solid Tumor Study

Shares of TCR2 Therapeutics traded 30% higher after the firm released encouraging results from the Phase 1 portion of its clinical study of TC-210 in treating advanced mesothelin-expressing solid tumors. - 07/27/2020

Milestone Shares More than Double After Presenting Updated Clinical Plan for Heart Condition

Shares of Milestone Pharmaceuticals traded 150% higher after the company reported regulatory guidance and updated its clinical development plan for etripamil nasal spray designed for self-administered use in PSVT treatment. - 07/23/2020

Biopharma's Therapeutic Jumps to Phase 2 Testing for COVID-19 'to Shut Down the Cytokine Storm'

A development update on Sorrento Therapeutics' three coronavirus-related products is provided in a Dawson James report. - 07/22/2020

HCA Healthcare Shares Move Up on Q2 Earnings and Resumption of Non-Emergency Procedures

Shares of HCA Healthcare traded more than 10% higher after the company reported Q2/20 financial results and advised it has seen a gradual rise in patient volumes in May and June for elective and non-emergency procedures. - 07/22/2020

Owens & Minor Shares Trade 75% Higher on Preliminary Q2 Earnings and Raised FY Guidance

Shares of Owens & Minor reached a new 52-week high after the company reported preliminary Q2/20 results and raised FY/20 earnings guidance. - 07/21/2020

AI Tech Firm Provides COVID-19 Contact Tracing Solution Update

Loop Insights continues to educate governments and venue operators around the world about its easily implemented platform. - 07/20/2020

Innovative Telehealth Company to Acquire Firm with Mental Health Platform

With this transaction, CloudMD Software & Services will become Canada's first telemedicine company with both primary care and mental health care components. - 07/18/2020

Dynavax Shares Rise 20% on Partnership with Mount Sinai to Develop Universal Flu Vaccine

Shares of Dynavax Technologies reached a new 52-week high after the company reported that it is collaborating with Mount Sinai to develop a universal influenza vaccine candidate with CpG 1018 adjuvant. - 07/17/2020

Cheap Valuation and Fastest Revenue Growth in Telemedicine? Analyst Says Yes.

In the time of Covid-19, Peter Epstein of Epstein Research breaks down the investment opportunity offered by CloudMD. - 07/17/2020

Threat Detection Company's AI Division Partners with Healthcare Firm to Increase Cancer Testing Access

Patriot One Technologies reported its Xtract AI division is working with Canexia Health to increase access to cancer testing as part of the Digital Technology Supercluster COVID-19 Program project. - 07/16/2020

AC Immune Shares Rise 19% as Firm Advances Alzheimer's Vaccine in Phase 1b/2a Trial

AC Immune SA shares set a new 52-week high after the Swiss biotech firm reported that interim data from its Phase 1b/2a phospho-Tau Alzheimer's Vaccine study reconfirms promising safety and Tau-specific immunogenicity observed in the prior clinical trial. - 07/16/2020

Taiwan Liposome Shares Rise 60% on Inhalable Liposomal HCQ Potential Covid-19 Treatment Claims

Shares of Taiwan Liposome Co. reached a new 52-week high after the company released a manuscript describing how its inhalable liposomal hydroxychloroquine may provide clinical benefit and offer a potential treatment for Covid-19. - 07/15/2020

Virtual Healthcare Tech Firm's Contract in Puerto Rico Is Its Largest by 400%

Reliq Health Technologies' agreement with digiiMED makes its platform available to more than 200,000 patients. - 07/15/2020

Potential Covid-19 Treatment Is Ready for Prime Time

Small-cap Algernon Pharmaceuticals is about to begin a multinational Phase 2b/3 trial for Ifenprodil, a repurposed drug with a known safety record. - 07/14/2020

INmune Bio Shares Double after Reporting Positive Phase 1b Alzheimer's Trial Data

Shares of INmune Bio reached a new 52-week high after the company reported interim data from its Phase 1b study of XPro1595 that demonstrated decreased neuroinflammation in Alzheimer's patients. - 07/14/2020

Analyst: Integrated Model Positioned to Monetize on Telehealth Emergence

Echelon Capital Markets initiates coverage and explains why it is bullish on CloudMD Software & Services. - 07/13/2020

Biotech Partners to Develop, Offer Alzheimer's Disease Tests

ProMIS Neurosciences and its collaborator make their relationship official with a joint venture agreement. - 07/13/2020

BioNTech Shares Rise as FDA Grants It and Partner Pfizer Fast Track Status for Two Covid-19 Vaccine Candidates

Shares of BioNTech SE traded 15% higher after the company reported that, together with its partner Pfizer, it has received FDA Fast Track designation for two separate mRNA-based vaccine candidates against SARS-CoV-2. - 07/13/2020

Threat Detection Company Forms Partnership to Advance Covid-19 Pathogen Screening

Patriot One Technologies reported it is collaborating with ecoMine Technologies to advance pathogen screening applications as part of Canada's Digital Technology Supercluster's Covid-19 program. - 07/12/2020

Altimmune Shares Up 20% Upon Forming Partnership for Intranasal COVID-19 Vaccine

Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVID™, its COVID-19 vaccine candidate. - 07/09/2020

Biotech with Phase 3 Rheumatoid Arthritis and Psoriasis Trials Raises Capital, Now 'Funded Through Catalysts'

An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report. - 07/08/2020

Preclinical COVID-19 Vaccine Data 'Encouraging'

Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report. - 07/08/2020

Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial

In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications. - 07/08/2020

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. - 07/01/2020

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. - 07/01/2020

Life Sciences Firm Submits IND Application to FDA for Phase 3 COVID-19 Study

Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2. - 07/01/2020

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. - 07/01/2020

Biopharma's Multinational COVID-19 Study Receives US Ethics Approval

Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well. - 06/30/2020

Life Sciences Firm Gains Approval to Sell Non-Antibiotic Livestock Feed Additive in Brazil

Avivagen reported it received approval for use of OxC-beta™ Livestock in Brazil and it has signed an agreement with a São Paulo company for distribution. - 06/25/2020

Vaxart Shares Rise 95% After Signing Agreement for Oral Tablet COVID-19 Vaccine

Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually. - 06/25/2020

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. - 06/24/2020

Telemedicine Firm to Acquire Majority Interest in Ontario Clinic

With this transaction, CloudMD Software & Services expands its size and reach. - 06/23/2020

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines

Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas. - 06/23/2020

Invitae Corp. Enters into Definitive Agreement to Acquire ArcherDX

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. - 06/22/2020

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients

Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. - 06/19/2020

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. - 06/18/2020

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. - 06/17/2020

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment

The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. - 06/17/2020

Biotech Makes 'Significant Progress' Creating Highly Accurate COVID-19 Antibody Test

ProMIS Neurosciences states that the current version of the ProMIS-BCNI assay achieves 99.9% sensitivity and 99.5% specificity for SARS CoV-2, the coronavirus causing COVID-19. - 06/17/2020

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. - 06/16/2020

Digital Health Company Growth Continues with Acquisition of BC Medical Clinic

CloudMD reported that it has signed a binding agreement to acquire a British Columbia medical clinic with 12 on-staff physicians in a cash and stock deal valued at CA$700,000. - 06/15/2020

Life Sciences Firm Expands Collaboration Efforts with Major U.S. University to Develop Psilocybin-Based Medicines

Revive Therapeutics Ltd. reported it has expanded its research partnership for novel formulation development and clinical research of psilocybin with the University of Wisconsin-Madison. - 06/15/2020

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study

Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. - 06/15/2020

Reata Pharma Announces $350 Million Strategic Investment from Blackstone Life Sciences

Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases. - 06/11/2020

Life Sciences Firm Pursues Phase 3 COVID-19 Treatment Trial in Canada

Revive Therapeutics met with Health Canada to discuss how best to proceed. - 06/10/2020

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. - 06/10/2020

Coverage Initiated on Company at 'Forefront of the Telehealth Revolution'

A review of CloudMD Software & Services and the reasons why it makes a compelling investment are provided in a Beacon Securities report. - 06/08/2020

Enochian Shares Trade Up 50% upon Concluding FDA Meeting for Potential HIV Cure

Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV. - 06/08/2020

Aurora Cannabis 'Upside Breakout Looks Imminent'

Technical analyst Clive Maund charts the cannabis company and explains why he calls it an "immediate strong buy." - 06/08/2020

Mackie Research: Small Cap a World Leader in Health and Safety Wearables

Mackie Research believes Blockchain Holdings' TraceSafe tracking platform could tap into the "exceptionally large market" for contact tracing during the Covid-19 pandemic. - 06/05/2020

FDA Greenlights Biopharma for Trial of Possible COVID-19 Therapeutic

Algernon Pharmaceuticals prepares to commence the Phase 2b study as soon as possible. - 06/04/2020

Micro-Cap Pharma Moving Ahead with Plans for Phase 3 US Trial of a Repurposed Drug for Covid-19

Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations. - 06/03/2020

Telemedicine Firm Achieves Record Revenue in Q1/20

Also during the quarter, CloudMD Software & Services completes an acquisition, releases an app and upgrades its stock listing. - 06/03/2020

COVID-19: A Catalyst for Small-Cap Outperformance

Steve Palmer, president and chief investment officer of AlphaNorth Asset Management, outlines why he believes Canadian companies on the TSX Venture Index remain good investments in a time of pandemic uncertainty. - 06/03/2020

Immunotherapy Firm Releases Data Showing Treatment Potential Against Sepsis

Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report. - 06/03/2020

AI Firm Receives Grant to Create Deep Learning Tools to Enhance Organ Donation Processes

Xtract AI has secured a CA$150,000 grant from the Innovative Solutions Canada program to utilize artificial intelligence to increase organ donations and improve transplant success rates. - 06/03/2020

Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data

Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease. - 06/03/2020

Virtual Healthcare Tech Firm Reports Q3 FY20 Revenue Up 359% YOY

Demand for Reliq Health Technologies' offerings continues to grow due to the COVID-19 pandemic. - 06/01/2020

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. - 06/01/2020

AI Firm Develops Tool That Helps Radiologists Diagnose COVID-19

Patriot One Technologies and its partners have created a model that automatically calculates, from a radiological scan, the degree of a patient's affected lungs, a COVID-19 indicator. - 05/30/2020

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil. - 05/27/2020

Surgical Equipment Firm Delivers Innovative Imaging Systems to Leading Urologists

Imagin Medical delivered two functional i/Blue™ Imaging Systems for use in conducting in vivo studies and virtual demonstrations for evaluation by leading urologists. - 05/27/2020

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. - 05/27/2020

Biotech Identifies Antibody with 100% SARS-CoV-2 Inhibition

The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report. - 05/27/2020

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. - 05/27/2020

Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial

Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373. - 05/26/2020

Vertically Integrated Hemp/CBD Player Sweet Earth Holdings Debuts on CSE

With CBD showing some promise against Covid-19 and cannabis stocks rising, Peter Epstein of Epstein Research discusses the market with Sweet Earth Holdings executives. - 05/26/2020

Positive Test Results in Dairy Cows Lead to Upsized Livestock Supplement Order

With this sale, Avivagen's antibiotics-free, immune-boosting feed additive enters the Mexican market. - 05/21/2020

Biotech Partnership to Develop Diagnostic Assay for Alzheimer's Disease

With its work on this and a SARS-CoV-2 test, ProMIS Neurosciences is applying its technology platform in new ways. - 05/20/2020

Surface Oncology Shares Trade Up 40% on Phase 1 Study Plans for SRF617 Combined with Merck's KEYTRUDA

Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. - 05/20/2020

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. - 05/20/2020

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. - 05/19/2020

Surgical Imaging Company Provides Update on COVID-19 Impact

Imagin Medical reported that its actions have mitigated the impact of the coronavirus on its business operations. - 05/18/2020

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. - 05/18/2020

Biopharma Seeks Ethics Approval in Australia to Test COVID-19 Treatment

Algernon Pharmaceuticals intends to test a repurposed drug for this indication, in a trial in three countries. - 05/18/2020

Cannabis Cultivator Shifts Focus to Commercializing Technology

Sproutly Canada has received capital investment from Infusion Biosciences. - 05/18/2020

Aurora Cannabis Shares Catch Fire on Positive Q3/20 Financial Results

Shares of Aurora Cannabis traded 60% higher after the company reported an 18% rise in net revenue, which included a 24% increase in consumer sales versus to the prior quarter. - 05/15/2020

Biotech Expands Antibody Research Across Multiple Neurodegenerative Diseases and Covid-19

ProMIS Neurosciences advances its various antibody programs related to neurodegenerative diseases and viral infections such as Covid-19. - 05/14/2020

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data

Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. - 05/14/2020

Acceleration of COVID-19 Vaccine Programs Could Benefit U.S. Biotech

The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report. - 05/13/2020

Biotech Advances Accurate SARS CoV-2 Antibodies Detection Test

Testing and validation of ProMIS Neurosciences' antibody targets will be conducted over the coming weeks. - 05/13/2020

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. - 05/11/2020

Pharmaceutical Firm Gains Ethics Approval for Phase 2 Human IPF and Chronic Cough Trial

Algernon Pharmaceuticals reported that it has received ethics approval in Australia for a Phase 2 human clinical study of NP-120 (Ifenprodil) for use in treatment of idiopathic pulmonary fibrosis and chronic cough. - 05/10/2020

Protagonist's Shares Nearly Double After Reporting Q1 Earnings and Positive Phase 2 Trial Results

Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer. - 05/08/2020

Canadian Firm Partners for US Sales of Its Telehealth Platform

This arrangement will bolster the use of CloudMD Software & Services' software in the United States. - 05/07/2020

Building a Better Covid-19 Antibody Test

ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. - 05/06/2020

California Biotech Partners for Manufacture of COVID-19 Vaccine Candidate

Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report. - 05/06/2020

Biotech Develops Antagonists for Protein Tied to Neurodegenerative Diseases

ProMIS Neurosciences' antagonists prevent dysfunctional protein aggregation. - 05/06/2020

Horizon Therapeutics Shares Rise 15% on Strong Q1 Results and Raised F/Y Sales Guidance

Shares of Horizon Therapeutics traded higher setting a new 52-week high price after the company reported a 27% y-o-y increase in net sales for Q1/20 and raised FY/20 net sales guidance. - 05/06/2020

Firm Partners with Canada's Largest Western Grocery Chain and Leading Community Pharmacy to Pilot In-Store Virtual Patient Care

CloudMD announced that it is partnering with Save-On-Foods grocery stores and Pure Integrative Pharmacy to pilot on demand, integrated virtual patient care through telemedicine kiosks placed in pharmacies' existing consult rooms. - 05/05/2020

Alexion's Buyout of Portola Pharmaceuticals Gets Investors' Blood Flowing

Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals. - 05/05/2020

Telehealth Platform Added to Vendor Lists of Leading Medical Associations

Use of CloudMD Software & Services' health solution is seeing significant growth. - 05/04/2020

Firm Creates Novel Intrabodies for ALS and Other Neurodegenerative Diseases

ProMIS Neurosciences reported it has generated novel intrabodies that are highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in several neurologic disorders. - 05/04/2020

Stemline Shares Take Off on $677 Million Buyout Offer by Global Pharmaceutical Firm

Shares of Stemline Therapeutics traded 150% higher after the company reported that it has entered into a definitive agreement to be acquired by Italy's Menarini Group in a deal valued at up to $677 million. - 05/04/2020

Seattle Genetics Shares Trade Higher on Q1/20 Earnings and 22% Growth in ADCETRIS Sales

Seattle Genetics shares traded 8% higher, reaching a new 52-week high, after the company reported Q1/20 financial results which included a 10% y-o-y increase in net revenues fueled by a 22% increase in sales of ADCETRIS® and a strong debut for PADCEV™ in its first full quarter of sales. - 05/01/2020

Biotech Cleared for Phase 2b/3 Trial of NMDA Receptor Antagonist for COVID-19 Patients in Canada

Algernon Pharmaceuticals reported it received approval from Health Canada for a Phase 2b/3 multinational clinical study of Ifenprodil in COVID-19 patients to prevent progression to intubation and mechanical ventilation. - 04/30/2020

Mobile Health Solutions Firm Welcomes 8 New Texas Clients to Its Telemedicine Platform

Reliq Health Technologies reported that it has signed contracts to add eight new customers in Texas including an oncology practice that will be using its new iUGO Care Principal Care Management module. - 04/30/2020

US Counties to Use Tech Firm's Software for COVID-19 Contact Tracing

Demand has been taking off for HealthSpace Data Systems' platform released two weeks ago. - 04/29/2020

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients

Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. - 04/29/2020

With Contact Tracing Key to Reopening the Economy, New Cloud Platform Attracting High-Profile Users

As contact tracing moves to center stage as a key to reopening the economy, HealthSpace releases a scalable cloud-based system that is rapidly being adopted, including by the state of Hawaii. - 04/28/2020

Why These 2 Investment Professionals Say This Telemedicine Company Is One of Their Top Picks

As the coronavirus pandemic has accelerated the move to telemedicine, two investment professionals are following CloudMD, a small cap rapidly expanding in Canada. - 04/28/2020

CloudMD Is My TeleHealth Stock

With telehealth becoming a rising star in the coronavirus era, Keith Schaefer discusses why one company rapidly expanding in Canada stands out. - 04/28/2020

SmileDirectClub Awarded US Patent for SmileShop Concept and Plans to Reopen Stores in May

SmileDirectClub shares traded 20% higher after the company reported it has been awarded a U.S. patent for its SmileShop retail concept and treatment process and that it plans to reopen stores on a rolling basis starting in May. - 04/28/2020

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. - 04/27/2020

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. - 04/24/2020

West Pharma Services' Shares Rise 10% on Q1 Sales Growth and Raised FY Earnings Guidance

Shares of West Pharmaceutical Services traded higher and established a new 52-week high price after the firm reported Q1/20 earnings that included a 10.8% increase in YoY revenues. - 04/23/2020

Biopharma Approved to Launch COVID-19 Trial in South Korea

Algernon Pharmaceuticals will evaluate one of its drugs in coronavirus-infected patients with severe pneumonia. - 04/23/2020

BARDA Award Provides 'Lift-off for Biotech's COVID Vaccine'

The ways in which Moderna is to use the funds are explained and an update on its coronavirus vaccine is provided in a ROTH Capital Partners report. - 04/22/2020

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. - 04/22/2020

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced renal cell carcinoma. - 04/20/2020

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. - 04/15/2020

Lifeway Foods' Shares Rise 40% on Positive Q1 Sales Data with March Revenue Up 13% Y-O-Y

Shares of Lifeway Foods traded higher as the company reported it has increased production to support accelerated demand during the COVID-19 health crisis. - 04/15/2020

MEI Pharma Shares Rise 50% on $682.5M Partnership with Japanese Company to Treat B-cell Malignancies

Shares of MEI Pharma traded higher after the company announced that it has entered into development and global licensing agreement with Kyowa Kirin for its oral selective PI3Kδ inhibitor (ME-401) used for treating B-cell malignancies. - 04/14/2020

CytoSorbents Shares Trade 20% Higher as FDA Grants CytoSorb EUA for COVID-19

Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19. - 04/13/2020

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment

Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shares traded nearly 17% higher today on the Korean Stock exchange. - 04/10/2020

MediciNova Shares Rise 40% on Plans to Initiate COVID-19 ARDS Clinical Trial

Shares of MediciNova traded higher after the company reported that it plans to initiate a clinical study of MN-166 (ibudilast) for COVID-19 acute respiratory distress syndrome. - 04/09/2020

Company Secures Largest Order to Date for Antibiotic-Free Feedstock Supplement

Avivagen Inc. has secured its largest ever order of OxC-beta™ Livestock from its long-standing Philippine partner UNAHCO. - 04/08/2020

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. - 04/08/2020

Novavax Announces Its First-in-Human Coronavirus Vaccine Trial Will Begin in Mid-May

Shares of Novavax traded 20% higher setting a new 52-week high price after the company reported that it has accelerated initiation of a Phase 1 clinical trial for its coronavirus vaccine candidate NVX-CoV2373. The study will commence in mid-May with preliminary results expected in July 2020. - 04/08/2020

Telemedicine Platform Grows to More Than 100,000 Registered Users

CloudMD attributed record weekly new user registrations to social distancing protocols and advised that it now has greater than 100,000 registered users on its telemedicine platforms. - 04/08/2020

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data

Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. - 04/06/2020

Animal Feed Supplement Maker Expands Asia Footprint

Avivagen receives new orders from two eastern countries for its product. - 04/04/2020

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. - 04/03/2020

Three COVID-19 Patients Treated with PLX Cells

Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. - 04/01/2020

Healthcare Firm Expands Telemedicine App to Ontario as Coronavirus Concerns Accelerate Demand

CloudMD reported that it has launched its telemedicine app in Ontario as coronavirus concerns have greatly increased the need for digital healthcare. - 04/01/2020

Chembio Launches COVID-19 Test that Provides Quick Results from a Simple Finger Stick

Chembio Diagnostics shares traded higher and set a new 52-week high price after the company reported that it has launched a DPP® COVID-19 serological point-of-care test which can deliver IgM/IgG antibody results in 15 minutes using a simple finger stick. - 04/01/2020

Cannabis Beverage and Edibles Supplier Signs Agreements with Manitoba and Saskatchewan

Sproutly Canada's subsidiary company Toronto Herbal Remedies has entered into a cannabis supply contract with Manitoba and Saskatchewan provinces to carry the firm's CALIBER brand indoor-grown dried flower products. - 03/31/2020

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

Shares of Kiniksa Pharmaceuticals traded higher after the company reported early success in treatment response for mavrilimumab in six patients with severe COVID-19 pneumonia and hyperinflammation. - 03/31/2020

Abbott Labs Launches Point-of-Care Diagnostic Tool that Can Detect COVID-19 in 5 Minutes

Shares of Abbott Laboratories opened 11% higher after the company reported that its ID NOW™ molecular point-of-care test to detect novel coronavirus will be available starting this week with plans to quickly ramp up production to deliver 50,000 tests per day. - 03/30/2020

Eton Pharma Shares Climb 20% After Firm Secures US Rights for Pediatric Kidney Disease Drug

Shares of Eton Pharmaceuticals traded higher after the company reported that it has acquired U.S. marketing rights to pediatric orphan drug Alkindi® Sprinkle from Diurnal Group Plc. - 03/27/2020

Maker of Antibiotic-Free Animal Supplement Lands First Order from Mexico

This new market is a significant one for Avivagen. - 03/26/2020

Inhaled Nitric Oxide Being Tested as COVID-19 Treatment

Nu-Med Plus has two collaborative, Phase 2 clinical trials in progress, which it is diligently monitoring. - 03/26/2020

Canadian Logistics Firm Partners with Cannabis Companies

ParcelPal Technology continues expanding its reach into this growing market. - 03/26/2020

Coronavirus Propels Telemedicine into the Spotlight

McAlinden Research Partners takes a look at how telemedicine companies are positioned to profit both during and in the wake of the current pandemic, and offers a couple of options for investors. - 03/26/2020

Digital Health Firm Expands Its Mobile Platform to Four U.S. States

Reliq Health Technologies has entered into an agreement with MedTech Evolutions to provide its iUGO Care platform to over 27,000 patients in Alabama, Illinois, Mississippi and Tennessee. - 03/26/2020

Drone Firm Chosen to Integrate Breakthrough Health Diagnosis Technology in Fight Against Coronavirus

Draganfly and its partners aim to rapidly deploy the groundbreaking technology so it can help combat COVID-19. - 03/26/2020

Coty Shares Rise 30% After Starting Production of Gel for Hand Sanitizer Use

Shares of Coty traded higher after the company reported that it has commenced production of hydro-alcoholic gel for use as hand sanitizer to help combat the COVID-19 virus. - 03/26/2020

Biopharma to Accelerate Alzheimer Trial Completion

The upcoming catalysts for Axsome Therapeutics and the effects of COVID-19 on its clinical activities are discussed in an H.C. Wainwright & Co. report. - 03/25/2020

Cannabis Firm Outlines Business Strategies for Custom Formulations

The company plans to accelerate the path to greater revenues and profitability. - 03/25/2020

T2 Biosystems Shares Nearly Double on Worldwide COVID-19 Testing License Deal

Shares of T2 Biosystems Inc. traded 90% higher after the company reported that a new COVID-19 assay licensed from Hackensack Meridian Health's Center for Discovery and Innovation will be adapted to run on its FDA-cleared T2Dx® Instrument. - 03/25/2020

Logistics Company Gears Up Operations to Meet Increased COVID-19 Related Demand

ParcelPal Technology hired 50 new staff members in order to guarantee that service levels can be maintained without disruption to clients and vendors as the firm faces major increases in demand. - 03/23/2020

Blockchain Holdings Acquires Monitoring System, Successfully Implemented in Hong Kong, to Help Stem the Spread of COVID-19

Simple, non-invasive hospital-style wrist band and SaaS technology could spell explosive growth for company as the world combats the coronavirus. - 03/21/2020

Telehealth Software Firm Responds to Client Needs Around COVID-19

Reliq Health Technologies explains how it is helping protect its customers' elderly patients. - 03/21/2020

Blockchain Holdings Acquires COVID-19 Quarantine Tracker Already in Use in Hong Kong

The company anticipates adoption of the TRACEsafe system by other countries soon. - 03/21/2020

Bellerophon Shares Take Off as FDA Grants Emergency Expanded Access for INOpulse for COVID-19 Treatment

Shares of Bellerophon Therapeutics reached a new 52-week high price after the firm reported that the FDA granted emergency expanded access for its INOpulse® nitric oxide delivery system device for use in treatment of COVID-19 virus. - 03/20/2020

Firm to Accelerate Launch of Immune Booster for Humans

Avivagen hires a firm to assist with the product's commercial debut. - 03/18/2020

Clinical Catalysts Impending for California-Based Biopharma

The firm's three upcoming potential stock movers are reviewed in a ROTH Capital Partners report. - 03/18/2020

iBio Shares Trade Up 40% After Announcing Development of Proprietary COVID-19 Vaccine Candidates

iBio Inc. shares traded higher after the company reported that it has filed several provisional patents for its SARS-CoV-2 Virus-Like Particle platform with the U.S. Patent and Trademark Office. - 03/18/2020

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. - 03/17/2020

Digital Health Firm Offers Free-Trial of Telemedicine Platform to Medical Providers Confronting Coronavirus Epidemic

CloudMD reported it will offer free-trial telemedicine solutions to healthcare professionals across North America to help manage the coronavirus pandemic. - 03/16/2020

Firm Inks Deal to Deliver Medicines and Covid19 Test Kits and Supplies in BC, Alberta and Ontario

ParcelPal Technology reported that it has signed an agreement to deliver pharmaceuticals and Covid19 supplies including test kits in three areas of Canada with the potential of reaching more than 40 pharmacies nationwide. - 03/13/2020

OPKO Health Partners with NY State Health Dept. to Create COVID-19 Drive-Thru Testing Facility

OPKO Health shares traded more than 30% higher after the company reported its subsidiary BioReference Laboratories has formed a partnership with the N.Y. State Department of Health to provide COVID-19 testing for the first public drive-through testing facility on the East Coast. - 03/13/2020

Predictive Oncology Launches AI Vaccine and Drug Platform & Acquires Technology

Shares of Predictive Oncology traded higher after the company reported that it launched a new AI vaccine and drug development platform targeting coronaviruses and acute respiratory syndromes and that it is acquiring Soluble Therapeutics assets including its HSC Technology. - 03/12/2020

Surgical Imaging Firm Reports Positive Physician Response to Bladder Cancer Visualization System

Imagin Medical announced on-going research feedback on its i/Blue™ Imaging System which allows simultaneous viewing of white and blue light images during bladder cancer resection procedures. - 03/11/2020

Vir Biotech Shares Rise on Joint Research Efforts with the NIH to Combat Coronaviruses

Vir Biotechnology shares traded higher after the company reported that it has entered into a research collaboration with the National Institutes of Health Vaccine Research Center on antibodies against coronaviruses including SARS-CoV-2. - 03/11/2020

Aytu Bio Shares Skyrocket After Gaining US Distribution Rights for Coronavirus Screening Test

Aytu BioScience shares rose by more than 750% at times today after the company reported that it secured an exclusive U.S. distribution agreement for COVID-19 point-of-care Rapid Test from a Hong Kong firm. - 03/10/2020

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment

Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. - 03/09/2020

Digital Health & Telemedicine Firm Increases Doctor Onboarding Amid Coronavirus Worries

CloudMD reported it's accelerating onboarding of physicians amid rising COVID-19 concerns. The firm also advised it is on track to close a new CA$3 million brokered financing on March 11, 2020. - 03/09/2020

U.S.-Based Biotech 'Growing into a Giant with AI'

How Moderna uses and benefits from digitization and artificial intelligence are described in a ROTH Capital Partners report. - 03/07/2020

Enzo Biochem Shares Rise 60% as the Firm Commences COVID-19 Lab Testing

Shares of Enzo Biochem traded higher after the company advised that they will launch coronavirus testing services starting next week. - 03/06/2020

Avivagen to Be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD on March 6

Webcast will be at 12 noon ET on Friday, March 6. - 03/05/2020

Antibody Developer Taken Out by Gilead at 'Hefty Premium'

The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report. - 03/04/2020

Digital Health Firm to Place Telemedicine Kiosks in Pharmacy Consult Rooms

CloudMD announced it will be installing proprietary kiosks in participating pharmacies to enable on-demand telemedicine visits with licensed physicians. - 03/04/2020

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. - 03/04/2020

Telemedicine Platform Provider for Community-Based Healthcare Adds 50,000 Medicare Members

Reliq Health Technologies reported that it has signed a contract with Blum Telehealth to provide its iUGO Care software platform to over 50,000 Medicare patients in the state of Louisiana. - 03/03/2020

GenMark Shares Trade 30% Higher on Yearly Earnings and Increased SARS-CoV-2 Virus Detection Test Kit Shipments

Shares of GenMark Diagnostics traded higher after the firm reported FY/19 financial results and announced that it has increased global shipment of its test kits designed to detect the SARS-CoV-2 virus. - 03/03/2020

Digital Health Firm Scales Up Telemedicine Services as Global Coronavirus Concerns Mount

CloudMD will be scaling up its freely accessible telemedicine app that allows patients to see a doctor in real-time using either a smartphone or desktop device. - 03/02/2020

Health Tech Firm to Service Sizable Home Healthcare Network

Reliq Health Technologies will provide its software and call center support. - 03/02/2020

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results

Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. - 03/02/2020

Sangamo Shares Trade 30% Higher on Q4 Earnings and Biogen Collaboration

Sangamo Therapeutics shares traded higher after the company reported Q4/19 and FY/19 earnings and advised that it signed a global collaboration agreement with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular and neurological diseases. - 02/28/2020

Teladoc Shares Trade 20% Higher on Virtual Medicine Tailwinds and Q4 Earnings

Shares of Teladoc Health climbed to a new 52-week high price after the firm reported Q4/19 and FY/19 financial results that included a 32% year-over-year increase in revenue and a 57% increase in patient visits. - 02/27/2020

Nemaura Medical Accelerates Launch of sugarBEAT Wearable Continuous Glucose Monitor

Shares of Nemaura Medical traded 20% higher after the firm reported that it is investigating using its non-invasive continuous glucose monitor sugarBEAT® jointly with its planned health subscription service BEAT®diabetes, to provide personalized lifestyle coaching for people with Type 2 diabetes and prediabetes. - 02/26/2020

Mobile Health and Telemedicine Provider for Community-Based Healthcare Teams Up with US Health Data Firm

Reliq Health Technologies advised that it has been selected as remote patient monitoring and chronic care management solutions partner by U.S. health data company MaxMD. - 02/26/2020

Moderna Shares Climb on Development of mRNA Vaccine for Phase 1 Coronavirus Study

Shares of Moderna traded 23% higher after the company reported that it has developed and shipped an mRNA vaccine against novel coronavirus for use in a Phase 1 testing study in the U.S. - 02/25/2020

Two Stock-Moving Catalysts Expected in March for Biopharma

These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report. - 02/25/2020

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial

Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. - 02/24/2020

Antibiotic-Free Feed Additive Shows Benefit in Cow Mastitis Trial

Avivagen's proprietary product yielded statistically significant results. - 02/24/2020

Healthcare Tech Firm Lands Contract in Florida

Reliq Health Technologies will provide the client with two telehealth platforms. - 02/22/2020

Tech Firm Announces New Deals Worth $1 Million

These newly signed contracts of HealthSpace Data Systems are with governmental agencies in two U.S. states. - 02/21/2020

Mobile/Telehealth Tech Firm Makes Stock Exchange's Top 10

Reliq Health Technologies is chosen based on three criteria. - 02/21/2020

Healthcare Firm Changes Name to Reflect Digital Health and Telemedicine Focus

Premier Health Group announced that it changed its name to CloudMD Software & Services Inc., and trading under the symbol DOC will begin Feb. 24. - 02/21/2020

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication

Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain. - 02/21/2020

FDA Approval of Biopharma's Pain Drug Expected This Year

The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. - 02/19/2020

The 'Virus' Technology That Kills Coronavirus Plus Lots of Other Pathogens

Fincom Investment Partners profiles TOMI Environmental Solutions, whose SteraMist disinfectant technology kills the coronavirus. - 02/18/2020

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation

Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. - 02/18/2020

Life Sciences Firm Contracts with Philippines Distributor

This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. - 02/18/2020

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates

Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. - 02/14/2020

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. - 02/10/2020

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

The events in that trio are presented in a ROTH Capital Partners report. - 02/08/2020

Telehealth Solutions Firm Gains Further Customer Traction in Texas

With the added clients, the company will expand into two more clinical realms. - 02/07/2020

Myriad Genetics Shares Fall 30% on Q2 Earnings and Executive Leadership Change

Shares of Myriad Genetics traded 30% lower after the firm released Q2/20 earnings and announced the appointment of a new interim CEO. - 02/07/2020

Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development

Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations. - 02/06/2020

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug

Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZE® (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. - 02/05/2020

Understanding Fortress Biotech

Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics. - 02/05/2020

MedTech Company Launches Direct to Consumer Telemedicine App

The product is initially available to residents of British Columbia. - 02/05/2020

Rapidly Growing Healthcare Tech Firm Appoints President

The appointed physician will be tasked with developing global business for the company. - 02/04/2020

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. - 02/03/2020

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. - 01/31/2020

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results

Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five institutional investors and secured a $30 million non-dilutive term loan facility. - 01/31/2020

CEO Reviews Life Sciences Firm's Year of 'Exceptional Accomplishment'

The company makes progress getting its products approved and sold in more countries. - 01/30/2020

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch

Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. - 01/30/2020

Two Approvals Underscore Biotech's Pipeline Quality

The green lights and their implications are discussed in an H.C. Wainwright & Co. report. - 01/29/2020

Accuray Shares Rise on Q2 Earnings, Increased Backlog and Raised FY/20 EBITDA Guidance

Shares of Accuray traded 15% higher today after the company reported Q2/20 financial results. - 01/29/2020

California Gold: Two U.S. Hemp Revenue Streams Coming Online This Quarter

Peter Epstein of Epstein Research discusses recent developments at the company. - 01/29/2020

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. - 01/28/2020

Inovio Pharma Awarded $9M Development Grant for Coronavirus Vaccine

Inovio Pharmaceuticals' shares rose 30%, setting a new 52-week high price, after the firm reported it received a grant of up to $9 million to develop a vaccine against the coronavirus. - 01/27/2020

Healthcare Tech Firm Now Has 90,000 Patients on Telemedicine Portal

The company continues to evolve this digital offering as well. - 01/24/2020

Life Sciences Firm Partners to Develop, Sell Canine Supplement

The product contains the firm's OxC-beta™ supplement. - 01/24/2020

Imaging System Developer Outlines Plan for 2020

The company continues to advance its device toward commercialization. - 01/24/2020

Premier Health Group Update: Charting 'Strongly Bullish' Movement

Technical analyst Clive Maund examines this potential of the company's stock. - 01/24/2020

eHealth Shares Rise 25% After Achieving 100% Increase in Quarterly Medicare Advantage Sales

Online medical exchange operator eHealth Inc.'s shares traded higher after the firm reported preliminary financial results for Q4/19 and FY/19. The company advised that both quarterly and annual revenues exceeded prior estimates. - 01/24/2020

Co-Diagnostics Utilizes CoPrimer Platform to Design New Coronavirus Detection Test

Molecular diagnostics company Co-Diagnostics' shares opened more than 144% higher after the firm reported it has designed a test for virus detection of the new coronavirus, 2019-nCoV, using its CoPrimer™ platform. - 01/23/2020

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant

Neurotrope's shares traded higher today after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm has also been awarded a $2.7 million grant from the National Institutes of Health to conduct additional clinical research for patients with advanced Alzheimer's disease. - 01/22/2020

Biopharma Shows 'Good Start to 2020 News Flow'

The two developments that already took place this year are addressed in an H.C. Wainwright & Co. report. - 01/21/2020

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. - 01/21/2020

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. - 01/20/2020

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. - 01/16/2020

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. - 01/15/2020

Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection

Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy. - 01/14/2020

Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery

The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.' - 01/14/2020

Healthcare Company Closes Acquisition of Telehealth Firm

The transaction brings numerous existing partnerships and digital technologies. - 01/14/2020

Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery

Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery. - 01/14/2020

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications. - 01/13/2020

Telemedicine Tech Firm Garners Five New US Clients

With these contracts, the company extends its geographic footprint to an additional county. - 01/10/2020

Life Sciences Firm Upgrades to OTCQB Venture Market

This is a significant achievement of this developing company. - 01/10/2020

Developer Completes Design Verification of Imaging Device for Bladder Cancer

In doing so, it gets one step closer to market approval from U.S. regulators. - 01/10/2020

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. - 01/10/2020

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results

Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020. - 01/09/2020

Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020

The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report. - 01/08/2020

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. - 01/08/2020

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria. - 01/07/2020

Kyorin's $175M Partnership Offers Good Life for aTyr Pharma in Japan

aTyr Pharma's shares traded 45% higher today after the firm reported that it had entered into a collaboration agreement with Kyorin Pharmaceutical for development and commercialization of its ATYR1923 drug in Japan. - 01/06/2020

Biopharma's Migraine Phase 3 Trial Results 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. - 01/03/2020

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. - 01/03/2020

Biopharma Releases Topline Results from Psoriasis Trial

The company, however, will continue to advance the same therapeutic in two other diseases. - 01/03/2020

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity financing from BeiGene and two other investment groups. - 01/03/2020

Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%

Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson. - 01/02/2020

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. - 12/31/2019

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). - 12/30/2019

Biotech Advances Imaging Product to Functional Development Phase

The company aims to conduct pilot production testing in Q1/20. - 12/27/2019

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results in Q1/20. - 12/27/2019

Biopharma Continues 'Positive Push Forward in Breast Cancer'

The latest clinical trial results and next step are reviewed in an H.C. Wainwright & Co. report. - 12/27/2019

Microbot Shares Soar on Claims It Has Created the World's First Fully Disposable Endovascular Robotic System

Shares of Microbot Medical traded 70% higher after the company reported that in January 2020 it will unveil the world's first fully disposable robotic system for endovascular procedures. The firm claims that its breakthrough technology features compact design, remote operation capabilities and an integrated "One & Done" tool to democratize endovascular procedures. - 12/24/2019

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'

The key business and investment points are presented in a ROTH Capital Partners report. - 12/23/2019

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. - 12/23/2019

Healthcare Innovator to Acquire Canadian Telehealth Firm

The purchase price for the company is 4.5 million shares. - 12/21/2019

Telehealth Firm Starts Pilot with Australian Aeromedical Agency

The program goal is to improve care access and health outcomes among residents of Australia's remote and rural areas. - 12/21/2019

NewLink Genetics Shares Shoot Higher after FDA Ebola Vaccine Approval

Shares of NewLink Genetics got a boost today after the firm reported that the FDA approved its ERVEBO V920 vaccine used in the treatment of Zaire Ebola virus. The company's shares set a new 52-week high price in mid-morning trading. - 12/20/2019

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. - 12/19/2019

Agreement Sets Stage to Secure Chinese Approval of Non-Antibiotic Livestock Feed Supplement

The requirements include, among others, trials of the company's livestock feed additive. - 12/18/2019

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 million over three years. - 12/18/2019

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. - 12/17/2019

Biopharma 'Keeps Executing and Securing Milestones'

The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report. - 12/17/2019

Feed Additive Developer Signs MOU with Philippine Distributor

This is the first step toward a binding, definitive agreement between the two companies. - 12/17/2019

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application filing in H2/20. - 12/16/2019

Animal Health Product Developer Lands First Sale in Malaysia

The maiden order comes on the heels of the country approving use of the product there. - 12/15/2019

Supplier Enters Canadian Recreational Cannabis Market

The Vancouver-based company debuts its premium brand dried flower in Alberta. - 12/13/2019

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug

Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. - 12/13/2019

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen

Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. - 12/12/2019

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. - 12/11/2019

Avid Bioservices' Shares Rise on Q2/20 Earnings and Confirmed Outlook

Shares of Avid Bioservices traded higher today, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020. - 12/10/2019

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. - 12/10/2019

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. - 12/09/2019

Antibiotic Alternative for Livestock Feed Approved for Malaysia

Now, the company has the green light to sell this product in eight countries. - 12/07/2019

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. - 12/06/2019

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. - 12/06/2019

Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data

Shares of Aurinia Pharmaceuticals traded much higher today after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. - 12/05/2019

Immuno-Oncology Firm Expands Agreement with AbbVie

The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. - 12/04/2019

Company Vies for New Brunswick Cannabis Contract

The opportunity is one of the largest in retail cannabis in Canada. - 12/04/2019

Cannabis Producer Signs Supply Contract with Province of Alberta

To start, the company will introduce its premium brand of dried flower there. - 12/04/2019

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system. - 12/04/2019

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. - 12/04/2019

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. - 12/03/2019

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. - 12/02/2019

Healthcare Tech Firm Expands Client Base in Texas

The company signs six new contracts for its telemedicine-based platform. - 11/26/2019

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed

The highlights of this investment story are outlined in a Zacks Small-Cap Research report. - 11/26/2019

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. - 11/26/2019

Regenerative Medicine Firm Advances Multifaceted Pipeline

The company continues advancing its cell therapies and medical device. - 11/26/2019

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. - 11/25/2019

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. - 11/22/2019

Cannabis Firm's Stock Poised for 'Substantial Gains'

Technical analyst Clive Maund charts how news from this company affects its investment thesis. - 11/21/2019

Hepion Pharma Shares Climb 50% Higher on NASH Liver Disease Treatment Results

Shares of Hepion Pharmaceuticals opened higher today after the company reported that its anti-fibrotic agent CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical liver disease model. - 11/21/2019

ICAN Leverages Leading California Brand with Expansion into Nevada, Introduces State-of-the-Art Pre-Roll Machine, for Aggressive Near-Term Growth

A recent acquisition is helping this company to expand its brand. - 11/20/2019

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. - 11/20/2019

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. - 11/19/2019

Medical Small Cap Moving Forward with Cutting-Edge Technological Innovations

Premier Health is methodically building an innovative telemedicine platform in Canada, is purchasing a venerable telemedicine firm, and sees 2020 as the year of execution. - 11/18/2019

Firm to Acquire CBD Products Designer

The deal encompasses all of the company's brands, formulations and processes. - 11/18/2019

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. - 11/18/2019

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. - 11/15/2019

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. - 11/15/2019

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. - 11/14/2019

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes

A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. - 11/13/2019

Biopharma Presents Data on Alcoholic Hepatitis Therapeutic at Liver Meeting

The company intends to follow up in 2020 with a Phase 2b clinical trial. - 11/13/2019

FDA Approval of Peanut Allergy Treatment Expected Next Year

The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. - 11/13/2019

Clinical Trial Results for Alcoholic Hepatitis Drug Delivered in Webcast

The online presentation coincides with The Liver Meeting 2019, at which data also are shared. - 11/13/2019

Electromed Earnings Spark a 25% Increase in Its Share Price

Shares of SmartVest maker Electromed traded 25% higher today after the firm reported Q1/20 earnings. The firm's shares set a 52-week high price after reporting a 14.1% increase in year-over-year quarterly revenue and a six-fold increase in net income per share. - 11/13/2019

Seachange in Mexico on Cannabis Could Benefit This Small Cap

Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. - 11/13/2019

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. - 11/12/2019

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue

Shares of melanoma and other skin cancers diagnostic firm Castle Biosciences Inc. traded more than 15% higher today after the firm announced Q3/19 financial and operational results. - 11/12/2019

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. - 11/08/2019

Dexcom Posts 49% YoY Revenue Growth, Sending Shares to 52-Week High

Glucose monitoring systems developer Dexcom's shares traded 30% higher today after releasing Q3/19 earnings and raising full-year 2019 guidance. - 11/07/2019

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

ProMIS' preclinical treatment could possibly outshine Biogen's candidate. - 11/06/2019

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance

Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. - 11/06/2019

Fulgent Genetics Hits 52-Week High After Posting 84% Q3 Revenue Increase

Fulgent Genetics shares traded more than 40% higher today after the company reported record revenue in Q3/19. The firm noted that it completed a record 20,697 billable tests in Q3/19, up 272% over the same period last year. - 11/05/2019

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. - 11/04/2019

Vancouver Firm Receives Cannabis Flower Sales License, First Order

Both of these events are significant achievements for the company. - 11/03/2019

Canadian Tech Firm Lands U.S. Medical Case Management Firm as Client

This new partner seeks to employ the company's telemedicine/mobile health system. - 11/03/2019

BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership

Shares of BeiGene Ltd. traded 35% higher today to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. - 11/01/2019

Tech Firm Partners With Pharmacy, Diabetes Management Entities

The Canadian company will provide its remote patient monitoring and chronic care management software solutions to these two U.S. enterprises. - 10/31/2019

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results

Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. - 10/29/2019

New Data Could Drive Use of Pancreatic Cancer Early Detection Test

The recent results and their implications are provided in an H.C. Wainwright & Co. report. - 10/29/2019

Tech Firm Releases Telemedicine Product Aiding Senior Care, Safety

The package encompasses wearable devices, two-way video communication and geofencing. - 10/28/2019

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. - 10/28/2019

ResMed Shares Set 52-Week Intraday High Price After Posting Q1 Earnings

Shares of respiratory medical device maker and software applications company ResMed Inc. traded 15% higher at times today after the firm posted positive Q1/20 earnings results. - 10/25/2019

Varian Shares Trade Higher on Yearly Earnings and FY/20 Guidance

Shares of Varian Medical Systems traded 10% higher at times today after the company reported quarterly and annual earnings. The company increased revenue 10% year-over-year and provided FY/20 guidance. - 10/24/2019

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses'

The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. - 10/23/2019

Mobile Health Solutions Provider Adds Clients in Multiple States, Verticals

The primary aim of the firm's technology platform is to support remote patient monitoring. - 10/23/2019

Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases

These therapeutic candidates add to those already in the firm's pipeline. - 10/23/2019

Boston Scientific Reports 13% Q3 Sales Growth and Raises Yearly Estimates

This morning shares of Boston Scientific traded 6% higher after the firm reported a 13.1% increase in revenue for Q3/19. The firm also raised its revenue guidance for both Q4/19 and FY/19. - 10/23/2019

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today. - 10/22/2019

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis

The details of this study and a second one are outlined in a ROTH Capital Partners report. - 10/21/2019

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. - 10/18/2019

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. - 10/17/2019

Healthcare Tech Firm Signs Five New Clients in Texas

The company just landed another five clients in Texas and now plans to build out sales teams in five additional states. - 10/16/2019

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer

Shares of Achillion Pharmaceuticals are trading much higher today after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. - 10/16/2019

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. - 10/16/2019

Healthcare Company to Use IBM's Watson AI in Telemedicine App

The goal is to reduce the time healthcare workers spend on mundane tasks and thereby improve patient care. - 10/15/2019

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. - 10/15/2019

Technical Analyst Expects Health Technologies Firm to Break Higher

Technical analyst Clive Maund outlines the reasons this stock might break higher. - 10/14/2019

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. - 10/14/2019

Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company

Technical analyst Clive Maund believes this stock could gain traction soon. - 10/12/2019

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights

Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. - 10/11/2019

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. - 10/10/2019

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference

Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Meeting. - 10/09/2019

Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial

Data from this study should be released by the end of this year. - 10/08/2019

Coverage Initiated on U.S.-Based Precision Therapy Developer

The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. - 10/08/2019

JV with Moosehead Breweries Readying Cannabis-Infused Beverages for Commercialization

Progress has been made in all areas, from testing the product to evaluating distributors. - 10/08/2019

Healthcare Tech Company Switches to EY Blockchain Platform

This will help its customers access the products and tools they need more sustainably. - 10/07/2019

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%

Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. - 10/07/2019

Healthcare Tech Firm Expands Patient Base in Texas

The company landed five new U.S. facilities as customers. - 10/04/2019

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. - 10/03/2019

Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders

Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018. - 10/02/2019

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. - 09/30/2019

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer

The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report. - 09/30/2019

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer

Shares of Dova Pharmaceuticals opened 38% higher today on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. - 09/30/2019

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. - 09/27/2019

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. - 09/26/2019

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials

The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hypercholesterolemia, which leads to high levels of LDL-C, and one for atherosclerotic cardiovascular disease. - 09/25/2019

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. - 09/25/2019

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'

The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. - 09/24/2019

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. - 09/24/2019

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study

Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. - 09/23/2019

Cannabis Company Expands Operations with New Plant

The firm will use this second manufacturing facility only for making reagents. - 09/20/2019

Mobile Health, Telemedicine Solutions Firm Lands Five New Clients

With these new contracts, the Vancouver-based company continues to build its momentum in Texas. - 09/20/2019

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Products for Human Use also adopted a positive opinion for Dupixent in a third indication. - 09/20/2019

Biopharma Reports Positive Data from Alcoholic Hepatitis Study

These results are from the recently completed clinical trial of the firm's lead drug candidate. - 09/18/2019

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. - 09/18/2019

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News

Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. - 09/16/2019

Healthcare Company Rolls Out Patient App Access to Electronic Medical Records System

This is one way the Canadian firm is providing convenient, patient-centric service. - 09/13/2019

Fibrocell Science Shares Rise 60% on Acquisition News

Fibrocell Science's shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. - 09/13/2019

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

Shares of Moderna Inc. traded up double-digits as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. - 09/12/2019

Company Develops Cannabinoid-Measuring Process for Liquids

This proprietary method ensures the firm meets the requirements for its cannabis-containing beverages and oils. - 09/11/2019

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. - 09/11/2019

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. - 09/11/2019

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%

This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. - 09/11/2019

Mallinckrodt Shares Up 60% as It Announces Sale of Unit

Shares of Mallinckrodt Plc are trading more than 60% higher today on news that the company is selling its CDMO subsidiary BioVectra Inc. to H.I.G. Capital for $250 million. - 09/10/2019

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results

Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. - 09/09/2019

Technology License Triggers $10 Million Milestone Payment for Biopharma

This is the first of many such potential payments under the related agreement. - 09/09/2019

Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthrough

After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly today, up more than 46% at times on nearly 100-times average daily volume, but has since pulled back greatly. - 09/06/2019

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. - 09/05/2019

Coverage Initiated on 'Biotech Machine'

The compelling reasons behind those descriptors are explored in a Dawson James Securities report. - 09/04/2019

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. - 09/04/2019

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. - 09/04/2019

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark

Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. - 09/03/2019

Lannett Signs Exclusive U.S. Distribution Deal with Sinotherapeutics; Shares Up 40%

Shares of Lannett Co. are up 40% today after announcing that it secured rights to be the exclusive U.S. distributor of Sinotherapeutics' antifungal drug that is an AB-rated generic for Noxafil. - 08/28/2019

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. - 08/27/2019

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'

Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. - 08/27/2019

'Topline Beat, All Eyes on Potential M&A' by Health Technologies Firm

An update on the Canadian company, including its Q2/19 results and its next expected catalyst, is provided in a Haywood report. - 08/27/2019

Developer of Premix for Livestock Feed Lands Sizable Order from Asia

Demand for the Canadian company's product is growing in the Asia-Pacific region. - 08/26/2019

Why Provention Bio Is in My Portfolio

Orphan drug and breakthrough therapy status, which could mean this company's lead candidate is on the FDA fast track, translates to huge opportunities for both those suffering from diabetes and investors, says Daniel Carlson of Tailwinds Research. - 08/23/2019

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. - 08/22/2019

Small-Cap Logistics Company Partners with Aphria to Deliver Medical Cannabis

The initiative, to start in Calgary, is expected to expand rapidly into other cities. - 08/22/2019

Life Sciences Firm's OxC-beta Approved for Livestock Feed in Mexico

The country represents a significant market for feed consumption. - 08/21/2019

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

The next steps for each of the programs are outlined in a Dawson James Securities report. - 08/20/2019

Medtronic Stock Hits All-Time High After Raising 2020 EPS Outlook

Dublin-based Medtronic reported Q1/20 earnings and revised its full-year earnings outlook upward sending shares up more than 5% today. - 08/20/2019

A Potential CBD Processor with 'Blue-Sky Prospects'

Peter Epstein of Epstein Research speaks with Martin Doane, CEO of Leviathan Cannabis Group, about the company's international plans to grow hemp and produce a hemp-derived CBD isolate and what sets the company apart from its peers. - 08/20/2019

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. - 08/16/2019

InMode Reports Solid Q2 Earnings and Appoints Paula Abdul as Brand Ambassador

InMode Ltd. reported Q2/19 earnings and announced that international pop superstar Paula Abdul will be its brand ambassador sending shares "Straight Up" 15% as investors "Rush Rush" to purchase shares today. - 08/14/2019

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results

Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. - 08/13/2019

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. - 08/12/2019

Amgen Shares React Favorably to Enbrel Patent Case Victory

Amgen shares are trading 5–6% higher today on news that the company has won its Enbrel (etanercept) patent court case. - 08/12/2019

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales

Shares in Puma Biotechnology are trading 20% higher today after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. - 08/09/2019

Avedro Shares Looking Up 35% with Glaukos Merger

Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. - 08/08/2019

Guardant Health Reports Quarterly Revenue Up 178%

Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180–190 million. - 08/07/2019

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. - 08/05/2019

Biotech 'Thinking Several Steps Ahead with Optimizing IVR Quality Control'

The company's latest science, presented at a recent conference, is discussed in a ROTH Capital Partners report. - 08/02/2019

Biotech's Mosquito Test 'Gains Market Acceptance'

This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report. - 08/02/2019

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide

Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. - 08/02/2019

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months

Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange. - 08/01/2019

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. - 08/01/2019

EMA Opinion Bodes Well for Biopharma's Drug Getting Orphan Status

The designation, opinion and asset are discussed in a ROTH Capital Partners report. - 07/31/2019

Firm's Cannabis Flower Yield Surpasses Expectations

Also, the company begins growing a second strain. - 07/29/2019

Mylan Gets a Shot in the Arm with Pfizer Merger Deal

EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. - 07/29/2019

Catasys: This Is Bigger Than You Think

Daniel Carlson of Tailwinds Research examines the "blockbuster" implications of a recent announcement about this company's OnTrak program. - 07/26/2019

eHealth Shares Up 25% as Quarterly Revenue Doubled and 2019 Guidance Raised

The prognosis for online exchange operator eHealth Inc. looks positive as the company reported a 101% increase in Q2/19 revenues over the prior year period and raised full year 2019 revenue estimates by $50 million to $365–385 million, compared with previous guidance of $315–335 million for 2019. - 07/26/2019

Align Technology Reports Strong Q2 Growth but China Sales Worries Leave Investors Frowning

Orthodontic and GP Dental medical device maker Align Technology announced a 24.6% increase in sales volume of its Invisalign products in its Q2/19 earnings report, but investors are not smiling much over China growth concerns as the shares of the company have fallen more than 25%. - 07/25/2019

Anixa Licenses Another Potential Blockbuster

Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year. - 07/24/2019

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report

Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. - 07/24/2019

Biotech Firm ''Creating Innovative Solutions' for Female Health

The company's most advanced assets are discussed in a Dawson James Securities report. - 07/23/2019

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. - 07/23/2019

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'

The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report. - 07/23/2019

Biopharma Presents Data on Its Therapeutic Candidates at Alzheimer's Conference

The company discussed both its Alzheimer's disease and ALS programs. - 07/22/2019

Innovative Healthcare Firm Closes Two Pharmacy Acquisitions

These assets complement the company's primary care clinics and telemedicine and electronic medical record functionality. - 07/22/2019

Biopharma Licenses Sustained Release Technology to Gilead for HIV Product

The two California-based companies will collaborate on specific related development activities. - 07/22/2019

California Gold Building Hemp Seed Propagation Greenhouse in Illinois

Peter Epstein of Epstein Research checks into the most recent developments announced by this company, which include planting 130,000 hemp plantlets on 40 acres. - 07/22/2019

Biopharma Receives PDUFA Goal Date for Nonopioid Pain Drug

The FDA deemed the firm's submission for analgesic approval complete. - 07/18/2019

Biotech Demonstrates Superiority of Polyp-Detecting Product

The study results and their meaning are reviewed in an H.C. Wainwright & Co. report. - 07/17/2019

Top Pick Status Given to Small-Cap with Pain Drug Candidate

The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. - 07/17/2019

Biotech Incorporates Urologists' Feedback Into Device Design

This step moves the product further down the development track. - 07/17/2019

Canadian Firm to Sell THC Cannabis Oil-Filled Capsules

The product will be launched under its brand for the recreational market. - 07/17/2019

Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion

Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline. - 07/17/2019

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued

A description of the asset and its potential are provided in a Dawson James report. - 07/16/2019

Logistics Firm Expands Into Another Cannabis Industry Segment

Its newly entered agreement offers potential for future growth in Canada. - 07/16/2019

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company. - 07/15/2019

Technical Analyst: Medical Device Stock Looking Set to Reverse

Technical analyst Clive Maund charts the stock of this company that has developed a device that uses a special light that visualizes cancer during minimally invasive surgery. - 07/12/2019

Illumina Shares Fall Sharply on Lower Revenue Guidance

Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance. - 07/12/2019

CVS Declares Quarterly Dividend and Gets a Boost from Relaxed Rebate Policy

CVS Healthcare announced a $0.50/share quarterly dividend yesterday and got an added boost today as news spreads regarding easing of federal restrictions on pharmacy rebate plans. - 07/11/2019

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication

A study description and expected data readouts this year are provided in a ROTH Capital Partners report. - 07/10/2019

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'

The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. - 07/10/2019

Physician Testing of EMR-Integrated, Medical Cannabis Evaluation Tool Completed

The two firms involved plan to have the offering fully rolled out by Q3/19. - 07/10/2019

Sangamo and Pfizer Report Positive Results for Hemophilia A Study

Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia. - 07/08/2019

Coverage Initiated on Biopharma With 'Low Risk/High Margin Assets'

The case is made in a ROTH Capital Partners report for investing in this U.S.-based pharma having multiple shots on goal. - 07/03/2019

Health Technology Company Recuperating Well

Technical analyst Clive Maund charts a medical technology firm and explains why he believes it is an interesting speculative play. - 07/03/2019

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress

Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. - 07/02/2019

Bioasis Engages With the FDA: Here's What It Means

Daniel Carlson of Tailwinds Research examines the implications of correspondence with the regulatory agency as the company advances its lead candidate addressing brain cancer. - 07/02/2019

Coverage Initiated on Developer of Neurodegenerative Disease Therapeutics

An H.C. Wainwright & Co. report presented the investment bank's reasons for its bullish view on this California-based biotech. - 07/01/2019

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. - 07/01/2019

Biotech's Data Well Received at Neurodegenerative Diseases Symposium

The company shared findings from its lead clinical program, in Alzheimer's disease. - 06/28/2019

Biopharma Responds to FDA Inquiry Concerning Non-Opioid Pain Reliever

The firm believes adequate therapeutic safety and efficacy data exist to support regulatory approval. - 06/28/2019

Dova Pharmaceuticals Shares Increase 35% Overnight with FDA Approval

The pharmaceutical stock enjoyed a large boost, thanks largely to FDA approval of its supplemental new drug application for DOPTELET for treatment of chronic immune thrombocytopenia. - 06/27/2019

Strategic Partnership Highlights Global Ambitions for NASH Therapy

The deal terms and the partner's attractive attributes are discussed in an H.C. Wainwright & Co. report. - 06/26/2019

Coverage Initiated on 'Solid Platform Company' with Sanofi Partnership

The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report. - 06/26/2019

Cannabis Company Has Successful Maiden Run Using Extraction Technology

The procedure resulted in two types of cannabinoids: water soluble and oil based. - 06/22/2019

Biotech in Neuro Diseases Adds Parkinson's Expert to Scientific Advisory Board

The expert brings to the board a deep knowledge of neurodegeneration. - 06/22/2019

Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study

The data and how the asset stacks up to others were covered in a ROTH Capital Partners report. - 06/19/2019

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

The highlights of the results were presented in an H.C. Wainwright & Co. report. - 06/19/2019

Biopharma Advances Dose Escalation Trial in Alcoholic Hepatitis

The company received approval to proceed with the next and final dose level. - 06/19/2019

Cannabis Producer Achieves Commercial Sale Milestone

The transaction marks the start of a revenue stream for the company. - 06/19/2019

Developer of Animal Nutrition Supplements to Form JV for Online Product Sales

The new partner has expertise in online marketing and e-commerce. - 06/15/2019

Biotech Receives FDA Approval of Second-Generation Medical Device

The product's improvements and the company's commercialization approach were summarized in a Ladenburg Thalmann report. - 06/12/2019

Interim Results Put Biopharma with Tenbagger Potential 'Back on the Map'

A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report. - 06/11/2019

Healthcare Tech Firm Expands Medical Client Base in Texas

These new customers' patient accounts are already being imported into the company's platform. - 06/11/2019

Biotech to Present Alzheimer's Disease Therapeutic at Keystone Symposium

The focus will be the Canadian company's lead monoclonal antibody candidate. - 06/08/2019

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic

An explanation of the categorization and its implications are provided in a Paradigm Capital report. - 06/05/2019

Bacteria Test Developer Reiterates Revenue Should Double in 2019

The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report. - 06/05/2019

Coverage Initiated on Biotech Whose Therapies 'Can Compete with CAR-Ts'

The reasons for the Buy rating on the U.K. firm are delineated in a ROTH Capital Partners report. - 06/05/2019

Canadian Cannabis Firm Featured in Investorideas.com 'Potcast'

The company's recent deal, progress on its cannabis beverages and its product ideas for the future were discussed. - 06/05/2019

Healthcare Firm Partners on Genetic Testing for Cannabis, Medication Responses

The offering should facilitate a more individualized treatment plan for patients. - 06/03/2019

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. - 05/28/2019

Biotech Identifies Antibodies for Toxic Tau in Alzheimer's Disease

The Canadian company's approach to this indication is now twofold. - 05/28/2019

California-Based Biopharma Signs Licensing Deal for Acquired Asset

The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report. - 05/25/2019

Oncology Vaccine Developer's Lead Programs 'On Track or Better'

The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. - 05/22/2019

Immuno-oncology Firm to Co-Develop Companion Diagnostic for Cervical Dysplasia

The partnership news and upcoming data readouts are reviewed in an H.C. Wainwright & Co. report. - 05/22/2019

U.S. Biopharma's 'Biggest Stock Moving Event' Imminent

With study results from this company due out shortly, an analysis of the possible outcomes was provided in a ROTH Capital Partners report. - 05/22/2019

Cancer Fighter Sesen Bio Leaps 13% on FDA Decision

Shares of this biotech stock were up significantly at the close of trading on Tuesday, May 21, attributed to the announcement of some good news from the FDA. - 05/21/2019

Firm Takes Steps to Launch Recreational Cannabis Brand

The company continues to make preparations while it awaits receipt of a sales license. - 05/17/2019

Harrow Comes Out of Allergan Lawsuit Unscathed

Sector expert Daniel Carlson offers his take on the recent jury decision, calling it "very positive." - 05/17/2019

Why Did ImmunoGen Plummet 32%?

This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. - 05/16/2019

Women's Wellness Device Developer Posts In-Line Quarter, Catalysts Looming

A review of this Colorado company's first numbers of the year was provided in a Ladenburg Thalmann report. - 05/15/2019

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer

An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. - 05/15/2019

Biopharma Releases Preliminary Data from Alcoholic Hepatitis Study

The results compare favorably to those of the historical control group. - 05/10/2019

Trial Milestone Reached; U.K.-Based Biopharma Gets $15 Million

The first patient has been treated in the second cohort of a Phase 2 study of a gene therapy targeting Parkinson's disease, explained an H.C. Wainwright & Co. report. - 05/08/2019

Price Target Raised on Biopharma Ahead of Leukemia Trial Update

The expected data and their implications were addressed in a ROTH Capital Partners report. - 05/08/2019

Shares of Plant-Based Meat Company Spike 53% (and It's Not Beyond Meat)

This small-cap nutrascience stock hit a new 52-week high on May 6th, extending a run that has the stock up 147% over a five-day period. - 05/06/2019

'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial

A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report. - 05/01/2019

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech

Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. - 05/01/2019

Firm's AR E-Commerce Solutions to Be Marketed, Sold to Dispensaries

With the signing of a reseller agreement, the tech firm continues to penetrate Canada's burgeoning legal cannabis industry. - 04/29/2019

'Undervalued' Biopharma Features Robust Pipeline, Future Upside

The case for investing in this company was made in an H.C. Wainwright & Co. report. - 04/24/2019

Health Tech Firm to Pilot Artificial Intelligence-Powered Patient Monitoring Tool

This effort is one way the company can innovatively offer patients care. - 04/24/2019

California Gold Mining Full Speed Ahead in Hemp

Peter Epstein of Epstein Research provides an update on a mining exploration company that is diversifying into the hemp market. - 04/18/2019

Health Technology Firm Aims to Extend Reach into Global Medical Cannabis Industry

This company is targeting geographies where the cannabis market is growing rapidly. - 04/17/2019

Analyst: Biopharma, Now Stronger Than Ever, Is an Ideal Takeout Target

An argument is made in a ROTH Capital Partners report for a potential imminent deal involving this drug maker. - 04/17/2019

Developer of Cannabinoid-Based Drugs to Resume Cancer Pain Trial

Calling this latest development "excellent news," Paradigm Capital has raised its target price on the company's stock. - 04/17/2019

Immunotherapeutic Agent Shows Efficacy in Rare Respiratory Disease

Trial results for this therapeutic, and their implications for this biotech, were discussed in an H.C. Wainwright & Co. report. - 04/10/2019

Augmented Reality Firm Moves into Medical Devices Arena

This technology company continues to diversify the end markets for its e-commerce platform. - 04/09/2019

Canadian Tech Firm Secures Largest Contract to Date

The new client, in the U.S., is a state governmental agency. - 04/06/2019

Biotech Achieves Development Milestone for Blue Light Imaging System

The surgical imaging firm continues to advance its first medical device toward commercialization. - 04/05/2019

Canadian Life Sciences Firm Seeks Collaborative Cannabis Partner

This represents the company's expansion into another business area. - 04/05/2019

Innovative Healthcare Tech Firm to Acquire Two Vancouver Pharmacies

The transaction will allow the company to add a prescription fill and fulfillment component to its telemedicine app. - 04/03/2019

Biopharma Expects Data Readouts in Psoriasis, NASH in H2/19

Two recently launched clinical trials, and related conference calls, were reviewed in an H.C. Wainwright & Co. report. - 04/03/2019

CBD Firm Tallies Strong Q4/18 Performance, 2019 Outlook

A ROTH Capital Partners report reviewed the numbers for 2018 and explained why this Colorado-based company should perform well this year. - 04/03/2019

Cannabis Beverages, Edibles Company Receives Key Permit

This represents a major milestone for the firm on its path to commercializing its products. - 04/03/2019

Best-of-Breed Hemp/CBD Producers

Fincom Investment Partners surveys the hemp-CBD landscape and discusses two companies it believes are "best of breed." - 04/02/2019

Biopharma Hits Milestone in Starting Enrollment for NASH Clinical Trial

The company will discuss the trial when it hosts a conference call about this specific disease indication in April. - 03/30/2019

Firm Signs Paid Pilot Agreements to Test Telemedicine Platform in 5 States

With this development, the Canadian company further expands its U.S. footprint. - 03/30/2019

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer

The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report. - 03/30/2019

California Gold Entering High-CBD Content Hemp Seed Market in the U.S.

Peter Epstein of Epstein Research profiles a gold company that plans to grow hemp seed on its land. - 03/28/2019

Premier Health Group Adding Medical Cannabis Support Tool

This clinical decision support software integration is the first of its kind, according to the company. - 03/27/2019

San Diego Biopharma Features 'Strong and Balanced Pipeline'

An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products. - 03/26/2019

Dosing Begins for California Biopharma's Proof-of-Concept Trial in Plaque Psoriasis

This U.S. study follows encouraging results from a Phase 1b trial in the same indication in Australia. - 03/25/2019

Biotech Stresses Need to Target Only Toxic Oligomer in Alzheimer's Therapies

The company cites the recent discontinuation of other firms' clinical programs as proof. - 03/25/2019

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. - 03/23/2019

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. - 03/22/2019

Rare Diseases Biotech Provides Opportunity

A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. - 03/21/2019

Tech Firm to Offer Solution to Inefficient, Expensive Health Clinic Business Model

The company will roll out virtual, remote medical services to change how primary care practices are run. - 03/20/2019

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. - 03/19/2019

Cannabis Firm Announces Brand for Recreational Aficionados

This Canadian company intends to next launch a marketing campaign for the new product suite. - 03/19/2019

5 Small-Caps on Fund Manager Steve Palmer's Radar Screen

Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention. - 03/19/2019

Antibody Therapeutics Developer to Present at March Alzheimer's/Parkinson's Conference

The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein. - 03/19/2019

Health Tech Firm Completes Enrollment for Female Sexual Function Trial

A Ladenburg Thalmann report reviewed the study design and purpose. - 03/15/2019

Disruptive Delivery Company Signs Deal for Cannabis Distribution

Technical analyst Clive Maund discusses both the fundamentals and technicals for this company that just signed a cannabis distribution agreement with a Vancouver-based retailer. - 03/15/2019

Logistics Firm Moves Further Toward Becoming 'Uber of Cannabis for Canada'

This company forges partnerships with cannabis companies to deliver, within an hour, their products to customers. - 03/14/2019

Tech Firm Launches Augmented Reality Showcase for Legal Cannabis Products

The new platform promises to provide a unique e-commerce experience in the legal cannabis industry, combining customer education and support for online transactions. - 03/14/2019

Marijuana: Up in Smoke

Sector expert Ron Struthers takes a look at a spectrum of cannabis companies, including one company that's gone from a high to a downer, a sector leader, and a firm that promotes CBDs as good for sex. - 03/13/2019

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

This California company expects results from clinical trials in liver disease and psoriasis in 2019. - 03/12/2019

Large US Market Now Open to Livestock Feed Antibiotic Replacement

Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. - 03/11/2019

Coverage Initiated on Cancer Vaccine Firm

An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company. - 03/09/2019

Coverage Initiated on Producer of Hemp-Derived Cannabidiol Products

A ROTH Capital Partners report presented the reasons for investing in this company. - 03/09/2019

Augmented Reality and Healthcare Tech Firms to Collaborate

The companies aim to combine their expertise to co-create immersive and compelling instructive medical tools. - 03/08/2019

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. - 03/06/2019

Firm Launches App to Help Physicians Provide Virtual Counseling

This new initiative combines emerging technologies and human skill-based expertise. - 03/05/2019

After Financing Close, Biotech's Subsidiary to Operate Independently

An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. - 03/05/2019

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types

This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. - 02/27/2019

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. - 02/25/2019

Livestock Feed Developer Partners to Initiate Product Sales in the U.S.

The arrangement represents this Canadian life sciences firm's entrée into a significant market. - 02/22/2019

Biopharma's Foundation Provides for Downside Protection, Upside Realization

An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate. - 02/20/2019

Canadian Company Completes Two Cannabis Harvests

The firm also makes progress in obtaining technology rights and various licenses. - 02/17/2019

Bringing Advanced Technology to the Cannabis Space

This cannabis technology company brings artificial intelligence, blockchain and cryptocurrency to the global medical cannabis marketplace to help patients make informed decisions and drive medical cannabis sales. - 02/13/2019

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease

The Canadian company continues seeking partners to leverage its discovery and development platform. - 02/13/2019

Clinical Movement Expected in 2019 on Pharma Firm's 'Gene Therapy Promise'

A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report. - 02/13/2019

Report Highlights Biopharma's Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases

Analyst expects "transformational year" for company with a phase 3 trial underway. - 02/13/2019

Biopharma's Drug Well Tolerated in Opioid Withdrawal Study

An H.C. Wainwright & Co. discussed these proof-of-concept data and described the company's planned Phase 1 study. - 02/09/2019

Medical Device Firm Develops Nitric Oxide Delivery Unit for Clinic Use

This new machine takes the company's product line count to four. - 02/06/2019

Is Elixinol the Fastest Growing Hemp/CBD Producer?

Fincom Investment Partners discusses Elixinol's Q4 earnings, previews Charlotte's Web and CV Sciences' earnings, and compares the three companies. - 02/04/2019

Accelerated Approval Could Be 'Game Changer' for Biotech

This Canadian company's immunotherapeutic targeting ovarian cancer could advance to market sooner, according to a Mackie Research Capital Corp. note. - 02/02/2019

Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments

This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings. - 02/02/2019

Specialty Pharma 'Advances Pipeline' Ahead of Commercializing Lead Skin Therapy

LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation. - 01/30/2019

Coverage Initiated on Developer of Therapies for Gastrointestinal Disorders

A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets. - 01/30/2019

Anixa Doesn't Disappoint

Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year. - 01/29/2019

Early Data for Biotech's Pain Drug Candidate 'Show Promise'

An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain. - 01/26/2019

Commercial Launch Planned for Schizophrenia Drug

A drug used to treat schizophrenic patients will launch commercially in February in the U.S. - 01/23/2019

Analyst: Reaction to Trial Data 'Unwarranted'

An analyst's note reviewed the recently announced study results in pancreatic cancer as well as the subsequent decline in stock price. - 01/23/2019

Analyst Shares 'Revelations from a Pooled Safety Analysis' of Pain Drug

An H.C. Wainwright & Co. report discussed the analgesic's safety profile and how it compares to an on-the-market competitor. - 01/23/2019

Phase 2 Study Begins for German Biopharma's Cancer Drug Candidate

A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated. - 01/16/2019

Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data

Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report. - 01/11/2019

Healthcare Solutions Provider to Acquire Medical Software Firm

The merger will allow the Canadian company to expand its online technology platform. - 01/10/2019

Target Raised on Nutraceutical Firm After It Inks 'Marquee Partnership'

The agreement terms and benefits of the partnership to this pharmaceutical company were relayed in an H.C. Wainwright & Co. report. - 01/09/2019

Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic

The background and justification for the deal was covered in an H.C. Wainwright & Co. report. - 01/05/2019

Potential Tenbagger Biopharma Displays 'Strong Start to New Year'

A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock. - 01/04/2019

Texas-Based Biopharma Gets PDUFA Date for Lead Orphan Disease Asset

An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production. - 01/02/2019

Coverage Initiated on Pharma 'Leveraging Large Markets with Differentiated Products'

A Ladenburg Thalmann report outlined the investment thesis for this Colorado-based life sciences firm. - 12/29/2018

Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning

An H.C. Wainwright & Co. report provided an update on the Q3/18 activities and achievements of this company targeting NASH. - 12/24/2018

Coverage Initiated on Vaccine Developer with 'Transformational' Data Expected

A Ladenburg Thalmann report discussed this biotech's late-stage clinical assets in RSV and influenza. - 12/24/2018

Analyst: Biopharma Makes 'Right Call' in Stopping Combination Agent in Trial

A Mackie Research Capital Corp. note reviewed recent and upcoming developments in this immunotherapy developer's clinical study. - 12/19/2018

Urgent Update on Canadian Health Company Acquisition

Technical analyst Clive Maund charts the potentially transformative acquisition of a medical software provider in Canada. - 12/18/2018

15 Reasons Why Hemp Producer Elixinol Should Be in Your Portfolio

With the U.S. government legalizing hemp in the recently passed 2018 Farm Bill, Fincom Investment Partners profiles a hemp company whose largest market is the U.S. - 12/17/2018

Small-Cap Firm Announces Major Medical Technology Acquisition

Ron Struthers of Struthers Resource Stock Report profiles an innovative medical firm in Canada that just announced the acquisition of a medical technology firm, a move that will expand its reach across Canada. - 12/17/2018

Telehealth Services Provider's Positive Q3/18 Results Reflect 'Robust Growth Rate'

A William Blair report reviewed the firm's operational and financial numbers for the period. - 12/12/2018

Coverage Initiated on Tech Firm Servicing Healthcare Industry

Haywood Securities presented the thesis for investment in this company, including its growth drivers and continued focus on acquisition. - 12/12/2018

Strong Health Stock 'Ready to Commence New Upleg'

Technical analyst Clive Maund analyzes a rapidly expanding company with medical clinics in British Columbia that is using advanced technology and AI. - 12/11/2018

Health Stock 'Looking Set to Bounce Back After 90% Drop'

Technical analyst Clive Maund charts a telemedicine technology company and explains why he believes the company's stock should rebound. - 12/11/2018

Small-Cap Company Could Be the Face of the Future of Medicine

A company in Canada that is changing the paradigm for providing healthcare in Canada and potentially elsewhere by integrating technology and artificial intelligence has just announced a major acquisition. - 12/10/2018

Biotech Delivers Positive Study Results for Prostate Cancer Prognostic Test

An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application. - 12/05/2018

Precision Medicine Developer Secures Another Patent for Drug Candidate

This company takes a step forward in its efforts to protect its intellectual property. - 12/05/2018

Biotech to Lead dMAB Tech Field with First Clinically Tested Product

An H.C. Wainwright & Co. report discussed recent articles covering results of this firm's preclinical studies. - 11/28/2018

Neuromonitoring Stock 'Ready to Rally'

Technical analyst Clive Maund charts a neuromonitoring company that he believes is undervalued. - 11/26/2018

Cannabis Provider to Debut Five More Dispensaries in Florida

This company plans to add even more this year as well. - 11/26/2018

Biopharma Agrees to $215 Million Acquisition Deal

An H.C. Wainwright & Co. report detailed the terms of the definitive agreement concerning the merger. - 11/21/2018

Biopharma to Accelerate Trial Timeline with Amendment

The change relates to the onset of dosing for patients with different degrees of disease. - 11/21/2018

Biotech Ramps Up Philippine Sales of Livestock Feed Premix

A distributor of the proprietary product places a third large order. - 11/21/2018

Life Science Company Addresses Antibiotic Resistance Problem

This firm's proprietary technology provides an alternative to antibiotic use in livestock production. - 11/18/2018

Biotech Files Patent Application for Nitric Oxide Delivery Device

With this development, the company advances blood/plasma transfusion technology. - 11/16/2018

Imprimis: Priming the Pumps for a Big 2019

Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on. - 11/15/2018

Catalysts Approaching for U.S. Developer of Cancer Therapeutics

An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch. - 11/10/2018

Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting

A ROTH Capital Partners report relayed the contents of both presented abstracts. - 11/10/2018

Target Price Raised on Biotech in Anticipation of Clinical Trial Presentation

An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy. - 11/07/2018

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer

A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. - 11/07/2018

Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says

This firm explains how its 15 years in drug development led to and supports this conclusion. - 11/07/2018

Hemp Sales Grow at CV Sciences: Q3 Beats Estimates, 2019 Outlook

Fincom Investment Partners takes a look at Q3 earnings for a U.S.-based CBD company and explains why it believes it offers good value. - 11/07/2018

A Canadian Cannabis Company for the Next Wave

Ron Struthers, who believes the ideal marijuana stock to buy at this time is one that is focused on cannabis oil, profiles one such company that he sees as undervalued. - 11/06/2018

Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'

A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. - 10/31/2018

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment

With this achievement, the firm expands its potential partnering opportunities. - 10/31/2018

Three Small-Caps on This Fund Manager's List

Steve Palmer, founding partner, President and Chief Investment Officer of AlphaNorth Asset Management, talks with Streetwise Reports about several small-cap companies from three sectors that he has been following. - 10/30/2018

Update on Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed

Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed. - 10/29/2018

This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers

Multiple governments around the world have unleashed mandates on livestock feed regulations that pose an opportunity for a Canada-based biotech company. - 10/27/2018

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs

Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. - 10/27/2018

Catasys…Future's So Bright

Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. - 10/27/2018

Biotech to Expand Precision Medicine Services via New Partnership

A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. - 10/24/2018

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View

Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp. - 10/24/2018

Animal Health Product Developer to Expand Sales Footprint

This Canadian company makes progress with its commercial uptake efforts. - 10/20/2018

Biotech Advances Monoclonal Antibody Technology and Is Awarded Gates Foundation Grant

An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology. - 10/20/2018

Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner

Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space. - 10/17/2018

Biotech Reports Encouraging Interim Gene Therapy Data for Skin Disorder

This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication. - 10/17/2018

Tech Firm Launches Medical Cannabis User Data App, Lands Partnership

This "patient-care solution" is designed to help retailers make product recommendations. - 10/13/2018

Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease

Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates. - 10/11/2018

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential'

A LifeSci Capital report presented a handful of key points about the firm. - 10/10/2018

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential

An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. - 10/10/2018

Texas Heart Takes to the CoreoGraft

Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. - 10/10/2018

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements

This Utah-based company rolled out an online campaign that highlights its strategic repositioning. - 10/09/2018

DURECT Receives Return on Schizophrenia Drug Approval

A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. - 10/03/2018

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters

An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. - 10/03/2018

Surgical Robotics Developer Demonstrates Technology at Medical Conference

A Ladenburg Thalmann report relayed how this Massachusetts company participated at the Transcatheter Cardiovascular Therapeutics annual meeting through a live transmission—the first ever—of a remote interventional procedure using the CorPath GRX system. - 10/03/2018

Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed

As the worldwide movement to ban antibiotics as a growth promoter in animal feed gains traction, technical analyst Clive Maund has called an "immediate strong buy" on a company that has developed an alternative. - 10/01/2018

Life Sciences Company Hits Sales Milestone with Livestock Product

With this development, the Canadian firm entered a new geography and an additional market segment. - 09/29/2018

Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm

This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia. - 09/26/2018

NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program

A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer. - 09/26/2018

Biotech's Preliminary Immunotherapy Data 'Positive,' Earns Coverage in Medical Journal

An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer. - 09/26/2018

Life Science Company Sells Large Order of Non-Antibiotic Growth Promoter for Livestock

This is the second large shipment to the Philippine distributor. - 09/25/2018

This Company Has Better Numbers than Tilray at 1/25th the Price

Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer. - 09/24/2018

Medical Use of Nitric Oxide Expands as Costs Come Down

Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. - 09/19/2018

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'

An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm. - 09/19/2018

Cancer Vaccine Developer Expands Its Collaboration with Merck

A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner. - 09/19/2018

U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan

Permission has been obtained to distribute time-release capsules. - 09/18/2018

Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment

With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. - 09/14/2018

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm

An Echelon Wealth Partners report discussed the deal terms. - 09/12/2018

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial

A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications. - 09/11/2018

Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device

A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company. - 09/05/2018

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent

A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. - 09/05/2018

Drug Company Receives $5 Million Milestone Payment

Company entitled to receive quarterly earn-out payments from patent agreement. - 08/31/2018

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment

The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. - 08/29/2018

Oncology-Focused Biotech Receives Orphan Status for AML Drug

An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. - 08/29/2018

Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News

An analyst discussed the implications to this firm of a competitive product's advancement. - 08/29/2018

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible

Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. - 08/22/2018

Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment

H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company. - 08/22/2018

Biosciences Company Announces Research Collaboration for Testing Cannabis Ingredients

The development of analytic methods is a key milestone in the development of water-soluble cannabis technology. - 08/21/2018

Medical Device Firm Anticipates Benefit from Patent Ruling

This company, which develops delivery products for inhaled nitric oxide, a gas used to treat newborns with low oxygen levels and patients with COPD, sees opportunity in a newly invalidated patent. - 08/15/2018

Medical Device Firm's Clinical Programs Progress in Q2/18

A Ladenburg Thalmann report reviewed the recent financial results for a California-based company that has developed treatments for vaginal laxity and female stress urinary incontinence. - 08/15/2018

Biotech Marks Progress on Programs for Cancer, Infectious Diseases

This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst. - 08/15/2018

Biopharma Signs Multimillion-Dollar Deal for Key Products in China

An H.C. Wainwright & Co. report reviewed the arrangement. - 08/08/2018

U.S. Medical Device Firm Pursues ISO 13485 Certification

With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system. - 08/01/2018

Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug

A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts. - 08/01/2018

Biotech Releases White Paper on Alzheimer's Disease Candidate

A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate. - 08/01/2018

Interim Readout for Pharma Trial 'Delivers Home Run'

An H.C. Wainwright & Co. report discussed the implications of data indicating "overwhelming evidence of efficacy" for this company's nonantibiotic anti-infective for treatment of catheter-related bloodstream infections. - 07/31/2018

Health Technology Stock 'Set to Break Higher'

Technical analyst Clive Maund charts a health technology stock whose platform allows hospitals and healthcare organizations to buy, sell and trade surplus medical equipment and supplies. - 07/24/2018

Biopharma Releases New Antibiotic in the US for Complicated UTIs

A LifeSci Capital report reviewed why uptake of a drug that targets complicated urinary tract infections could be significant and swift. - 07/24/2018

Australian Regenerative Medicine Firm 'Lands a Great Partner in China'

A Maxim Group report reviewed the deal between the two companies. - 07/22/2018

Healthcare Tech Company Receives US Patent

The U.S Patent and Trademark Office has granted the allowance to a technology company whose platform allows healthcare organizations to buy, sell and trade equipment and supplies. - 07/19/2018

Cannabis Firm Targets Sexual Health and Wellness

California, with nearly 40 million residents, offers a cannabis market as large as the whole of Canada, says Ron Struthers, editor of Struthers Resource Stock Report. He believes that companies that have a road into California will gain early traction, and he profiles one such firm. - 07/17/2018

Cell Therapy Company and Chinese Firm Sign Marketing Deal

This biotech, in Phase 1 development of regenerative technologies addressing skin and orthopedic indications, has finalized a commercialization deal with YOFOTO. - 07/15/2018

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC). - 07/11/2018

Three Companies Poised to Benefit from Proposed Medicare Home Health Monitoring Change

A proposed rule change would allow Medicare to reimburse home health agencies for remote patient monitoring, providing an opportunity for health technology companies. - 07/10/2018

Study Shows Biopharma's Lead Drug Mediates T Cell Tumor Infiltration

An Echelon Wealth Partners report discussed this firm's stock performance and how a recent clinical trial update impacted it. - 07/10/2018

Coverage Initiated on 'True Original' Using RNAi to Enhance Cancer Immunotherapy

An H.C. Wainwright & Co. report outlined the thesis for investing in this emerging biotech. - 07/10/2018

EpiPen Rival Lands Major Partner

An H.C. Wainwright & Co. report explains the deal, which concerns a new single-dose epinephrine injection for severe allergic reactions. - 07/03/2018

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat

A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. - 07/03/2018

Coverage Initiated on Biopharma with 'Opioid Sparing Solution for Post-Op Pain'

An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset. - 06/27/2018

Immunotherapy Firm's Triple Combination Trial for Glioblastoma Sees First Patient Dosed

A Maxim Group note discussed the latest clinical endeavor involving a three-pronged approach targeting glioblastoma. - 06/27/2018

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery. - 06/26/2018

Agreement Facilitates Progress Toward Medical Device Approvals

This medical device company enters a partnership to provide quality and regulatory services. - 06/20/2018

Coverage Initiated on Immunotherapy Developer with Phase 3 Lead Asset

A B. Riley FBR report provided an overview of this life sciences firm. - 06/20/2018

Transfusion Medicine Biotech Hits Target on Road to Commercialization

A BTIG report reviewed the news announced by this supplier of blood grouping reagents and control products. - 06/20/2018

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease. - 06/13/2018

Biotech Releases 'Unequivocally Positive' Topline NASH Study Results

An H.C. Wainwright & Co. report relayed the highlights of the new trial data from this Israel-based firm. - 06/13/2018

Mobile Health Platform Firm Signs Deal That Will Increase Pace of Onboarding Patients

A technology company that develops mobile health and telemedicine platforms for community-based healthcare has raised money, made a deal that will accelerate the number of patients it adds every month, and is breaking through its hardware logjam. - 06/06/2018

Biotech Consolidates Shares in Preparation for NASDAQ Listing

A Canaccord Genuity analyst provided an update on this late-stage Canadian life sciences firm targeting metastatic breast cancer. - 06/05/2018

Coverage Initiated on Developer of Women's Reproductive Health Products

A ROTH Capital Partners research report outlined the key drivers of the investment thesis for this firm. - 05/30/2018

Biotech Announces Encouraging HIV Vaccine Results

Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics. - 05/23/2018

Analyst: 'New CEO, Larger Sales Team and Greater SUI Focus Should Help Medical Device Growth'

Cowen analyst Dr. Joshua Jennings highlighted this medical device firm's Q1/18 developments and financial results. - 05/23/2018

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way

In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. - 05/16/2018

Biotech's Launch of Pain Product Shows Encouraging Early Metrics

Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset. - 05/12/2018

Concurrent Milestones for Biotech Set to Occur 'on the Horizon'

Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news. - 05/09/2018

Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company

The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. - 05/09/2018

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. - 05/02/2018

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. - 04/25/2018

Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'

Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. - 04/24/2018

Biotech Round-Up: M&As, Financings and Immuno-Oncology

John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. - 04/18/2018

Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal

A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. - 04/17/2018

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts

Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data. - 04/17/2018

Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick

Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status. - 04/11/2018

Biotech Announces Positive Topline Data in Tourette Syndrome

Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. - 04/11/2018

RNAi Therapeutics Developer Reports Positive Amyloidosis Data

Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. - 04/04/2018

CMS Unexpectedly Issues Product Billing Code to Biotech

Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm. - 04/04/2018

Biotech Delivers 'Excellent' Phase 2 Data

John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. - 04/03/2018

Medical Device Firm Posts 'Strong Performance' Globally in Q4/17

The company performed strongly in the U.S. and the Asia Pacific region. - 03/28/2018

Regrouped Biotech's Stock Price Could See Fifteenfold Increase

A recent conference call provided clinical and financial updates. - 03/28/2018

Convergence Will Drive the Ultimate Disruption of Life Sciences

Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. - 03/28/2018

Biotech Advances Treatments for Liver Disease, Pain, Mental Illness

With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018. - 03/22/2018

Two Biotechs Earn Analyst's Top Pick Ranking

Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well. - 03/19/2018

Price Target on Biotech Is a 700% Potential Increase

Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. - 03/19/2018

Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3

H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset. - 03/14/2018

Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'

Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm. - 03/14/2018

Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside

John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment. - 03/07/2018

Biotech Launches Trial Dosing Against Backdrop of Strong Balance Sheet

Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs. - 03/07/2018

Exciting Biotech Stock Now Breaking Out of Large Base

Technical analyst Clive Maund takes a look at a biotech stock that he views as a strong buy. - 03/05/2018

Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'

Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential. - 02/23/2018

Fund Manager Names Three Small-Caps with Strong Growth Profiles

The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects. - 02/22/2018

Can a Simple Test Really Predict Whether a Cancer Treatment Will Succeed?

Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma. - 02/20/2018

Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple

One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." - 02/20/2018

Medical Device Firm to Launch Trials for Treatment Targeting $12 Billion Incontinence Market

Anthony Vendetti, an analyst with Maxim Group, shared the results both of a pilot study for stress urinary incontinence and of a recent equity raise by this company. - 02/14/2018

Biotech with Tenbagger Potential Signs Deal with Chinese Firm

Joseph Pantginis, an analyst with H. C. Wainwright & Co., detailed prospects for this biopharmaceutical corporation's new partnership with an Asian biotech and other near-term plans. - 02/14/2018

Company Takes Aim at Approval of Colorectal Cancer Screening Test in EU

Two analysts take note as this biotech prepares to release data on its colorectal cancer screening product. - 02/13/2018

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle

Ron Struthers of Struthers Resource Stock Report discusses recent trends in cannabis investing and profiles a handful of cannabis companies. - 02/12/2018

Oncology Biotech with Precision Medicine Focus Added to Analyst's 2018 Top-Pick List

A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities. - 02/07/2018

Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'

Maxim Group analyst Jason McCarthy explained why investors should focus on this emerging technology and one developer that is well-positioned to capture value in the space. - 02/07/2018

Medical Device Firm Boosts Quarterly Revenue 50% YOY

A Maxim Group report noted the recently announced revenue achieved and anticipated by this producer of cancer treatment devices. - 01/31/2018

Coverage Initiated on Developer of Potential Breast Cancer Therapy Competitor

Jason Kolbert, an analyst with Maxim Group, explained the drivers behind adding this drug and drug delivery developer to his coverage universe. - 01/31/2018

Preliminary Phase 2 Clinical Data Provides 'First Spark to Game-Changing Thesis'

H.C. Wainwright & Co. reported on the significance of preliminary data for treatments for head and neck cancer, as well as for cervical cancer. - 01/31/2018

Pancreatic Cancer Trial Data Will Be Released Soon

A biotech company that has begun clinical testing of human antibodies to treat cancers is in discussion with potential partners. - 01/24/2018

Coverage Resumed on Developer of 'Drug Candidate with Blockbuster Potential'

André Uddin, an analyst with Mackie Research Capital Corp., shared his thesis for investing in this biotech. - 01/24/2018

Regenerative Medicine Company's China Deal is 'Dramatically Transformational'

Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance in Asia. - 01/18/2018

Several Milestones on Horizon for 'Top Pick' Immunotherapy Firm

Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status. - 01/17/2018

Test for Personalized Approach to Hodgkin's Lymphoma Treatment Entering Final Stages Before Commercialization

One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment. - 01/16/2018

Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's'

André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug. - 01/10/2018

Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018

As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. - 01/10/2018

2018 Biotech Watchlist: 'No One Space Is Going to Dominate'

Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors. - 01/10/2018

Firm Focused on Women's Health Posts 'Record' Sales of Treatment Device

A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts. - 01/10/2018

Portfolio Manager's Biotech Watchlist Picks for 2018

StoneCastle Investment Management has a high-growth fund that invests wherever it finds opportunities, and it is bullish on healthcare. In this interview with The Life Sciences Report, portfolio manager Bruce Campbell highlights four companies that he is putting on Streetwise Reports' 2018 Biotech Watchlist. - 01/02/2018

When to Take Profits in the Cannabis Sector

With a run-up in cannabis stocks, technical analyst Clive Maund shares his thoughts on when investors should take profits. - 12/28/2017

Biotech's Shares 'Undervalued' and Positioned for 'Long-Term Upside Potential'

Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease. - 12/27/2017

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA

Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect. - 12/27/2017

'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform

Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. - 12/20/2017

Biotech Receives 'Major Endorsement from World-Leading Pharma Company'

David Kideckel, an analyst with Beacon Securities Ltd., relayed news from this firm's recent annual meeting, including a private placement with a large pharma and an update on the Phase 3 trial of its lead therapy. - 12/20/2017

Updates from ASH Reinforce Analyst's Big Price Target Potential

Andrew Fein, an analyst with H.C. Wainwright & Co., discussed the implications of this biopharmaceutical's recently announced data, which support his "bullish" outlook for the firm's candidate in chronic graft versus host disease. - 12/20/2017

Cannabis Biotech Stock Starting to Advance Again

A technical analysis by Clive Maund on CliveMaund.com has a Buy on this cannabis biotech stock. - 12/15/2017

'The Market Gets it Wrong, Again'; Analyst Raises Target Price on Biotech

Ed Arce, an analyst with H.C. Wainwright & Co., explained the positive elements of this drug developer's recently released clinical trial data and why they did not warrant the market reaction they got. - 12/13/2017

A New Breed of Regenerative Therapy Companies Taking Hold

A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research. - 12/07/2017

Biotech Delivers 'Great' Phase 2 Data in NASH

John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market. - 12/07/2017

Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results

This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts. - 12/06/2017

Coverage Initiated on 'One of the Most Undervalued Biotech Companies in Canada'

David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm. - 12/06/2017

Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China

Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies. - 12/05/2017

Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate

Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation. - 12/04/2017

Potential Alzheimer's Therapies Focus on Early Intervention

After attending a conference on the latest in development of Alzheimer's disease treatments, Andrew Fein, an analyst with H.C. Wainwright & Co., provided an industry update. - 11/30/2017

Analysts Say Medical Device Firm Sees Record Quarterly Revenue Growth, 120% YOY

Following the company's release of its latest financial report, three analysts weighed in on the results. - 11/29/2017

Analyst's 'Top Pick' Advances Vaccine Candidates

Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus. - 11/21/2017

Stock Price Jump Reflects Biotech's Active October

This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment. - 11/20/2017

Maxim's Target Price on Biotech Makes It More Than a Tenbagger

Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets. - 11/20/2017

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate

André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer. - 11/20/2017

Biotech's Target Price Increased as Shares 'Deeply Undervalued'

Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer. - 11/15/2017

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing

Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer. - 11/15/2017

The Lowdown on Getting High in Canada

Some 600 tonnes of marijuana a year are up for grabs as Canada moves to legalize weed, says Rick Mills, founder of Ahead of the Herd, who puts forth his case on why cannabis stocks should be in every investor's portfolio. - 11/14/2017

Analyst Says Biotech Share Price Could Potentially 'Double'

Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. - 11/13/2017

Biotech with Solid Pipeline and 'Solid Partnership Outlook'

Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans. - 11/13/2017

Biotech Reports Positive Topline Data; Biologics License Application in Progress

Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications. - 11/06/2017

Target Price Raised on 'Undervalued' Antibiotics Developer

Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company. - 11/06/2017

Could a FDA Warning Letter Provide a Silver Lining to This Home Care Medical Device Company?

Maj Soueidan, cofounder of GeoInvesting, profiles his long history with a company providing medical devices for the home care market. - 11/06/2017

Drug Offers 'Best-in-Class' Potential

John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health. - 11/01/2017

Big Biotech's Value Is Bolstered by Focus on Alzheimer's Disease

An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications. - 11/01/2017

Biopharmaceutical Firm Receives FDA Priority Review and PDUFA Date

Neil Maruoka, an analyst with Canaccord Genuity, provided an update on this biotech's progress through the regulatory approval process for one of its therapeutics. - 10/25/2017

Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'

Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease. - 10/25/2017

Coverage Initiated on Gene Therapy Company

Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe. - 10/25/2017

Biotech Receives Device Approval in Five More Countries; Revenue Up 122% YOY

Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system. - 10/25/2017

Biotech Announces 'Late-Breaking' Addition to Immunotherapy Conference

Michael King Jr., an analyst with JMP Securities, reported this biopharmaceutical firm was recently added to the roster of presenters scheduled for an upcoming annual meeting. - 10/18/2017

Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials

With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia. - 10/18/2017

Reliq Health Technologies Quickly Gaining Traction in Fast Growing Telemedicine Market

The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, and Reliq Health Technologies is adding thousands of patients to its rolls. - 10/11/2017

Cannabis Company Forms Partnership to Develop Pharmaceuticals

Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. - 10/06/2017

Telemedicine Platform Is Quickly Gaining Traction in Fast Growing Market

The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. - 10/05/2017

Reliq Health Technologies Quickly Gaining Traction in Rapidly Growing Telemedicine Market

The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. - 10/05/2017

Japan Is Fertile Ground for Biotech Deals

Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. - 10/04/2017

Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia

A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts. - 10/04/2017

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End

With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi. - 10/04/2017

Immunotherapy Firm's Technology Demonstrates 'Potential Use in Treating Cancers and Bacterial Infections'

H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer. - 09/27/2017

Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential

André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. - 09/20/2017

Gout, Kidney Stones, Liver Disease & Cannabinoids

Danny Deadlock, founder of Microcap.com, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. - 09/15/2017

Biopharma Gets Green Light for Hypertension Study

Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts. - 09/13/2017

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy

The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components. - 09/01/2017

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena

Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella. - 08/30/2017

Analyst Says Cell Therapy Company's Move Decreases Risk

A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk. - 08/23/2017

Medical Cannabis Innovator Set to Go Public

A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21. - 08/18/2017

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection

Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations. - 08/16/2017

'Keep a Close Eye On' This Regenerative Medicine Firm

In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection." - 08/16/2017

Maxim Raises Target Price of Biotech Company

A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech. - 08/16/2017

Cell Therapy for Melanoma Impresses in
Phase 2

Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst. - 08/09/2017

Over-the-Counter Treatments for Joint Pain and Women's Health Propel Company into New Markets

With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach. - 08/09/2017

Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover

A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8. - 08/07/2017

This Just Changed Everything: Green Profits Are Being Unleashed

Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities. - 08/03/2017

Loan Provides Driver for Growth for Medical Device Firm

Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth. - 08/02/2017

Canadian Medical Cannabis Provider Expanding into US Market Through RTO

A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26. - 07/25/2017

DNA-Based Compound Shuts Down Seasonal Flu in Preclinical Study

A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018. - 07/19/2017

Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating

News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company. - 07/19/2017

Biotech with Alzheimer's Focus Makes Progress on Several Fronts

In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development. - 07/18/2017

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17

If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. - 07/13/2017

Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange

A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14. - 07/11/2017

Analysts Take Note as Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial

With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis. - 07/05/2017

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story'

Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs. - 06/29/2017

With Completion of Offer, Analyst Says This Biotech Stock Could Triple

A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential for "3x upside." - 06/28/2017

Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray

A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year. - 06/21/2017

Phase 3 Trial for Inovio's VGX-3100 in Cervical Dysplasia Gets FDA Go-Ahead

Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors. - 06/14/2017

RXi Pharmaceuticals Expands Collaboration with Norwegian Cancer Firm; Gears Up for 2017 Milestones

The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts. - 06/07/2017

HIV Vaccine Clinical Study Results in High Immune Response Rates in Healthy Subjects

A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts. - 05/31/2017

Neuromonitoring Company Founded by Former NFL Quarterback Set to Go Public

Assure Holdings, an intraoperative neuromonitoring company founded by former NFL quarterback Preston Parsons, will begin trading on the TSX Venture Exchange on May 29, under the trading symbol IOM. - 05/26/2017

What Is Chen Buying? Gold, Cobalt, Phosphate and Biotech. . .

With the market in flux, Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? is hedging his bets with investments in a variety of companies in different sectors. - 05/25/2017

Innovative Company Focused on Women's Health Completes Record-Breaking Quarter

Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts. - 05/24/2017

Small-Caps Rushing to Fill the NASH Treatment Pipeline

NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials. - 05/24/2017

Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program. - 05/17/2017

Inovio Moves Forward on Brain Cancer and Cancers Caused by HPV; Zika and Ebola Vaccines Also Advance

Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. - 05/17/2017

Big Pharma Sets Its Sights on NASH Epidemic

Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name. Closely linked with obesity, the disease does not become symptomatic until very late stage. Ed Arce, managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, organized the recent inaugural NASH Investor Conference. In part one of his interview with The Life Sciences Report, Arce discusses the disease, its market potential and how companies large and small are trying to fix the current dearth of treatments. - 05/17/2017

DURECT and Sandoz Ink $293 Million Deal for POSIMIR

DURECT Corp. and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for the U.S. for POSIMIR. - 05/10/2017

3D Signatures' Platform Taps into the Power of the Genome

How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment. - 05/10/2017

The ProMIS of an Alzheimer's Cure

With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report. - 05/03/2017

Mesoblast Heart Failure Trial Delivers Positive Interim Results

Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interim data, which prompted the Maxim Group to comment favorably on the study's design and progress. - 05/03/2017

Good Epilepsy Data from Zynerba Pharmaceuticals Would Set Stage for Pivotal Trials

Maxim Group noted that data from Zynerba's Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials. - 04/26/2017

VistaGen's Fast-Acting Antidepressant Targets Multibillion-Dollar Market

Maxim Group recently initiated coverage of VistaGen Therapeutics, citing its progress on development of a fast-acting therapy to treat major depressive disorders. - 04/26/2017

Trial Results Set Up DURECT Corp. for 'Exciting Year'

Positive results in a Phase 1b trial of DURECT Corp.'s candidate for the treatment of nonalcoholic steatohepatitis (NASH), which were presented at the 2017 International Liver Congress, prompted comments from a pair of analysts. - 04/26/2017

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market

The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year. - 04/19/2017

String of Positive Trial Results Boosts RepliCel's Profile

Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss. - 04/12/2017

Five Companies with Favorable Risk/Reward Profiles from the AlphaNorth Capital Conference

The 4th annual AlphaNorth Capital Conference brought together over 40 emerging growth companies with top investors. In this interview with Streetwise Reports, Steve Palmer, founder and president of AlphaNorth Asset Management and a co-organizer of the conference, discusses a diverse group of companies that were selected to attend the conference, including three biotech companies. - 04/12/2017

RXi Pharmaceuticals Receives Japanese Patent for RNAi Platform

With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform. - 04/12/2017

Four Biotech Mid-Caps Fund Manager Eden Rahim Believes Have Favorable Catalysts

Biotech may be the last great bastion of stock picking, posits Eden Rahim, who manages the Toronto-based Next Edge Bio-Tech Plus Fund. The fund is up 40% in the last 12 months. In this interview with The Life Sciences Report, Rahim provides his view of the sector and profiles four companies he believes may have great upside. - 04/05/2017

VistaGen Therapeutics Advances New-Generation Antidepressant Approved by European Patent Office

In a milestone for South San Francisco-based VistaGen Therapeutics, the European Patent Office (EPO) has issued a Notice of Intention to grant the company patents for its antidepressant prodrug, AV-101. - 04/05/2017

Cash-Rich Zynerba's Synthetic Cannabinoid Product Line Ready to Rumble

Zynerba Pharmaceuticals specializes in developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Devon, Pennsylvania-based company's Q4/16 financial results disclose a substantial cash kitty of ~$78M available to fund its pipeline of medical marijuana products, ZYN001 and ZYN002. - 04/05/2017

3D Signatures' TeloView Can Diagnose Alzheimer's with Cheek Swab

With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form. - 03/30/2017

Many Paths to Success with DURECT's Pipeline

DURECT has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the potentially groundbreaking epigenetic regulator DUR-928, POSIMIR's late-stage testing for postoperative pain and an abuse-deterrent oral technology. - 03/29/2017

Therapix IPO on NASDAQ Could Catapult It into the Big Leagues

Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs. - 03/21/2017

RepliCel's Phase 1 Trial for Hair Loss Completed Successfully

RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. - 03/16/2017

3D Signatures' Disruptive Technology Moving Ahead for Prostate Cancer and Hodgkin's Lymphoma

3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests. - 03/08/2017

Stellar Biotechnologies (SBOT:NASDAQ) Inks Multiyear KLH Supply Agreement with Amaran Biotechnology; Stellar Up 13% on News

Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to the biopharmaceuticals manufacturer. - 03/02/2017

Stellar Biotechnologies (SBOT:NASDAQ) Could Rise with KLH Vaccine Trial Success

Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Maxim currently has a price target of $4 on Stellar and the stock currently trades at around $1.65. - 03/01/2017

Major Funds Betting On Trump Sector

Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.S., says Tom Beck, editor of Portfolio Wealth Global. - 02/25/2017

Buckle Up: Inflation at 58-Month High

The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena. - 02/23/2017

RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology

RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. - 02/22/2017

Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth

As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice. - 02/22/2017

Investing in Life Sciences Under the Trump Presidency

Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. - 02/16/2017

Regeneus Hits the Fast Track with Major Japanese Partnership

Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. - 02/08/2017

Luminor Drives the Scout DS Forward

Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. - 02/06/2017

The Future of Cannabis Investing

The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global. - 02/03/2017

ContraVir's Hep B Drug Could Be a Game Changer

In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company. - 02/01/2017

Companies Flocking to Japan for Biotech Deals

For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. - 02/01/2017

Inovio's Zika Vaccine Generates Robust Immune Responses

Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. - 01/25/2017

2017 Small-Cap Biotech Watchlist: Takeaways for Investors

Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. - 01/18/2017

Time to Go Long on BrainStorm Cell Therapeutics?

Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. - 01/16/2017

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist

Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. - 01/03/2017

Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries

The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S. - 12/21/2016

VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma

VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. - 12/21/2016

Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth

3D Signatures, a Canadian company developing a platform of "disruptive" personalized prognostic tests for patients with 13 different cancers and Alzheimer's disease, has attracted the attention of several stock watchers with its most recent announcements. - 12/14/2016

What Will Happen to Cannabis Investments with Jeff Sessions as US Attorney General?

Technical analyst Clive Maund charts movements in the cannabis sector after the Nov. 8 legalization votes and the appointment of anti-cannabis firebrand Jeff Sessions as U.S. Attorney General. - 12/09/2016

Why the Canadian Marijuana Sector Is the Next Big Thing and Why Emblem Is Our Top Pick

Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp., which begins trading on the TSX.V on Dec. 12 under the symbol EMC, is their top pick. - 12/08/2016

Reliq Health Technologies Pilots Remote Patient Monitoring Program

Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology. - 12/07/2016

Can Biotech's Trump Bump Last?

In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. - 12/02/2016

Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena

By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future. - 11/14/2016

Why the Election Is Not as Relevant to Drug Stocks as You Might Believe

Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Dr. Len Yaffe of Stoc*Doc Partners sheds light on the issues in this analysis of drug price negotiation policy, and focuses in on one California ballot proposition that aims to rein in costs. - 11/02/2016

Exploring Solutions to Healthcare's Spending Crisis

Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures. - 10/19/2016

Analysts Keep Focus on DURECT's DUR-928

The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma. - 10/06/2016

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition

Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function. - 10/05/2016

Stock-Moving Catalysts Anticipated for Regeneus in Q4/16

Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan. - 09/28/2016

Imagin, a Better Way to Detect Bladder Cancer

Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. - 09/20/2016

Regeneus Secures Government Funding for R&D

The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. - 09/14/2016

Three Shots on Goal in Q4/16 for DURECT Corp.

With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp. - 09/08/2016

Soligenix's Diversified Pipeline Advances on All Fronts

The late-stage biopharmaceutical company Soligenix has had a string of good news. Revenue is up, the FDA awarded orphan status to a key drug, and BARDA and NIAID have granted the firm additional funding, plus the company is developing vaccines against Ebola and ricin, and has several other ongoing trials. Analyst Grant Zeng of Zacks Investment Research assesses the landscape. - 08/31/2016

Inovio Expands Ebola Vaccine Trial

Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination. - 08/24/2016

Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs

Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. - 08/17/2016

The ASX: Investing in an Emerging Biotech Frontier

Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under. - 08/10/2016

Resverlogix Seeks Orphan Status for Lead Drug Candidate

With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications. - 08/03/2016

Nobilis Moves Forward with New President and New Canaccord Coverage

Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy. - 07/20/2016

DURECT's Abuse-Deterrent Opioid Poised for FDA Approval

Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative. - 07/13/2016

How Sick Will Brexit Make Biotech and Pharma?

In tandem with the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union. Given the uncertainty and dire economic forecasts, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry. - 06/29/2016

Partnerships Propel Stellar Biotechnologies' Vaccine Technology

Maxim analyst Jason McCarthy sees nothing but blue sky for Stellar Biotechnologies Inc., even though its product originated in the deep blue sea. With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore. - 06/22/2016

Soligenix Develops Defenses Against Bioterrorism

Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company. - 06/15/2016

Investment in Cell and Gene Therapies Ramps Up

After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way. - 06/08/2016

OncoSec Delivers Cancer Therapy Straight to the Tumor

Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment. - 06/01/2016

How Nobilis Health Will Break Out of the Healthcare Payment Mold

Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise. In this interview with The Life Sciences Report, Ozonian discusses his company's newest technology and talks about how Nobilis will achieve critical mass. - 05/25/2016

With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016

Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company. - 05/18/2016

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology

Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully. - 05/11/2016

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse

Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications. - 05/11/2016

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE

Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. - 05/04/2016

Delving Deep into Immune Pharmaceuticals' Diverse Pipeline

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future. In this article for The Life Sciences Report, analyst Jason Napodano digs into the company's pipeline and investment potential. - 05/04/2016

Let Volatility Power Your Micro-Cap Biotechs

ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock, no matter how far into the depths it may have sunk. In this interview with The Life Sciences Report, Pantginis presents his detailed growth theory on two names, and he leaves two Focus Picks on the table for investors to do further diligence on. - 04/27/2016

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need

With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases—a type of lymphoma and pediatric Crohn's disease—are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio. - 04/27/2016

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer

Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose—a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men. - 04/20/2016

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse

To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
- 04/20/2016

Drug Pricing, Presidential Politics, and Three Biotechs with Promise

While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk. In this interview with The Life Sciences Report, George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold. - 04/13/2016

How Three Companies Have Been Resurrected from Failed Clinical Trials: George Zavoico of JonesTrading

Data can create or destroy the value of a biotech investment in an instant, but hitting or missing an endpoint doesn't always tell the story. For instance, Genentech's Herceptin (trastuzumab) is a blockbuster, bringing in $7.4B in revenue during 2015, but at one point investigators thought it was a complete failure. It took patience, time, additional capital and careful analysis of subpopulations of breast cancer patients to figure out that Herceptin would ultimately save many lives. In this interview with The Life Sciences Report, George Zavoico of JonesTrading Institutional Services discusses the growth prospects of three biotech names that have been wrecked and left for dead, but could ultimately resurrect themselves from a misleading pile of rubble. - 04/06/2016

Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans